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Facioscapulohumeral muscular dystrophy (FSHD) is mainly characterized by progressive 
and often asymmetric weakness and wasting of muscles of the face, shoulder girdle, 
and upper arms1. Immunodeficiency, centromeric instability, and facial anomalies (ICF) 
syndrome is mainly characterized by an absence or strong reduction of immunoglobulins 
and facial anomalies, often combined with developmental delay2. Although FSHD and 
ICF have very distinct phenotypes, both diseases are related to errors in chromatin 
modifiers that are involved in the epigenetic regulation of repetitive DNA3; 4. In this 
thesis the mutation spectrum in these chromatin modifiers involved in FSHD and ICF 
syndrome is expanded.
Epigenetic regulation of the genome
In the nucleus DNA is organized and packed into a proteinaceous structure called 
chromatin. DNA is wrapped around an octet of core histone proteins, called the 
nucleosome. Nucleosomes are composed of pairs of 4 histone proteins (H2A, H2B, 
H3 and H4) that form the core of the nucleosome with their histone tails protruding 
outwards5; 6. Histones can be post-translationally modified mostly at their histone 
tails, and this generally affects the accessibility of the DNA in the chromatin7; 8. DNA 
accessibility can also be influenced by the spacing of nucleosomes, or by replacement 
of core histones with histone variants9; 10. The DNA itself can be modified by methylation 
of primarily CpG dinucleotides or in rare cases by other chemical modifications such as 
hydroxymethylation11; 12.
 Although almost every somatic cell in the human body contains essentially the 
same genome, the epigenetic regulation of the chromatin structure differs between 
cell types resulting in the differential expression of genes thereby creating cell diversity. 
Epigenetics is defined as ‘the study of mitotically and/or meiotically heritable changes 
in gene function that cannot be explained by changes in DNA sequence’13. Epigenetic 
regulation is established by chromatin modifiers, proteins which can deposit, remove, 
or bind to modifications on DNA or histones, or remodel the positioning of nucleosomes 
(Fig. 1)14.
Writers, erasers and readers of chromatin modifications
Epigenetic marks are written (deposited), erased (removed) or read (recognized) by a 
variety of chromatin modifier proteins15. Nucleosomes are post-translationally modified 
on their histone tails and these modifications include methylation, acetylation, 
phosphorylation, ubiquitination and many others, which are established by chromatin 
modifiers referred to as ‘writers’ of histone modifications. These modifications can 
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also be removed by ‘erasers’ of histone modifications. Acetylation of histone tails, 
for example, is established by histone acetyltransferases (HATs) and occurs on lysine 
residues, neutralizing their positive charge. Histone acetylation is associated with 
increased accessibility of the DNA to the transcription machinery. After transcription, 
lysine acetylation is removed by histone deacetylases (HDACs), re-establishing the 
positive charge and attracting negatively charged DNA to tighten DNA-histone 
contacts. This process of acetylation and deacetylation is highly dynamic8. Methylation 
of histone tails is most well studied on lysine residues, but can also occur on arginine 
and histidine residues. Lysine methyltransferases and lysine demethylases write and 
erase methyl groups from histone tails, respectively14. Lysines can be methylated once 
(monomethylation, me1), twice (dimethylation, me2), or three times (trimethylation, 
me3)16. Depending on the lysine residues that are mono/di/trimethylated it might be 
associated with e.g. actively transcribed loci (e.g. H3 Lysine 4 trimethylation, H3K4me3) 













FIGURE 1. Schematic representation of epigenetic regulation of the genome by chromatin 
modifiers. DNA is wrapped around nucleosomes, which consists of 8 histones (2x H2A, 2x H2B, 
2x H3, 2x H4). The tails of the histones are pointing outwards and can be modified by writers and 
erasers of histone tail modifications (e.g. histone methyltransferases and histone demethylases) 
at e.g. lysine 4 (K4) or lysine 27 (K27). DNA methyltransferases (DNMTs) methylate the DNA, 
and this modification can be removed by Ten eleven translocation (TET) proteins. Nucleosome 
remodeling enzymes determine the positioning, occupancy and composition of nucleosomes.




 Similarly, there are chromatin modifiers responsible for the establishment and 
removal of DNA methylation. The family of DNA methyltransferases DNMT1, DNMT3A, 
DNMT3B, and DNMT3L, establish DNA methylation, or act as a cofactor in case of 
DNMT3L12. DNMT3A and DNMT3B are de novo methyltransferases, mainly responsible 
for the establishment of DNA methylation during early development. Last year 
another de novo methyltransferase (Dnmt3C), which is only conserved in muroid 
rodents, was identified in mouse17. DNMT1 is a maintenance methyltransferase, which 
preferably methylates hemimethylated DNA during replication. However, it recently 
has been recognized that both DNMT3 and DNMT1 enzymes have a function in both 
the establishment and maintenance of DNA methylation12. Ten eleven translocation 
proteins TET1, TET2, and TET3 remove DNA methylation by oxidizing methylgroups at 
cytosines, as a first step in the removal process18. DNA methylation is generally related 
to gene silencing, but is also identified in actively transcribed gene bodies19.
 DNA accessibility is also defined by the positioning of nucleosomes, which is 
important for the regulation of gene expression. Most genomic DNA is occupied by 
nucleosomes, however nucleosome occupancy is lower for regulatory regions, such 
as promoters and enhancers. Nucleosome positioning is determined by nucleosome 
remodelling enzyme complexes in combination with the DNA sequence and 
transcription factor binding10. Nucleosome remodelling enzyme complexes, such as 
the SWI/SNF (SWItch/Sucrose NonFermentable) complex, use ATP hydrolysis to slide, 
dissociate, or replace histones and thereby change the chromatin accessibility for e.g. 
transcription factors20. Nucleosome remodelling enzyme complexes are also involved 
in the exchange of histones for histone variants, which can have small or large amino 
acid differences compared to the ‘canonical’ histones. Histone variants affect chromatin 
organization and function by changing the structure and stability of nucleosomes, and 
influencing their post-translational modifications and protein interactions9.
Histone modifications and DNA methylation can be recognized by ‘reader’ proteins, 
which bind to specific combinations of modifications. These readers can be architectural 
proteins, nucleosome remodelling enzymes, chromatin modifiers establishing or erasing 
other modifications, or proteins involved in processes such as transcription, replication 
or DNA repair21. Some reader proteins create crosstalk between different histone 
modifications and/or DNA methylation to reinforce chromatin states. Two examples 
are SET domain bifurcated 1 (SETDB1), which methylates H3K9 only in the absence of 
H3K4me322, and methyl-CpG binding protein 2 (MECP2), which binds to methylated 
DNA and interacts with histone deacetylases and histone methyltransferases23.
 Another class of epigenetic regulators are long non-coding RNAs (lncRNAs) that 
form thermodynamically stable secondary structures, and contribute to epigenetic 
regulation by binding and recruiting chromatin modifying proteins to their target sites. 
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Both lncRNAs that act in cis (at the site of transcription) and in trans (at a target away 
from their site of transcription) have been identified, where they modulate chromatin 
structure and gene expression24. An example of a lncRNA that functions in cis is HOTTIP 
(HOXA transcript at the distal tip). HOTTIP is transcribed from the 5’ of the HOXA locus 
and recruits the WD repeat-containing protein 5/mixed lineage leukemia (WDR5/
MLL) complex to HOXA genes. Recruitment of the WDR5/MLL complex drives H3K4 
trimethylation, creating a positive feedback loop for active transcription of the HOXA 
genes25.
Euchromatic and heterochromatic regions
DNA and histone modifications along with reader proteins generate three major 
types of chromatin: euchromatin, facultative heterochromatin, and constitutive 
heterochromatin. Euchromatin is relatively accessible chromatin, which is in 
general gene rich, and contains actively transcribed loci. Common histone marks at 
euchromatic regions include mono/di/tri-methylation of H3K4 (H3K4me1/2/3) and 
acetylation of histone residues14. Conversely, heterochromatin is found in gene poor 
regions and genes in heterochromatic regions are generally silenced. Heterochromatin 
is characterized by histone hypoacetylation and DNA methylation. Two types of 
heterochromatin can be distinguished: facultative and constitutive heterochromatin26. 
Facultative heterochromatin contains high levels of H3K27me3, which is established 
by Polycomb repressive complex 2 (PRC2) and bound by Polycomb repressive complex 
1 (PRC1) at these regions. Facultative heterochromatin is often found at genes which 
are transcriptionally silent in certain cell types, while active in others27. Constitutive 
heterochromatin is more stable then facultative heterochromatin and contains high 
levels of H3K9me3 and is mainly identified at repetitive regions. Silencing of these 
repetitive regions is important for maintaining genome stability26; 28.
Repetitive DNA
The human genome is comprised of more than 50% repetitive DNA29. Two major 
constituents of repetitive DNA are the interspersed repeats and tandem repeats. 
Interspersed repeats are identical, or nearly identical, DNA sequences dispersed 
throughout the genome. Interspersed repeats include long terminal repeat elements 
(LTRs) and long/short interspersed elements (LINES/SINES), which amplify over the 
genome by retrotransposition, as well as DNA transposons, which transpose directly 
from one location in the genome to another30. Tandem repeats are organized in a head 
to tail fashion and are found near telomeres and centromeres. Based on the size of the 
repetitive unit, they are classified as microsatellites, minisatellites, or macrosatellites. 
Microsatellite and minisatellites have a repetitive unit of 1-8 basepairs (bp) and 9-100 




bp, respectively and occur in both coding and non-coding regions of the genome31; 
32. Macrosatellites have a repetitive unit of >100 bp, but are usually multiple kilobases 
(kb) per unit and often located at subtelomeric or centromeric regions33. Some 
macrosatellites contain protein-coding sequences in every unit34.
Chromatin modifiers in disease
Regulation of the chromatin structure by chromatin modifiers is essential for correct 
gene expression patterns. Therefore, it is not surprising that errors in epigenetic 
regulation of the genome can result in human disease. The most well-known example 
is cancer, where variants in genes encoding chromatin modifying proteins are often 
involved35. In cancer cells, DNA methylation patterns are often greatly disturbed by 
global CpG hypomethylation, which is often combined with hypermethylation of 
CpG islands of certain promoters36. In addition, histone modifications, as well as the 
positioning, occupancy, and composition of nucleosomes can be altered in cancer cells 
as a result of variants in chromatin modifiers35. These epigenetic changes can activate 
the expression of oncogenes, silence tumor suppressor genes, and create chromosomal 
instability36.
 Errors in epigenetic regulation of repetitive DNA, such as DNA hypomethylation 
of repeats, can lead to aberrant transcription and genome instability, which can 
cause disease. This thesis focuses on expanding the variant spectrum in chromatin 
modifiers involved in two epigenetic diseases that share a common feature of 
hypomethylation at repetitive DNA: Facioscapulohumeral muscular dystrophy (FSHD) 
and Immunodeficiency Centromeric instability and Facial anomalies (ICF) syndrome. 
FSHD is characterized by hypomethylation of the D4Z4 macrosatellite repeat array in 
the subtelomere of chromosome 4q. In ICF there is genome-wide hypomethylation of 
satellite repeats, mainly at centromeres. Both disorders and the chromatin modifiers 
involved will be further introduced below.
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Prevalence
FSHD is one of the most common forms of muscular dystrophy, and was first described 
in 1885 by Landouzy and Dejerine37; 38. Since the introduction of DNA diagnostics for 
FSHD, its prevalence was found to be on average 5 per 100 000. A recent study in the 
Netherlands, however, suggests a prevalence of 12 per 100 000, which is more than 
twice as high as previously thought38. There are two genetic forms of FSHD, called 
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FSHD1 (OMIM 158900) and FSHD2 (OMIM 158901). FSHD1 is the most common form 
which affects about 95% of the patients. FSHD1 and FSHD2 share many of the same 
clinical characteristics and are described below as ‘FSHD’.
Clinical features
FSHD is characterized by a typical distribution of muscle weakness1. In most cases, 
FSHD presents with progressive and irreversible weakness of facial muscles and/
or shoulder girdle and upper arm muscles. As the disease progresses, muscles of the 
trunk and lower extremities may become involved as well. Age at onset is typically in 
the second decade of life, but varies from early childhood to onset beyond age 60. The 
weakness is often asymmetrical and slowly progresses over life, but life expectancy is 
generally not reduced. Severity and rate of progression are largely variable, ranging 
from isolated facial weakness to severe generalized weakness, with approximately 20% 
of patients eventually requiring a wheelchair39. There is a high percentage (20–30%) 
of asymptomatic or minimally affected gene carriers. Even within the same family, 
large differences in disease severity can occur. In most cases, FSHD is inherited in an 
autosomal dominant pattern, but 10–30% of cases are caused by de-novo deletions, 
which often occur post-fertilization and result in gonosomal mosaicism40. Systemic 
involvement is rare but can include retinal vasculopathy, sensorineural hearing loss, 
restrictive lung disease and (incomplete) right bundle branch block, although all are 
most often subclinical41. Patients with early onset severe disease are more at risk of 
developing symptomatic extramuscular manifestations.
Chromatin relaxation at the D4Z4 repeat
FSHD is genetically linked to the D4Z4 macrosatellite repeat located in the subtelomere 
of chromosome 4q42. Each D4Z4 repeat unit is 3.3 kb in size and contains a copy of the 
double homeobox 4 (DUX4) retrogene43. Two almost equally common major haplotypes 
of the 4q subtelomere exist, 4qA and 4qB 42; 44. FSHD is specifically linked to the 4qA 
(FSHD-permissive) haplotype which contains a somatic DUX4 polyadenylation signal 
(PAS) following the most distal repeat unit, which is essential for stable expression of 
DUX4 in somatic cells (Fig. 2)43. Although every D4Z4 repeat unit contains a copy of the 
first two exons of the DUX4 gene, stable DUX4 expression occurs most efficiently from 
the last repeat unit which is followed by a PAS, and is much less prevalent from internal 
D4Z4 units45. In FSHD there is chromatin relaxation of the D4Z4 repeat associated with 
expression of DUX4 in skeletal muscle, which is considered as the molecular hallmark 
of FSHD. In muscle cells of FSHD patients there is variegated expression of DUX4 
since relatively high levels of DUX4 protein are only detected in a small percentage 
of myonuclei3. In controls, the D4Z4 repeat is transcriptionally silent in somatic cells, 




and is marked by both heterochromatic (H3K9me3 and H3K27me3) and euchromatic 
histone marks (H3K4me2 and H3Ac). H3K9me3 at D4Z4 is established by the H3K9 
methyltransferase SUV39H1 (suppressor of variegation 3-9 homolog 1) and bound 
by HP1γ (heterochromatic protein 1γ) and cohesin46. Furthermore, the GC rich D4Z4 
repeat (73%) is highly methylated in controls47; 48. In FSHD patients the chromatin of 
the D4Z4 repeat is less compacted as indicated by a lower chromatin compaction score 
(H3K9me3:H3K4me2 ratio) and reduced CpG methylation levels compared to controls48; 
49. Additionally, HP1γ and cohesin are also reduced in FSHD patients46. Together these 
changes emphasize the chromatin relaxation at D4Z4 in FSHD patients.
Genetic mechanism 
The two genetic forms of FSHD, FSHD1 and FSHD2, are clinically almost 
indistinguishable50. Both forms share the chromatin relaxation of the D4Z4 
macrosatellite repeat array on chromosome 4 and the transcriptional derepression of 
the D4Z4 encoded DUX4 gene in skeletal muscle. In the most common form, FSHD1, 
D4Z4 chromatin relaxation and DUX4 expression are associated with a contraction of 
the D4Z4 repeat to an array of 1–10 units (Fig. 2)51. This repeat varies between 8 and 
100 units in the control population, with FSHD-sized alleles of 8-10 units found in 1-3% 
of the control population52; 53. The D4Z4 contraction must occur on a 4qA permissive 
chromosome (containing a DUX4 PAS for stable expression) to cause FSHD. Contractions 
on 4qB chromosomes or of the very homologous D4Z4 repeat on chromosome 10 are 
associated with chromatin relaxation, but they are not associated with FSHD since these 
repeats lack a DUX4 PAS. FSHD2 is characterized by D4Z4 chromatin relaxation of both 
4q chromosomes as well as the very homologous D4Z4 repeats on chromosome 10, 
but without repeat contraction. FSHD2 patients carry at least one permissive 4qA allele. 
The median size of the shortest permissive allele in FSHD2 patients is 16 units, which 
is smaller than the median size in the control population (23 units)54. Heterozygous 
variants in the chromatin modifier structural maintenance of chromosome flexible hinge 
domain containing 1 (SMCHD1) gene have been identified as the most common cause 
of FSHD2 (Fig. 2)54-59. The mutation spectrum of SMCHD1 includes missense variants, 
insertions, deletions, nonsense and splice site variants and they are distributed over the 
entire SMCHD1 gene. Haploinsufficiency as well as expected loss of function variants are 
found in FSHD2 patients, indicating that both types of functional outcomes of SMCHD1 
variants can cause FSHD2. Heterozygous SMCHD1 variants explain about 85% of the 
FSHD2 patients. In some FSHD2 families, characterized by their clinical phenotype 
and D4Z4 hypomethylation, no exonic SMCHD1 variant that affects function could be 
identified. This suggests that FSHD2 is genetically heterogeneous.
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FIGURE 2. Genetic mechanisms of FSHD. In controls the D4Z4 repeat array (triangles) on 
chromosome 4q varies between 8 and 100 units and adopts a repressed chromatin structure 
(red wavy lines) characterized by high CpG methylation (me). Each D4Z4 repeat contains a copy 
of the DUX4 gene, without a polyadenylation signal (PAS). Only on 4qA chromosomes (and not 
on 4qB chromosomes) the last repeat unit is followed by a third exon which contains a PAS 
which can stabilize the DUX4 transcript from the last repeat unit. FSHD is related to chromatin 
relaxation (green wavy lines) of the D4Z4 repeat array, facilitating the stable expression of 
DUX4 from a 4qA chromosome. This chromatin relaxation is associated with reduced CpG 
methylation. FSHD1 is caused by a contraction of the D4Z4 repeat array to a size of 1-10 units. 
FSHD2 is caused by a variant in a chromatin modifier, most often SMCHD1. Variants in SMCHD1 
can also act as a modifier of disease severity in FSHD1.




SMCHD1 is an epigenetic regulator of D4Z4
SMCHD1 is an atypical member of the SMC gene superfamily of proteins, which are 
involved in chromosome organization and dynamics 60; 61. SMCHD1 contains a functional 
GHKL (gyrase, heat-shock protein 90, histidine kinase, MutL) type ATPase domain and 
a hinge domain flanked by a coiled-coil domain on both sides. The hinge domain is 
involved in homodimerization of SMCHD1 and essential for chromatin binding61; 62.
 Smchd1 was originally identified as regulator of epigenetic silencing in an 
N-ethyl-N-nitrosourea (ENU) mutagenesis screen in mice63. Female embryos 
carrying a homozygous nonsense variant in Smchd1 show mid-gestation lethality 
and a defect in X-chromosome inactivation64. X-chromosome inactivation ensures 
dosage compensation in female mammals, by epigenetic silencing of one of the two 
X-chromosomes. It is initiated by expression of Xist (X-inactive specific transcript) 
lncRNA, which covers the X-chromosome in cis and recruits PRC1 and PRC2. These 
complexes establish repressive histone modifications on the Xist bound X-chromosome 
to from facultative heterochromatin, resulting in silencing of most genes on the inactive 
X-chromosome65. Smchd1 has been shown to play an important role in methylation 
of CpG islands and gene silencing on the inactive X-chromosome64; 66; 67. Additionally, 
SMCHD1 interacts with XIST associated H3K27me3 domains and compacts the 
X-chromosome by an interaction with HBiX1 bound to HP1 associated H3K9me3 
domains68. Besides its role in X-chromosome inactivation, Smchd1/SMCHD1 is involved 
in silencing of several autosomal loci, including imprinted genes and the clustered 
protocadherin genes67; 69-71.
 With respect to FSHD, chromatin immunoprecipitation (ChIP) showed that SMCHD1 
binds directly to D4Z4 and this binding is reduced in muscle cells of FSHD2 patients55. 
Knockdown of SMCHD1 in control myotubes with a permissive D4Z4 allele activates 
DUX4 expression and increases DUX4 expression in FSHD1 myotubes55; 56. Conversely, 
moderate overexpression of SMCHD1 with lentiviral systems in FSHD1 and FSHD2 
myoblasts reduces DUX4 expression. Interestingly, SMCHD1 protein levels decrease 
during muscle cell differentiation, suggesting that muscle might be more prone to D4Z4 
derepression72. Together this indicates that SMCHD1 has an important role in silencing 
the D4Z4 repeat in somatic tissue such as skeletal muscle and that DUX4 derepression 
as observed in FSHD muscle is reversible.
Transcriptional (de)repression at D4Z4
Detailed knowledge about the mechanisms of (de)repression at D4Z4 is thought to 
be essential for the development of therapeutic strategies aimed at silencing DUX4 in 
FSHD patients. As discussed above, SMCHD1 has been identified as a key chromatin 
modifier for D4Z4. Besides SMCHD1, other chromatin modifiers which bind to D4Z4 
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include SUV39H1, HP1γ and cohesin. However, knockdown of these proteins did not 
increase DUX4 expression in primary myotube cultures72. Additionally, members of the 
PRC2 complex are also binding to D4Z4 in control and FSHD proliferating myoblasts73; 
74. Specifically in FSHD2 increased levels of H3K27me3 and the PRC2 protein SUZ12 
were detected compared to controls. Inhibition of a member of the PRC2 complex 
increased DUX4 expression but only in FSHD2 myotubes, indicating that although the 
epigenetic (mis)regulation of D4Z4 is highly similar in FSHD1 and FSHD2, there are also 
differences72.
 The transcription of small and long non-coding RNA fragments from D4Z4 also 
influences D4Z4 (de)repression. A lncRNA transcribed from the D4Z4 repeat was 
identified specifically in FSHD patients. This lncRNA, DBE-T (D4Z4 binding element 
transcript), recruits the H3K36 methyltransferase ASH1L (ASH1 like histone lysine 
methyltransferase) and activates DUX4 expression74. Small RNA fragments (siRNAs and 
miRNAs) are bidirectionally transcribed from the D4Z4 repeat in fibroblasts and muscle 
cells of controls and FSHD patients45. It was discovered that these siRNAs also contribute 
to D4Z4 silencing, since knockdown of DICER and AGO2 (argonaute2), components of 
the endogenous siRNA pathway, upregulates DUX4 expression in control muscle cells. 
On the other hand, exogenous siRNAs targeted against the region upstream of the DUX4 
transcription start site increase AGO2 recruitment and H3K9me2 at the D4Z4 repeat and 
repress DUX4 expression75.
 The opening of the chromatin structure at D4Z4 in FSHD patients might render the 
repeat more accessible for proteins that are not present at the repeat in controls. Two 
examples are PARP1 (poly(ADP-ribose) polymerase 1) and DNMT1, which interact with 
the DUX4 promoter only in immortalized myoblasts from an FSHD patient, but not in 
the myoblasts from an unaffected sibling. Treatment with PARP1 inhibitors can suppress 
DUX4 expression in these FSHD immortalized myoblasts, indicating that PARP1 might 
modulate DUX4 expression76.
DUX4 is a transcription factor toxic to skeletal muscle
Variegated DUX4 expression in skeletal myocytes is common to both forms of FSHD and 
is thought to be necessary for the disease to develop. DUX4 is a transcription factor, 
which is normally expressed in the luminal cells of the testis and in the thymus, and 
suppressed in most other somatic tissues3; 77. Because of the D4Z4 chromatin relaxation, 
sporadic DUX4 expression can be detected in a small and variable percentage of 
myonuclei from FSHD patients, and sometimes also at very low levels in some control 
muscle biopsies3; 78. How DUX4 expression leads to muscle weakness is under active 
investigation, but ectopic expression in myocytes leads to a complex cascade of events 
eventually leading to muscle cell death79. Close homologues of DUX4 have only been 




identified in primates and afrotheria80; 81. Nevertheless, overexpression of DUX4 induces 
cell death not only in human cell lines82, but also in adult mouse muscle,83 in Xenopus 
laevis84, in Zebrafish45; 83 and in Drosophila85. This DUX4 induced apoptosis seems to be 
dependent on P5383; 86. DUX4 contains a N-terminal double homeobox domain involved 
in DNA binding and a C-terminal activation domain. The N-terminal double homeobox 
domain can bind DNA in the absence of the C-terminal domain, but it lacks the ability 
to activate DUX4 target genes and its overexpression is not toxic87; 88. The C-terminal 
activation domain of DUX4 interacts with p300/CBP (CREB-binding protein) and DUX4 
might upregulate the expression of (part of ) its target genes by recruiting p300/CBP, 
which induces acetylation of H3K27 and activates transcription89.
 As DUX4 is a transcription factor, several studies analysed the transcriptional 
consequences of the presence of DUX4 in muscle cells. Differentially expressed genes 
include both direct targets of DUX4, as indicated by DUX4 binding sites identified 
by ChIP-sequencing, as well as indirect targets79; 87; 90. A comparison of transcriptional 
profiles of muscle cells expressing DUX4 from different origins (endogenous DUX4, 
lentiviral transduced DUX4, or doxycycline inducible DUX4) revealed highly correlated 
gene expression signatures. The transcriptional consequences of DUX4 expression 
include activation of germ line genes, suppression of the innate immune response, 
and disruption of RNA metabolism, as well as other pathways79; 87; 90. In DUX4 expressing 
myoblasts there is accumulation of alternative transcripts containing premature stop 
codons and aberrant spliced exons, which might be related to the inhibition of nonsense-
mediated decay (NMD) by DUX4, as its expression triggers the degradation of UPF1 (up-
frameshift protein 1), a central component of NMD79; 86. Since DUX4 is also a target of NMD, 
the inhibition of NMD stabilizes DUX4 mRNA and this feedback loop might contribute 
to the burst of DUX4 expression86. Overexpression of DUX4 in immortalized myoblast 
cultures also increases the level of reactive oxygen species and induces DNA damage, 
which possibly affects myogenic differentiation of FSHD myoblasts91. Furthermore, both 
endogenous and exogenous DUX4 expression in myotubes induce coaggregation of 
two DNA/RNA binding proteins FUS and TDP43, and disruption of the structure of some 
nuclear bodies (PML bodies and SC35 speckles)92; 93. These alterations in nuclear body 
structure might disturb (epi)genetic gene regulation in DUX4 expressing myotubes93. 
The contributions of these processes to FSHD pathology need to be studied further.
 Besides DUX4, other genes proximal to D4Z4, such as FRG1 (FSHD region gene 1), 
FRG2 (FSHD region gene 2) and FAT1 (FAT atypical cadherin 1) might also be deregulated 
in FSHD either by DUX4 directly or independently, or a combination thereof94-96. Their 
clinical relevance to disease warrants further investigation as some FSHD families 
genetically exclude a direct role for proximal 4qter genes43; 97; 98.




The high clinical variability in FSHD raises the question whether (epi)genetic factors 
influence disease severity. Indeed, in FSHD1, there is a rough inverse correlation between 
residual D4Z4 repeat array size and disease severity, which was recently confirmed in 
Korean and Chinese cohorts99; 100. Individuals with D4Z4 repeats of 7–10 units typically 
have milder phenotype or remain non-penetrant and have lower disease grades for 
their muscle biopsies101; 102. In addition, D4Z4 repeats of 7–10 units on disease permissive 
4qA chromosomes are found in 1–3% of the control population, illustrating the reduced 
penetrance of these alleles52; 53. However, unaffected carriers exist for smaller repeat sizes 
(1–3 units) as well, indicating that repeat size seems not always predictive for disease 
severity, which can only be partly attributed to somatic mosaicism103. Furthermore, in 
some FSHD1 families with borderline repeat sizes and D4Z4 hypomethylation, SMCHD1 
variants were identified that modify disease severity (Fig. 2). While carriers of both an 
FSHD1 sized allele and an SMCHD1 variant were typically severely affected, familial 
carriers of only one of these conditions showed a very mild phenotype56; 57.
 The relevance of the epigenetic state of the D4Z4 repeat for disease severity was 
shown in multiple studies, which use D4Z4 methylation as a measure of chromatin 
relaxation54; 104-106. A correlation between D4Z4 methylation and D4Z4 repeat array 
size was identified at different sites in the repeat using two methods: methylation 
sensitive Southern blotting and bisulfite sequencing. Digestion of the D4Z4 repeat 
with the methylation sensitive digestion enzyme FseI followed by Southern Blot is 
used to determine the methylation at the FseI site in a sequence identical to the DUX4 
promoter region of the most proximal unit of the D4Z4 repeats on chromosomes 4 
and 10 simultaneously55. A significant correlation between the total number of D4Z4 
repeat units on chromosomes 4 and 10 and the methylation level at this FseI site was 
found in PBMCs of controls, FSHD1 and FSHD2 patients54. With this correlation the 
methylation can be predicted based on repeat size. The Delta1 value is defined as the 
observed methylation minus the predicted methylation in controls. The delta1 value 
varies between -10% and 10% in controls and FSHD1 patients and is <-21% in FSHD2 
patients54.
 In contrast to Southern blotting, D4Z4 bisulfite sequencing enables the analysis 
of the methylation status of multiple CpGs simultaneously. The first study that used 
D4Z4 bisulfite sequencing identified specific regions in D4Z4 with reduced methylation 
in FSHD patients107. A recent study performed bisulfite sequencing specifically in the 
region immediately distal to D4Z4 on 4qA alleles and identified a correlation between 
D4Z4 methylation at a specific CpG (called ‘CpG6’) in the PAS region and the repeat 
array size of the 4qA allele. An additive effect of D4Z4 repeat array size and SMCHD1 
variants was seen in FSHD2 patients, which showed much lower methylation at this CpG 




compared to FSHD1 patients and controls with the same 4qA length106. Furthermore, a 
linear correlation was found between the age-corrected clinical severity score and the 
methylation at the FSHD allele in FSHD1 and FSHD2 patients (individuals with a 4qA 
and 4qB allele)106. These studies indicate that D4Z4 methylation is dependent on D4Z4 
repeat array size, and that FSHD2 patients have lower D4Z4 methylation than expected 
based on repeat array size.
 In addition, a significantly reduced Delta1 value was detected in affected but not 
in unaffected carriers of an FSHD1 sized allele of 7-10 units. This indicates that D4Z4 
methylation is lower than predicted based on the sizes of the repeats for affected carriers 
of a FSHD1 sized allele of 7-10 units54. In another study, bisulfite sequencing identified 
lower methylation levels in myocytes from FSHD1 patients compared to myocytes from 
unaffected relatives with an FSHD1 sized allele at a region upstream of the DUX4 open 
reading frame (DR1) and at the gene body in the distal D4Z4 repeat105. These studies 
emphasize that FSHD1 affected individuals are epigenetically more susceptible to DUX4 
expression and disease presentation. Indeed, myocytes from FSHD1 affected individuals 
were more responsive to treatment with compounds that relieve epigenetic repression 
of DUX4 than myocytes from their unaffected relatives105. It is possible that expression 
levels of, or polymorphisms in chromatin modifiers, such as SMCHD1, could influence 
this epigenetic susceptibility.
 For FSHD2, the size of the smallest permissive repeat is suggested to contribute 
to the epigenetic susceptibility to disease presentation54. In FSHD2 patients the 
D4Z4 methylation attributed to the smallest permissive allele correlates with disease 
severity, with shorter repeats being associated with lower methylation and a higher 
disease severity54. In addition, the nature of the SMCHD1 variant influences the extent 
of hypomethylation with open reading frame (ORF) preserving variants resulting in 
significantly lower D4Z4 methylation than ORF disrupting variants54. SMCHD1 forms 
homodimers through its hinge domain61; 62, and open reading frame preserving variants 
might result in malfunctioning dimers, which could explain why these variants have a 
more severe effect on methylation. Altogether, this suggests that FSHD1 and FSHD2 are 
representatives of the same disease spectrum, where a combination of the D4Z4 repeat 
array size and its epigenetic state influence disease severity.
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IMMUNODEFICIENCY CENTROMERIC INSTABILITY AND FACIAL 
ANOMALIES SYNDROME
Clinical characteristics
Immunodeficiency, centromeric instability and facial anomalies syndrome (ICF) is a rare, 
autosomal recessive disease. The first patients were described in two reports from the 
late 1970s and the acronym ICF was introduced in 1988108-110. The immunodeficiency of 
ICF patients is characterized by hypo- or a-gammaglobunemia (an absence or strong 
reduction of immunoglobulins), in the presence of circulating B-cells. However, only naive 
B-cells have been detected in blood of ICF patients, while memory B-cells were absent, 
which suggests a defect in B-cell maturation in ICF patients111. The immunodeficiency 
causes susceptibility to severe infections of the respiratory and/or gastro-intestinal tract, 
which can be fatal2. Most ICF patients are treated with immunoglobulin replacement 
therapy (intravenous immunoglobulin (IVIG)). In some patients with severe infections 
hematopoietic stem cell transplantation was successfully performed112; 113. Facial 
anomalies are observed in almost all patients, and most often include flat nasal bridge, 
hypertelorism, and epicanthus. Besides the immunodeficiency and facial anomalies, ICF 
patients often have a delay in motor and/or speech development2.
Centromeric instability
The cytogenetic hallmark of ICF is centromeric instability of chromosomes 1, 9, and 16. 
In mitogen stimulated lymphocytes of ICF patients, and at lower frequencies in other 
cell types, a variety of chromosomal anomalies involving the pericentromeric regions of 
mainly chromosomes 1 and 16 can be recognized. Chromosome 9 is involved to a lesser 
extent. These chromosomal anomalies include whole-arm deletions, pericentromeric 
breaks, multibranched chromosomes, and decondensed chromosomes114. Similar 
chromosomal anomalies can be found in lymphocytes cultures treated with 
demethylating agents, which provided the first clue that ICF patients suffer from a DNA 
methylation defect115. Indeed, ICF patients show hypomethylation of satellite repeats, 
which are highly abundant at the centromeric region of chromosomes 1, 9, and 16, and 
are involved in the chromosomal anomalies115; 116.
Genetic heterogeneity
Genetically ICF is a heterogeneous disease. The first gene defect for ICF was discovered 
in 1999 and is defined by recessive variants in the DNA methyltransferase 3B (DNMT3B) 
gene117; 118. However, only about half of the ICF patients can be explained by variants in 
DNMT3B (ICF1; OMIM 602900). Furthermore, DNMT3B variant-negative patients showed 




additional hypomethylation of alpha satellite DNA119, while hypomethylation of the 
D4Z4 macrosatellite repeat seems to be specific to ICF1 patients. In 2011 variants in the 
zinc-finger and BTB domain containing 24 (ZBTB24) gene were identified in the majority 
of DNMT3B variant negative patients (ICF2; OMIM 614064)50. Recently, variants in the cell 
division cycle associated 7 (CDCA7, ICF3; OMIM 616910) gene and variants in the helicase, 
lymphoid-specific (HELLS, ICF4; OMIM 616911) gene have been identified in ICF patients 
negative for both DNMT3B and ZBTB24 variants120.
ICF1
About 50% of the ICF patients carry recessive variants in DNMT3B (ICF1)2. DNMT3B is 
considered a de-novo methyltransferase, which is responsible for the establishment 
of DNA methylation during early development, together with DNMT3A and the 
stimulatory cofactor DNMT3L12. It contains a PWWP domain, an ADD (ATRX, DNMT3, 
DNMT3L) domain and a catalytic domain located at the C-terminus. The PWWP domain 
is involved in targeting of DNMT3B to chromatin marked by H3K36me3121. The ADD 
domain binds to histone H3 when it is unmethylated at lysine 4 (H3K4), this binding 
is blocked by H3K4me3122. Together these domains target the catalytic activity of 
DNMT3B to regions of the genome with H3K36me3 and without H3K4me312. Most ICF1 
variants are missense variants in the catalytic domain of DNMT3B, leading to reduced 
methyltransferase activity in vitro123; 124. Some patients carry a nonsense variant, but this 
is always combined with a missense variant2. This suggests that homozygous nonsense 
variants might be embryonic lethal, as is observed for homozygous Dnmt3b knockout 
mice. In Dnmt3b knockout embryos, but not in Dnmt3a knockout embryos, reduced 
methylation levels of centromeric minor satellite repeats were detected, indicating that 
these repeats are specific targets of Dnmt3b125. Mice carrying homozygous or compound 
heterozygous ICF1 variants show hypomethylation of three repetitive sequences: 
major satellite repeats, minor satellite repeats, and C-type retrovirus. Their methylation 
levels are however higher than in knockout mice indicating that mutated Dnmt3b 
retains some functionality126. Mice with homozygous or compound heterozygous 
hypomorphic Dnmt3b variants also show hypomethylation and upregulation of germ 
line genes as well as reduced viability, facial anomalies, runting phenotype, and T-cell 
apoptosis126-128. Interestingly, in contrast to ICF patients, no B-cell defect is detected 
in the ICF1 mouse models. Similarly, to the ICF1 mouse models, ICF1 patients show 
hypomethylation of various repetitive regions such as centromeric satellite repeats, 
Alu repeats116, interspersed LINE-1 repeat elements on the X-chromosome129, the D4Z4 
macrosatellite repeat, and NBL2 repeat130.




ICF2 patients carry recessive variants in ZBTB24, often nonsense variants, suggesting 
that these patients lack full length ZBTB24 protein. In addition, some patients with 
homozygous or compound heterozygous missense variants have been reported. In 
contrast to humans, where the complete absence of ZBTB24 seems to be compatible 
with life, a homozygous Zbtb24 BTB domain deletion mouse, which lacks functional 
Zbtb24 protein, was found to be embryonic lethal131.
 The function of ZBTB24 is largely unknown. ZBTB24 is a member of the BTB-ZF 
family of proteins and contains an N-terminal BTB domain suggested to be involved 
in dimerization and protein-protein interaction, an AT hook which is predicted to 
bind AT-rich sequences, and eight C-terminal zinc fingers, typically involved in DNA 
binding. Many BTB-ZF proteins are involved in the development of the immune system 
and they are thought to function as transcriptional suppressors. Recently, a role of 
ZBTB24 as transcriptional repressor was discovered in human B-cell line Raji cells, 
where downregulation of ZBTB24 upregulates the expression of two transcriptional 
factors (Interferon regulatory factor 4 (IRF-4) and B lymphocyte-induced maturation 
protein-1 (Blimp-1))132. However, a role for ZBTB24 as transcriptional activator of a subset 
of genes, most prominently the ICF3 gene CDCA7 was recently reported as well131. 
Mouse Zbtb24 was also shown to colocalize with HP1α, a heterochromatic protein, in 
NIH3T3 cells133, and it has a role in the maintenance of CpG methylation at centromeric 
repeat in MEFs120. These properties fit with the hypomethylation at centromeric and 
pericentromeric repeats in ICF2.
ICF3 and ICF4
The recent discovery of two new disease genes genetically confirmed ICF syndrome in 
8 families negative for DNMT3B and ZBTB24 variants. Homozygous variants in CDCA7 
were identified in four ICF families. These variants were all missense variants and affect 
residues near the first two zinc-finger motifs in the conserved carboxyterminal 4-CXXC-
type zinc finger domain120. The molecular function of CDCA7 is unknown, however some 
interaction partners and transcriptional activators of Cdca7 have been identified. Cdca7 
is a transcriptional target and interaction partner of Myc and is involved in neoplastic 
transformation134; 135. Cdca7 was also identified as a Notch target gene and contributes 
to hematopoietic stem cell emergence136. In mouse embryonic fibroblasts transiently 
depleted for Cdca7 a reduction of CpG methylation at minor satellite repeats was 
detected, indicating that Cdca7 also has a role in the maintenance of CpG methylation120. 
This is consistent with the hypomethylation detected in ICF patients.




 In four other ICF families recessive variants in HELLS were identified, including a 
missense variant, nonsense variants and an in frame deletion of an amino acid120. Two 
of the ICF4 patients carry homozygous or compound heterozygous nonsense variants 
in HELLS, suggesting that the absence of HELLS is compatible with human life120. This is 
in contrast to homozygous deletion of Hells in mice, which causes perinatal lethality137. 
HELLS is an ATP dependent chromatin remodelling protein of the SNF2 family of 
helicases and is involved in DNA methylation during development. HELLS/Hells is an 
interaction partner of DNMT3B/Dnmt3b, and in mouse embryonic stem cells Hells 
recruits Dnmt3b to repeat elements138-140. This implies a functional connection between 
the ICF1 and ICF4 genes in the establishment of CpG methylation at repeat elements, 
which is reduced in ICF patients. Additionally, transient depletion of Hells in mouse 
embryonic fibroblasts reduced CpG methylation at minor satellite repeats, suggesting 
that Hells has an additional role in the maintenance of CpG methylation120. There are 
still few genetically unexplained ICF patients, suggesting that there is at least one more 
gene ICF gene involved.
Functional studies 
Most functional studies on ICF syndrome have been performed on a limited set of 
samples, mainly of ICF1 patients and in a heterogeneous set of cell types. They include 
multiple studies aimed at defining methylation and expression profiles. Besides the 
hypomethylation of repetitive regions in ICF1 patients, there is a genome wide loss of 
methylation and upregulation of expression at various non-repetitive regions, including 
multiple coding genes involved in e.g. immune function, development, neurogenesis, 
and germ line pathways141-145. Hypomethylated positions were identified in both genic 
and intergenic regions as well as promoters141. For some hypomethylated genes a 
concomitant loss of repressive histone marks (H3K37me3 and H3K9me3) and increase 
in active histone marks (H3K4me3 and H3K9ac) was identified as well, indicating that 
the epigenetic changes in ICF1 syndrome are not limited to CpG hypomethylation142. 
In ICF1 patient cell lines hypomethylation of subtelomeric regions was associated with 
decreased telomere lengths in these patients146. Additionally, higher levels of H3K4me2 
and reduced levels of H3K9me3 were measured at subtelomeres, co-occurring with 
increased expression of the lncRNA TERRA (telomeric repeat containing RNA) that 
originates from subtelomeric regions146; 147. The genome wide loss of methylation is also 
present in induced pluripotent stem cells (iPSCs) derived from ICF1 patients. A global 
loss of non-CG methylation and a loss of CpG methylation was detected at some 
promoters and enhancers, as well as at large regions in the centromeric and subtelomeric 
regions. Almost all of the alterations remain present in iPSC-derived mesenchymal 
stem cells (MSCs), which suggests that induced pluripotent stem cells (iPSCs) might 
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be a useful tool to study ICF syndrome144. Although the telomeres in ICF1-iPSCs are 
elongated compared to their parental fibroblasts, high TERRA levels and subtelomeric 
hypomethylation were still present in ICF1-iPSCs. When iPSCs are differentiated to 
fibroblast-like cells, they maintain high TERRA levels and accelerated shortening of 
telomere148.
 Besides changes in methylation patterns, the nuclear architecture is also altered 
in ICF syndrome. The average area of juxtacentromeric heterochromatin from 
chromosome 1 and the association of these regions with the nuclear periphery were 
reduced in B-lymphoblastoid cell nuclei from an ICF1 and ICF2 patient compared to 
controls. The changes in nuclear organisation might contribute to alterations in gene 
expression independent of DNA methylation differences as exemplified by two genes 
from chromosome 1 that are upregulated in ICF and show reduced co-localisation 
with juxtacentromeric heterochromatin compared to controls149. Also in fibroblasts 
from a female ICF1 patients an altered nuclear localization of some genes at the 
inactive X chromosome was identified, including genes more distant from the site of 
hypomethylation150. The changes in the chromatin structure and nuclear architecture 
might be responsible for changes in replication timing. In ICF1 patient cell lines advanced 
replication timing of satellite 2151 and telomeres146, as well as genes in facultative 
(Inactive X-chromosome)152 and constitutive heterochromatin153, was detected.
 The functional studies did not yet reveal a plausible explanation for the immune 
defect, as well as other comorbidities. Furthermore, since almost all these studies were 
performed in ICF1 patient cells, the hypomethylation and expression profiles of different 
ICF subtypes cannot be compared to identify common changes which might play a role 
in the pathogenic mechanism.
OUTLINE OF THIS THESIS
This thesis focuses on expanding the mutation spectrum in chromatin modifiers 
involved in two epigenetic diseases that share a common feature of hypomethylation 
of repetitive DNA: FSHD and ICF syndrome. In chapters 2, 3 and 4 we expand the 
SMCHD1 mutation spectrum in FSHD2. In chapter 5 we identified a new FSHD2 gene, 
DNMT3B, which was previously shown to cause ICF syndrome. In chapter 6 we expand 
the mutation spectrum of ICF1 and ICF2.
 In chapter 2 we describe three FSHD2 families in which the proband carries two 
potentially damaging SMCHD1 variants. We investigated whether these variants 
were located in cis or in trans and whether they contribute to D4Z4 hypomethylation 
independently. In one of the families the variants were located in trans and contribute 




synergistically to D4Z4 hypomethylation and disease penetrance in FSHD2. This family 
also shows that carrying two SMCHD1 missense variants in trans is compatible with life 
in males and females.
 In chapter 3 we describe two FSHD2 families with a large deletion spanning several 
genes on chromosome 18p, including SMCHD1. These families show that a deletion of 
SMCHD1 can also cause FSHD2 and this might put 18p deletion carriers (with a deletion 
including SMCHD1) at risk of developing FSHD2. We identified D4Z4 hypomethylation 
in these 18p deletion cases and combined with the distribution of D4Z4 repeat array 
size and frequency of permissive alleles, we estimated that 1:8 of the 18p deletion cases 
is at risk of developing FSHD2.
 In chapter 4 we identified two FSHD families with a (deep) intronic variant 
in SMCHD1. In both families this results in alternative transcripts with premature 
stopcodons. In one family an intronic variant in SMCHD1 leads to the inclusion of the 
last 14 base pairs of intron 13 into the transcript, which is predicted to disrupt the 
open reading frame. In the other family a deep intronic variant in SMCHD1 creates a 
splice acceptor site, which results in exonisation of 53 base pairs from intron 34 into the 
transcript, which is predicted to disrupt the open reading frame. This variant modifies 
disease severity in an FSHD1 family.
 Because some FSHD2 cases cannot be explained by variants in SMCHD1, we 
performed whole exome sequencing in eight families with D4Z4 hypomethylation 
without a pathogenic SMCHD1 variant. In chapter 5 we describe that in two of 
these families we identified missense variants in DNMT3B segregating with D4Z4 
hypomethylation and increased penetrance of FSHD. Since recessive DNMT3B variants 
were previously shown to cause ICF1, we investigated ICF characteristics in these FSHD 
families, as well as DUX4 expression in ICF1 patients. We identified some mild epigenetic 
characteristics of ICF in one DNMT3B variant carrier from these FSHD families, but without 
an immunophenotype. Additionally, we identified DUX4 expression in myoblasts 
from one ICF1 patient as well as in MyoD transduced fibroblasts from two other ICF1 
patients. Both the short life expectancy of ICF1 patients as well as the absence of a short 
permissive allele in their parents might explain why a muscle phenotype has so far not 
been reported in ICF1 families.
 Finally, in chapter 6 we expand the mutation spectrum of the two most common 
types of ICF, ICF1 and ICF2. We describe seven new ICF1 cases from four different 
families, which carry in total six different DNMT3B missense variants, which have not 
previously been reported in ICF syndrome. Additionally, we described five ICF2 cases 
from five different families, including one ICF2 patient that carries a homozygous 
deletion including ZBTB24. This patient confirms that complete absence of ZBTB24 
protein is compatible with life. Additionally, we analysed the prevalence of the different 
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ICF subtypes in the literature and this study. This revealed that 56% of the cases have 
ICF1, 31% ICF2, 7% ICF3 and 7% ICF4. Interestingly, in ICF2, we noticed a gender bias, 
with 79% male patients and only 21% females. This suggests that ZBTB24 variants are 
more deleterious in females.
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DOUBLE SMCHD1 VARIANTS IN FSHD2: 
THE SYNERGISTIC EFFECT OF TWO SMCHD1 
VARIANTS ON D4Z4 HYPOMETHYLATION 
AND DISEASE PENETRANCE IN FSHD2
Van den Boogaard et al. 2016, European Journal of Human Genetics, 24(1)78-85




Facioscapulohumeral muscular dystrophy (FSHD) predominantly affects the muscles 
in the face, trunk and upper extremities and is marked by large clinical variability in 
disease onset and progression. FSHD is associated with partial chromatin relaxation 
of the D4Z4 repeat array on chromosome 4 and the somatic expression of the D4Z4 
encoded DUX4 gene. The most common form, FSHD1, is caused by a contraction of the 
D4Z4 repeat array on chromosome 4 to a size of 1-10 units. FSHD2, the less common 
form of FSHD, is most often caused by heterozygous variants in the chromatin modifier 
SMCHD1, which is involved in the maintenance of D4Z4 methylation. We identified 
three families in which the proband carries two potentially damaging SMCHD1 variants. 
We investigated whether these variants were located in cis or in trans and determined 
their functional consequences by detailed clinical information and D4Z4 methylation 
studies. In the first family both variants in trans were shown to act synergistically on D4Z4 
hypomethylation and disease penetrance, in the second family both SMCHD1 function-
affecting variants were located in cis while in the third family one of the two variants did 
not affect function. This study demonstrates that having two SMCHD1 missense variants 
that affect function is compatible with life in males and females, which is remarkable 
considering its role in X inactivation in mice. The study also highlights the variability 
in SMCHD1 variants underlying FSHD2 and the predictive value of D4Z4 methylation 
analysis in determining the functional consequences of SMCHD1 variants of unknown 
significance.
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INTRODUCTION 
Facioscapulohumeral muscular dystrophy (FSHD; OMIM 158900) is a common 
myopathy in adults, with a recently reported prevalence of ~1:8 0001. FSHD is clinically 
characterized by weakness of the facial, shoulder girdle, trunk and upper arm muscles, 
which can be asymmetric, and progresses to involve humeral, anterior lower leg muscles 
and pelvic girdle muscles2. The onset of the disease is typically in the second decade of 
life, but the disease progression and severity are highly variable3. 
The genetic forms identified thus far, FSHD1 and FSHD2, are clinically 
indistinguishable4. Both forms are associated with partial chromatin relaxation of the 
D4Z4 macrosatellite repeat array on the subtelomere of the long arm of chromosome 4 
and transcriptional derepression of the D4Z4 unit-encoded DUX4 retrogene in skeletal 
muscle5-9. DUX4 is a germ line transcription factor that is normally repressed in somatic 
cells7. Its expression in skeletal muscle activates genes involved in germ line and early 
stem cell development, as well as specific classes of repeat elements, and overexpression 
of DUX4 in somatic cells causes cell death10-12.
To cause FSHD, D4Z4 chromatin relaxation must occur on a specific genetic 
background of chromosome 4 (most often 4A161) that facilitates the production of 
stable DUX4 mRNA due to the presence of a polymorphic DUX4 polyadenylation 
signal distal to the D4Z4 repeat array8; 13. D4Z4 chromatin relaxation on non-permissive 
chromosomes lacking a DUX4 polyadenylation signal, do not cause FSHD in the absence 
of detectable levels of DUX4 mRNA8; 14.
Autosomal dominant FSHD1 is the most common form of FSHD (>95%), in which 
D4Z4 chromatin relaxation and DUX4 expression are caused by a contraction of the 
D4Z4 repeat array to a size of 1-10 units15; 16. In the uncommon form of FSHD (FSHD2), 
D4Z4 chromatin relaxation occurs in the absence of D4Z4 repeat array contraction5. In 
FSHD1 chromatin relaxation and CpG hypomethylation are restricted to the contracted 
allele, whereas in FSHD2 chromatin relaxation and CpG hypomethylation occur at the 
D4Z4 repeat arrays of both copies of chromosome 4, and in the highly homologous 
repeat arrays on chromosome 104; 9.
Heterozygous variants in the structural maintenance of chromosomes flexible hinge 
domain containing 1 (SMCHD1) gene on chromosome 18 account for the majority of 
FSHD2 cases14. SMCHD1 is an atypical member of the SMC gene superfamily, a family 
of proteins which is involved in chromosome condensation and cohesion, genome 
maintenance and gene regulation17-19. Chromatin immunoprecipitation (ChIP) studies 
showed the presence of SMCHD1 on the D4Z4 array, and its reduced binding to D4Z4 
in SMCHD1 mutation carriers14. SMCHD1 variants can also modify the disease severity in 
FSHD1 families, explaining some of the clinical variability seen in FSHD20.
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As a measure of D4Z4 chromatin relaxation, often D4Z4 methylation is used. We 
have established a reliable and informative measure of D4Z4 methylation by measuring 
the methylation of all D4Z4 arrays simultaneously at a unique methylation-sensitive 
restriction site (FseI) in the D4Z4 unit14. The methylation level at this site is significantly 
lower in FSHD2 compared to both FSHD1 and controls, and a threshold of 25% was 
established for FSHD214. Recently we showed that D4Z4 methylation level at this site 
is repeat array size-dependent21. We introduced a new methylation parameter, Delta1, 
which represents the difference between the experimentally observed methylation and 
the predicted methylation level based on repeat size in controls. In SMCHD1 mutation 
carriers the average Delta1 score is highly negative ranging between -20 and -45 
suggesting a strong contribution of the variant to D4Z4 hypomethylation21. Accordingly, 
a second model was then fitted to predict the methylation in SMCHD1 variant carriers, 
which resulted in the Delta2 score. For SMCHD1 variants that preserve the open reading 
frame (ORF) a mean Delta2 score of -1.8% was found, which is significantly lower than the 
mean Delta2 of ORF-disrupting variants (mean 2.7%). This suggests that ORF-preserving 
variants are more deleterious for the maintenance of a repressed D4Z4 chromatin state 
in somatic cells21. 
Several studies have so far identified disease causing variants in SMCHD1 in 
approximately 70 FSHD2 families. Heterozygous disease causing SMCHD1 variants are 
distributed over the entire SMCHD1 locus and include splice site, insertion-deletion, 
missense and nonsense variants14; 20-24. We have shown that a combination of the size 
of the permissive D4Z4 array and the type of SMCHD1 variant together determine 
the epigenetic susceptibility to disease presentation21. Until now, only heterozygous 
SMCHD1 variants, which are dominant in combination with a permissive haplotype, 
have been reported. Here we describe three families in which two SMCHD1 variants 
which potentially affect function were identified in each proband. For each family we 
investigated whether the variants were located in cis or in trans and analyzed if both 
variants were contributing to D4Z4 hypomethylation independently and what the 
effect was on the FSHD phenotype.
MATERIAL AND METHODS
Subjects
Three families (Fig. 1) were studied after informed consent and the study protocol was 
approved by the relevant institutional review boards. Clinical assessment of disease 
severity was performed using the 10 point (0: unaffected – 10: wheelchair bound) 
standardized Clinical Severity Score (CSS)25.
15127-vandenboogaard-layout.indd   46 09/01/2018   15:26
47




% D4Z4 methylation % Delta1 (Δ1)
% Delta2 (Δ2)
D4Z4 units 4q allele 1 D4Z4 units 4q allele 2


























































FIGURE 1. Pedigrees of the three FSHD2 families presented in this study. Shown are families 
with information about D4Z4 methylation, Delta scores, sizes of 4q-linked D4Z4 repeats, clinical 
severity scores at age of examination, and SMCHD1 variants. Key is shown below. N/A: not 
available. 
The first family (Rf947) consists of a single patient living in the United States of 
America. We were not able to get additional family information from this individual. 
The second family (Rf1414) is a Dutch family, with one individual diagnosed with FSHD. 
After the identification of the two SMCHD1 variants in the proband, additional clinical 
information and blood samples from two relatives could be collected. The third family 
(Rf385) is a Spanish family, with one individual diagnosed with FSHD and four relatives.
D4Z4 repeat sizing, haplotype analysis and methylation analysis
For genotyping high quality genomic DNA was isolated from peripheral blood 
mononucleated cells (PBMCs). The sizing of the D4Z4 repeats on chromosomes 4 and 10 
was done by pulsed field gel electrophoresis (PFGE) as described previously8. Haplotype 
analysis was done by hybridization of PFGE blots with probes A and B in combination 
with SSLP analysis according to previously described protocols8.
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For D4Z4 methylation analysis genomic DNA was double digested with EcoRI 
(Thermo Fisher Scientific inc., Waltham, MA, US) and BglII (Fermentas, Thermo Fisher 
Scientific) overnight at 37 °C, and cleaved DNA was purified using PCR extraction 
columns (NucleoSpin®  Gel and PCR Clean-up, Machery-Nagel/BIOKÉ, Leiden, The 
Netherlands). Purified DNA was then digested with FseI (New England Biolabs/BIOKÉ) 
for ≥4 h, separated by size on 0.8% agarose gels, transferred to a nylon membrane 
(Hybond XL, Amersham, GE Healthcare, Diegem, Belgium) by Southern blotting and 
probed using the p13E-11 32P labeled probe. Probe signals were quantified using the 
Storm 820 Phosphorimager (Amersham) and ImageQuant™ TL software (Amersham). 
The signal from the 4,061-bp fragment (methylated) was divided by the total amount 
of hybridizing fragments at 4,061 bp and 3,387 bp (unmethylated) to yield the average 
percentage of methylated FseI sites within the most proximal D4Z4 unit on all four D4Z4 
arrays. The Delta1 and Delta2 scores were calculated as described in Lemmers et al. 2014.
SMCHD1 variant analysis
For the index cases SMCHD1 variant analysis was performed by Sanger sequencing after 
PCR amplification of all coding exons using intronic primers at a position of at least 
50 nucleotides from the splice donor or acceptor site. The SMCHD1 genomic sequence 
was obtained from Ensemble (build 37) [GRCh37:18:2655286:2805615] (Genomic 
Refseq: NG_031972.1, Transcript Refseq: NM_015295.2). Exons were numbered like in 
NG_031972.1 and primers were published previously21. The functional consequences of 
variants were predicted using Alamut Visual version 2.4 (Interactive Biosoftware, Rouen, 
France). Identified variants are submitted to the Leiden Open Variation Database (http://
databases.lovd.nl/shared/individuals/SMCHD1: submission IDs 00028967- 00028973)
For individual 385-203 Sanger sequencing of exons 24 and 45 in relatives was 
used to identify if the two SMCHD1 variants were located in cis or in trans. To identify 
if the two SMCHD1 variants found in individual 947-201 and individual 1414-201 were 
present on different alleles, both alleles were PCR amplified and then cloned in a TOPO 
vector (Zero Blunt® TOPO® PCR Cloning Kit, Invitrogen by Life technologies, Bleiswijk, 
The Netherlands).
For individual 947-201 SMCHD1 exon 21 was PCR amplified and cloned in pCR™-
Blunt II-TOPO® vector and transformed in DH5α heat shock competent cells (Subcloning 
Efficiency™ DH5α™ Competent Cells, Invitrogen™, Life Technologies). Multiple clones 
were analyzed, by sequencing their insert, to find clones containing either of the alleles.
For individual 1414-201 a long range PCR (Phusion® High-Fidelity DNA Polymerase, 
Phusion® GC Buffer Pack, New England Biolabs) from SMCHD1 exon 25 to exon 28 was 
performed (primers 25F + 28R, product 8708 bp), and product ends were ligated using 
T4 DNA Ligase (Thermo Scientific). An additional PCR was performed using the SMCHD1 
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exon 28F and exon 25R primers to amplify the artificially fused exons 25 and 28, this PCR 
product was cloned in the pCR™-Blunt II-TOPO® vector and transformed in DH5α heat 
shock competent cells. Multiple clones were analyzed, by sequencing their insert, to 
find clones containing either of the amplified alleles.
RNA analysis
From individual 947-201 RNA was isolated from a PAXgene Blood RNA Tube using the 
PAXgene Blood RNA Kit (PreAnalytiX, GmbH, Hombrechtikon, Switzerland). cDNA was 
synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) 
using random hexamer primers. Reverse transcriptase PCR was performed using primers 
2481F (5’-CATGGAGGAAAATGGCCTTA-3’) and 2981R (5’-TTCAGTCGACGAGGGTGAC-3’) 
located in exon 18 and exon 23, respectively. Subsequently, PCR products were 
separated by size on 2% agarose gels and PCR products were gel purified and analyzed 
by Sanger sequencing.
RESULTS 
Two SMCHD1 variants in cis in Rf947
Individual 201 of Rf947 was suspected of FSHD based on physical examination with a 
clinical severity score (CSS) of 7 at the age of 71 (Fig. 1)25. Genetic analysis showed that he 
carries a permissive allele of 13 D4Z4 units and the D4Z4 methylation analysis revealed 
a methylation level of 9% (Delta1 score -28%), which is consistent with the diagnosis 
of FSHD2. SMCHD1 Sanger sequencing identified two SMCHD1 variants in exon 21 
in individual 947-201 (Table 1). The first variant (c.2656C>T p.Arg886*) is a nonsense 
substitution that is predicted to result in a premature stop codon. The second variant 
(c.2700+1G>T) is a splice donor site variant, which is predicted to result in the skip of 
exon 21 by multiple splicing predictors (MaxEnt, NNSPLICE and HSF). Both variants have 
not been reported previously.
To investigate if the two variants in individual 947-201 were located in cis or in trans, 
genomic DNA of SMCHD1 exon 21 was PCR amplified and cloned. Sanger sequencing 
of individual exon 21 PCR clones showed that both variants were located on the same 
allele (Fig. 2A). cDNA analysis by an RT-PCR from SMCHD1 exon 19 to exon 23, followed 
by Sanger sequencing showed the presence of two PCR products representing wild type 
transcript, and the mutant transcript, which lacks exon 21 (Fig. 2B,C). This confirms that 
the splice donor site variant c.2700+1G>T results in a skip of exon 21 (r.2604_2700del). 
Skipping of exon 21 neutralizes the p.Arg886* nonsense variant but will result in the 
disruption of the ORF by a premature stop codon in exon 22. The intensity of the PCR 
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products suggests that wild type and mutant allele are equally expressed. In contrast to 
previous findings where disrupting ORF variants seem to result in haploinsufficiency21, 
this mutant allele might not be subject to nonsense mediated mRNA decay, and possibly 
a truncated protein will be produced.















Rf947 Nonsense Exon 21 g.2724949C>T c.2656C>T p.Arg886* -
Rf947 5’ splice site Exon 21 g.2724994G>T c.2700+1G>T - r.2604_
2700del
Rf1414 5’ splice site Exon 25 g.2732490_
2732494del 
c.3276_3276+4del - -
Rf1414 Missense Exon 28 g.2740724G>A c.3538G>A p.Gly1180Arg -
Rf385 Missense Exon 24 g.2729300T>G c.2941T>G p.Tyr981Asp -
Rf385 Missense Exon 45 g.2784496C>G c.5596C>G p.Arg1866Gly -
Two SMCHD1 variants in trans in Rf1414 of which one affects function
Individual 201 of Rf1414 was suspected of FSHD based on physical examination with a 
CSS of 7 at the age of 49 (Fig. 1). Genetic analysis showed that he carries a permissive 
allele of 13 units and the D4Z4 methylation analysis revealed a methylation level of 6% 
(Delta1 score -37%), supportive of FSHD2.
SMCHD1 Sanger sequencing identified two SMCHD1 variants in individual 1414-
201, one located in exon 25 (c.3276_3276+4del) and the other in exon 28 (c.3538G>A 
p.Gly1180Arg) (Table 1). Deletions in the 5’ splice site of exon 25 were previously reported 
in eight other FSHD2 families suggesting it to be a mutation hotspot21; 24. Previous RNA 
analysis of an independent FSHD2 family with a c.3276_3276+1del variant showed that 
this variant results in both cryptic splicing and in complete skipping of exon 25, both 
with retention of the ORF21. The same splice effect is expected for the c.3276_3276+4del 
variant in individual 1414-201. The variant in exon 28 has not been reported previously. 
The missense predictions of SIFT and MutationTaster defined the variant in exon 28 as 
deleterious and disease causing, respectively, whereas Align GVGD gives a score of C15 
which indicates that is not very likely that the variant interferes with protein function 
(Table 2).
15127-vandenboogaard-layout.indd   50 09/01/2018   15:26
51


































exon 20 exon 21
exon 20 exon 22
GT T T T T T T T T T T T T TG GG G GGG G G GG GA A A A A A A A A A A A A AC C C C C C C C C C
GT T T T T T T T T T T TG GG G GGG G G GG GA A A A A A A A A A AA A AC C C C C C C C C CC G
A A A A A A A A A A A ACCCC C C CGG G GGGG GT TT T T T T T T TT T T T T T
A A A A AACCCC C GG GGG T TT T T AAT T T T T T T TC CCG GGA A A A A A
GT T T T T T T T T T T TG GG G GGG G G GG GA A A A A A A A A A AA A AC C C C C C C C C CC GRef. 
FIGURE 2. Two SMCHD1 variants in cis in Rf947. (a) Sanger sequence tracks from two clones 
showing the different SMCHD1 alleles of individual 947-201. Allele 1 contains the two variants 
in exon 21 at positions c.2656C>T and c.2700+1G>T, indicated with the arrows. Allele 2 contains 
the reference nucleotides at these positions. (b) RT-PCR of SMCHD1 with primers in exon 18 
and exon 23 for a control and individual 947-201. The expected PCR product size for wild type 
transcript is 491 bp, additionally there is a smaller PCR product for 947-201, indicating an 
alternatively spliced mutant transcript. (c) Sanger sequence tracks of the wild type and mutant 
RT-PCR products, showing skipping of exon 21 in the mutant transcript. 
To investigate if the two variants were located on the same allele, a long range 
PCR of SMCHD1 exons 25-28 was performed. This PCR product was circularized and an 
additional PCR was performed to amplify the fused exons 25 and 28. The PCR product 
was cloned in a TOPO vector and individual clones were sequenced demonstrating that 
the two variants are located on different alleles (Fig. 3).
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Conservation (PhyloP) Moderate (4.16) Moderate (2.38) Weak (1,09)
Grantham distance Moderate (125) Large (160) Moderate (125)
Align GVGD C15 (GV: 206.04 - GD: 
124.98)
C65 (GV: 0.00 - GD: 
159.94)
C65 (GV: 0.00 - GD: 
125.13)
SIFT Deleterious (Score:0) Deleterious (Score:0) Deleterious (Score:0)
Mutation taster Disease causing  
(p-value: 0.999)
Disease causing  
(p-value: 0.689)








A A A A A A AC C CT T TG G GG A A TT A A G AT T TC CC A AT
Ref.
A A A A A A AC C CT T TG G GA
A A A A A A AC C CT T TG G GG
A A T TA A A G T A A GT AT C T
A A T TA A A G T A A GT AT C T
FIGURE 3. Two SMCHD1 variants in trans in Rf1414. Sanger sequence tracks from two clones 
showing the different SMCHD1 alleles of individual 1414-201. Allele 1 contains the variant in 
exon 25 (c.3276_3276+4del) and allele 2 contains the variant in exon 28 (c.3538G>A), both 
indicated with an arrow. 
To establish if both variants affect function, two additional family members were 
clinically evaluated and genetic analysis was performed. Sanger sequencing showed that 
the mother (1414-102) of individual 1414-201 carries the variant in exon 28. She shows 
no FSHD phenotype (CSS of 0 at age of 78) and has no FSHD permissive chromosome. 
D4Z4 methylation analysis indicated that her D4Z4 methylation level (62%, Delta1 score 
18%) is within the normal range (Fig. 1). The sister of the index case (1414-202) does 
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not carry either of the SMCHD1 variants, no D4Z4 hypomethylation (59%, Delta1 score 
8%) and had no clinical signs of FSHD (CSS of 0 at age of 53). Information about the 
father (1414-101) of individual 1414-201 was not available. This suggests that although 
individual 1414-201 carries two SMCHD1 variants, only the variant in exon 25 causes 
D4Z4 hypomethylation and is causal to FSHD.
Two SMCHD1 variants in trans in Rf385 with additive effect 
Individual 203 of Rf385 was suspected of FSHD based on physical examination with a 
CSS of 8 at age 42 (Fig. 1). Genetic analysis showed that he carries a permissive allele of 
27 D4Z4 units and the D4Z4 methylation analysis revealed a methylation level of 5% 
(Delta1 score -39%), which is consistent with the diagnosis of FSHD2.
One of the sisters (385-206) of the index case suffered from a meningitis in childhood 
and she is mentally disabled. Furthermore she broke both her arms and a leg in the past 
and the neurologist was unable to conclusively establish the clinical diagnosis of FSHD. 
However, she does carry one permissive allele and D4Z4 methylation analysis revealed 
a methylation level of 1% (Delta1 score -37%), which is suggestive of FSHD2. 
The other sister (385-202) does not show symptoms of FSHD with a CSS of 0 at age 
38. She does carry two non-permissive alleles and D4Z4 methylation analysis revealed 
a methylation level of 24% (Delta1 score -9%), which is higher than the Delta1 range 
between -20% and -45% observed in carriers of an SMCHD1 variant that affects function21. 
The father (385-101) and mother (385-102) of 385-203 do not show symptoms of FSHD, 
having a CSS of 0 at age 70 and CSS of 0 at age 67, respectively. The mother (385-102) 
carries one permissive allele and D4Z4 methylation analysis revealed a methylation 
level of 10% (Delta1 score -31%), suggestive of FSHD2. The father (385-101) carries two 
non-permissive alleles and D4Z4 methylation analysis revealed a methylation level of 
20% (Delta1 score -25%). 
SMCHD1 Sanger sequencing identified two SMCHD1 variants in 385-203 and his 
sister (385-206) (Fig. 4). The first variant is a missense variant in exon 24 (c.2941T>G, 
p.Tyr981Asp), the second variant is a missense variant in exon 45 (c.5596C>G 
p.Arg1866Gly) (Table 1). Both variants have not been reported previously. The father 
(385-101) carries the SMCHD1 variant in exon 24, and the mother (385-102) carries the 
SMCHD1 variant in exon 45 (Fig. 4). This shows that both variants are located on different 
alleles. The other sister (385-202) does not carry either of the SMCHD1 variants. 
The missense predictions of SIFT and MutationTaster predict both variants as 
deleterious and disease causing, respectively. The Align GVGD scores of C65 also 
indicate that the variants are both likely to interfere with protein function (Table 2). 
Additionally, both variants are individually associated with D4Z4 methylation levels and 
Delta1 scores in the FSHD2 range. However, D4Z4 methylation levels and Delta1 scores 
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are more strongly reduced in the two family members with both variants than in the 
single variant carriers. This indicates that the effect of the variants is additive and that 












AA ACC C T T TTTT TT G GG A A A A A AC CT T TTGG G G G
AA ACC C T T TTTT TT G GG
AA ACC C T T TTTT TT G GG
G
AA ACC C T T TTTT TT G GG
G
AA ACC C T T TTTT TT G GG
A A A A A ACT T TTGG G G G
A A A A A AC CT T TTGG G G G
A A A A A AC CT T TTGG G G G





AA ACC C T T TTTT TT G GG A A A A A AC CT T TTGG G G GRef.
FIGURE 4. Two SMCHD1 variants in trans in Rf385. Sanger sequence tracks from Rf385 family 
members showing that the two variants are located in trans. Individuals 385-203 and 385-
206 carry both SMCHD1 variants (c.2941T>G and c.5596C>G), both indicated with an arrow. 
Individual 385-101 carries only the SMCHD1 variant in exon 24. Individual 385-102 carries only 
the SMCHD1 variant in exon 45. Individual 385-202 carries the reference nucleotide for both 
variants. 
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DISCUSSION
In this study we analyzed three FSHD2 families in which two SMCHD1 variants that 
potentially affect function were found in each proband. Of the six SMCHD1 variants 
described here, one was reported previously, one we demonstrated to be neutral based 
on segregation analysis, and the other four variants are novel SMCHD1 variants that 
affect function. 
In individual 947-201 two variants in exon 21, separated by only 45 nucleotides, 
were identified on the same allele. Multiple variants in close proximity are seen 
more often and might result from chronocoordinate events due to transient error-
prone conditions26-29. In this case, both variants could individually be expected to 
affect function. The first variant (c.2656C>T) is a nonsense substitution, which will 
cause reading frame interruption by a premature stop codon. The second variant 
(c.2700+1G>T) is located in the splice donor site of exon 21 and this variant is predicted 
to cause skipping of exon 21. mRNA analysis revealed that the splice donor site variant 
c.2700+1G>T indeed results in a skip of exon 21. The skipping of exon 21 will disturb 
the ORF, resulting in a premature stop codon in exon 22. The intensity of the mutant 
transcript on gel indicates that this may not lead to nonsense mediated mRNA decay 
but we were unable to study the variant at the protein level. The mean Delta2 score 
for ORF disrupting variants is 2.7%, while it is -1.8% for ORF preserving variants21. The 
Delta2 score of 947-201 is 0%, which in this case is inconclusive. With the skipping of 
exon 21, the nonsense substitution c.2656C>T has no effect on the transcript. However, 
if this variant would be present independently, it would also disrupt the ORF, probably 
resulting in hypomethylation and an FSHD phenotype.
In individual 1414-201 two variants on different alleles were identified. Although 
the missense substitution in exon 28 was predicted to affect function by SIFT and 
MutationTaster (but not by Align GVGD), segregation analysis showed that this variant 
does not independently cause D4Z4 hypomethylation, and is therefore likely a neutral 
variant, even on a FSHD-permissive background. The second variant found in individual 
1414-201 is a splice donor site variant in exon 25. Splice donor site variants in exon 
25 have already been reported in eight other FSHD2 families to segregate with D4Z4 
hypomethylation and disease presentation, confirming the functional consequences of 
this variant21; 24. 
In individual 385-203 two variants on different alleles were detected. Both variants 
are predicted to affect function by SIFT, MutationTaster and Align GVGD. In accordance, 
both variants cause D4Z4 hypomethylation independently, as observed in the parents 
of 385-203. In this family, the combination of both variants further decreases the Delta1 
score at D4Z4 from -25% in the father (385-101) and -31% in the mother (385-102), 
which both carry one SMCHD1 variant, to -39% in the patient (385-203) and -37% in his 
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sister (385-206), both double SMCHD1 variant carriers (Fig. 1). This suggests a synergistic 
effect of both variants. The other sister (202) has a Delta1 score of -9%, indicating that she 
has moderate D4Z4 hypomethylation, independent of an SMCHD1 variant. Therefore, 
the data are consistent with an additive effect of having one or two SMCHD1 missense 
variants on D4Z4 methylation. This additive effect is also shown by the Delta2 scores, 
which are reduced in 385-203 (-7%) and 385-206 (-9%), which carry both missense 
variants, compared to the father (7%) and mother (-1%). 
The synergistic effect of both variants also explains the very low D4Z4 methylation 
levels and severe FSHD phenotype of individual 385-203. It is unfortunate that it is not 
possible to establish whether the sister 385-206 is affected with FSHD. The father (385-
101) carries two non-permissive D4Z4 alleles, which explains why he is not affected with 
FSHD. In regards to the mother (385-102), the size of her permissive allele (27 units) 
might explain why she is not affected with FSHD, despite her SMCHD1 variant and D4Z4 
hypomethylation. In 2010, de Greef et al. showed that the average size of the shortest 
permissive allele in FSHD2 is 16 units, which is much shorter than the average of 28 units 
found in control individuals, which was confirmed in a later study4; 21. The permissive 
allele in the proband (385-203) and his mother (385-102) is 27 units, relatively long for 
FSHD2. This might partially explain why the mother does not show an FSHD phenotype 
and why two SMCHD1 variants are necessary in this family to present FSHD symptoms. 
However, it is also known that there are FSHD2 patients carrying a single SMCHD1 
variant and a single permissive allele of as much as 40 units21.
Furthermore, variability in clinical representation is a hallmark of FSHD, which is 
seen both within and between families, and more often in females than in males30-32. 
Some, but not all, of this variability can be explained by the size of the permissive D4Z4 
repeat and presence and type of an SMCHD1 variant21. Both variants in this family 
are ORF preserving variants, which have in general a more profound effect on D4Z4 
methylation level than ORF disrupting variants21.
In the mouse, Smchd1 has a role in the establishment and maintenance of 
CpG methylation of a subset of genes on the inactive X-chromosome and in the 
expression of several autosomal gene clusters which are monoallelicly expressed33-37. 
Female homozygous MommeD1 mice, which completely lack Smchd1 protein, die at 
midgestation because of a failure in X inactivation38. Family Rf385 shows that having 
two SMCHD1 copies with a missense variant is viable, both in males and in females. 
This suggests that either SMCHD1 is not essential in human or, more likely, that the 
variants in family Rf385 only partially abrogate SMCHD1 protein function. This may also 
be true for the other variants found in FSHD2 patients, because so far no comorbidities 
for FSHD2, with regard to SMCHD1 function, have been identified. 
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This report describes four new SMCHD1 variants which affect function and a neutral 
variant, in addition to the approximately 70 variants that already have been identified 
since the discovery of SMCHD1 as the most common FSHD2 gene in 2012. This is the 
first report of families with individuals carrying two SMCHD1 variants and this study 
highlights the usefulness of D4Z4 methylation analysis to determine the functional 
consequences of SMCHD1 variants. These families highlight the variability in SMCHD1 
variants underlying FSHD2. In one of the three families both variants contribute 
separately to the disease, as is reflected by the Delta1 and Delta2 scores in this family 
and the penetrance of the disease. Importantly, this family shows that a combination of 
two ORF-preserving variants in SMCHD1 is compatible with life.
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Facioscapulohumeral muscular dystrophy (FSHD) is most often associated with 
variegated expression in somatic cells of the normally repressed DUX4 gene within the 
D4Z4 repeat array. The most common form, FSHD1, is caused by a D4Z4 repeat array 
contraction to a size of 1-10 units (normal range 10-100 units). The less common form, 
FSHD2, is characterized by D4Z4 CpG hypomethylation and is most often caused by loss 
of function mutations in the structural maintenance of chromosomes hinge domain 
1 (SMCHD1) gene on chromosome 18p. The chromatin modifier SMCHD1 is necessary 
to maintain a repressed D4Z4 chromatin state. Here we describe two FSHD2 families 
with a 1.2 Mb deletion encompassing the SMCHD1 gene. Numerical aberrations of 
chromosome 18 are relatively common and the majority of 18p deletion syndrome (18p-) 
cases have, like these FSHD2 families, only one copy of SMCHD1. Our finding therefore 
raises the possibility that 18p- cases are at risk of developing FSHD. To address this 
possibility, we combined genome wide array analysis data with D4Z4 CpG methylation 
and repeat array sizes in individuals with 18p- and conclude that approximately 1:8 18p- 
cases might be at risk of developing FSHD.
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Individuals with facioscapulohumeral muscular dystrophy (FSHD; MIM 158900 [FSHD1] 
and MIM 158901 [FSHD2]) have progressive and often asymmetric muscle weakness 
affecting the face, shoulder, and upper arms, followed by involvement of the distal and 
proximal lower extremities1; 2. These symptoms are associated with a higher probability 
of skeletal muscle expression of the DUX4 retrogene (OMIM 606009) which is normally 
repressed in somatic tissue3. There are at least two genetically distinct causes of 
FSHD that are clinically indistinguishable. The most common form, FSHD1, is caused 
by a variant of the polymorphic D4Z4 macrosatellite repeat array on chromosome 
4 that is between 1 and 10 units4. In unaffected individuals this polymorphic repeat 
array ranges between 11-100 D4Z4 units and is heavily CpG methylated in somatic 
tissue thereby repressing expression of the region5. The shorter array in individuals 
with FSHD1 is insufficient to maintain the repressed chromatin state necessary for 
sustaining repression of the DUX4 retrogene expression. The less common form, FSHD2, 
is also characterized by a partial loss of CpG methylation at D4Z4 but with repeat array 
sizes > 10 units and is usually caused by mutations in the structural maintenance of 
chromosomes hinge domain 1 (SMCHD1) gene (OMIM 614982) on chromosome 18p5-7. 
SMCHD1 is a chromatin modifier that binds to the D4Z4 repeat array and is necessary 
to maintain a repressed D4Z4 chromatin state in somatic cells. Each of the 3,3kb large 
D4Z4 units contains a copy of the double homeobox 4 (DUX4) retrogene8. In FSHD1, 
with the short D4Z4 repeat array, or in FSHD2 with heterozygous SMCHD1 mutations, 
either cause leads to a partial derepression of the D4Z4 repeat array in somatic cells. This 
derepression is marked by D4Z4 hypomethylation, a partial loss of repressive chromatin 
marks and other chromatin changes and the sporadic expression of DUX4 in a small set 
of muscle nuclei5; 9-11.
 However, either mechanism; D4Z4 short repeat sizes, or SMCHD1 mutations, 
leading to depression of D4Z4 by themselves are not sufficient to cause FSHD. The D4Z4-
embedded DUX4 retrogene requires a polyadenylation signal in the 3’ untranscribed 
region to produce a stable transcript and hence DUX4 protein in somatic cells12. This 
DUX4 polyadenylation signal can only be found immediately distal to the last DUX4 
copy, but its existence is polymorphic in the population and is only found on 4qA-type 
chromosomes. 4qB chromosomes, that are equally common, or 10q chromosomes 
that contain a highly homologous copy of the D4Z4 repeat array, do not have a DUX4 
polyadenylation signal12-14. Thus, digenic inheritance of a short D4Z4 repeat array in cis 
with a DUX4 polyadenlylation signal in FSHD1, or a heterozygous SMCHD1 mutation and 
a DUX4 polyadenylation signal in FSHD2, are both mechanisms for the development of 
FSHD6; 12.
 We previously reported that the average repeat array size of the 4qA (i.e. DUX4 
producing) chromosome in FSHD2 patients is most often between 11-16 units, which is 
at the lower end of the repeat size spectrum of 4qA chromosomes in control individuals 
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(Fig. S1)15; 16. We define FSHD2 patients by a methylation level of <25% measured by 
Southern blotting at the methylation-sensitive FseI restriction site in D4Z4, a threshold 
that has been instrumental in identifying SMCHD1 as FSHD2 disease gene6; 16; 17. In our 
recent SMCHD1 mutation screen in affected individuals with FseI methylation levels 
<25%, we showed that mutations that do not disrupt the open reading frame (ORF) are 
more deleterious than those that introduce a premature stop codon16. This conclusion 
was based on the difference in D4Z4 hypomethylation for the two types of mutations. 
We found a significant correlation between the cumulative number of all D4Z4 repeat 
units in the arrays on chromosomes 4 and 10 and the average methylation of the D4Z4 
repeats in controls and FSHD patients. This correlation allowed us to define the Delta1 
value, which is the observed CpG methylation level at this site in D4Z4 minus the 
predicted methylation based on control individuals. The average Delta1 in controls is 
about zero and ranges between -13% (5% percentile) and 17% (95% percentile), while 
in carriers of an SMCHD1 mutation this value is about -30% and ranges between -42% 
(5% percentile) and -22% (95% percentile)16. Therefore, the Delta1 value represents 
the methylation defect corrected for the size of the D4Z4 repeat array, emphasizing 
the strong effect of SMCHD1 mutations on D4Z4 methylation. We also introduced the 
Delta2 value, which is the observed methylation minus the predicted methylation based 
on SMCHD1 mutation carriers and reveals the significance of the mutation16. SMCHD1 
mutations that preserve the ORF most probably result in a dominant negative type 
mechanism and lead to the lowest Delta1 value, and a negative Delta2 value in somatic 
cells. ORF disrupting SMCHD1 mutations, seem to be associated with nonsense mediated 
RNA decay suggesting a haploinsufficiency type mechanism and are associated with 
lesser degrees of D4Z4 CpG hypomethylation resulting in positive Delta2 values. The 
observation that both the nature of the SMCHD1 mutation and the size of the D4Z4 
repeat array determines the D4Z4 methylation and the disease severity in FSHD2, 
led to a model in which haploinsufficiency-causing mutations require medium short 
D4Z4 arrays (most often in the range of 11-16 units) to cause FSHD2, while dominant 
negative SMCHD1 mutations can also cause FSHD2 with larger 4qA array sizes (Fig. S1)16. 
Thus, while establishing FseI methylation and Delta values are not standard operating 
procedures in diagnostic settings, these values have contributed to our understanding 
of FSHD pathogenesis.
 In approximately 15% of the FSHD2 families, identified by phenotype and D4Z4 
hypomethylation, we could not identify a mutation in SMCHD16; 16. In six out of ten of 
these families, Sanger sequencing of SMCHD1 in the index case did not reveal a causal 
variant but showed absence of heterozygous SNPs in all of the 48 exons and flanking 
sequences. These families were subjected to whole exome sequencing and genome 
wide array analysis.
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 The first family (Rf898) reported in this study came to our attention because of 
classical features of FSHD, while FSHD1 was excluded by D4Z4 repeat array sizing 
(Fig. 1A and Table S1). The index case (898.205) was diagnosed at age 49 when he 
presented with difficulty lifting his arms overhead. In retrospect, he recalls having 
shoulder difficulties when he was 12 years of age. His physical examination showed a 
combination of facial weakness, scapular winging and mild foot dorsiflexor weakness 
as well as mild abdominal muscle weakness. Two additional family members (898.202, 
898.301) were moderately affected with similar clinical features. Subject 898.202 was 
asymptomatic but had definite signs of FSHD with scapular weakness, foot dorsiflexion 
weakness and mild abdominal muscle weakness when examined at age 65. Her son 
(898.301) reports symptom onset at age 13 with clear signs of FSHD when examined at 
age 36 (Supp. Table S1). All carry an 11 units D4Z4 repeat array on a 4qA chromosome 
containing a DUX4 polyadenylation site. Methylation analysis provided evidence for 
reduced D4Z4 methylation levels and Delta1 values consistent with FSHD2 in all three 
affected individuals, but also in two unaffected individuals. Subject 898.303 carries 
the same 11 unit 4qA allele as his affected father, reports shoulder pain and weakness 
since the age of 24 but shows no clear signs of weakness on examination at age 36. 
An EMG study, however, showed myopathic units in his supraspinatus and cervical 
paraspinal muscles. Individual 898.204 is unaffected at the age of 59, but carries a 
35 unit repeat array on a permissive 4qA allele, which appears to be too long to be 
pathogenic based on previous findings in carriers of a haploinsufficiency-causing 
SMCHD1 mutation16. SMCHD1 mutation analysis by Sanger sequencing failed to identify 
potentially damaging variants. Whole exome sequencing on 898.301 and 898.303 failed 
to identify the causative gene, but extended the region of homozygosity into several 
SMCHD1 neighboring genes, suggestive of a heterozygous deletion of the SMCHD1 
locus. Subsequently, we performed a genome wide array analysis in these subjects and 
identified a 1.2Mb deletion that spans the METTL4, NDC80, SMCHD1, EMILIN2, LPIN2 
genes (Fig. 1B). This deletion was confirmed in subjects 898.202, 898.204 and 898.205 
and this variant was submitted to the Leiden Open Variation Database (http://databases.
lovd.nl/shared/variants/SMCHD1).
 In the second family (Rf929), we identified two FSHD individuals carrying a 13 
D4Z4 unit repeat array on 4qA and CpG hypomethylation at D4Z4 suggesting FSHD2 
(Fig. 1C; Table S1). The index case’s (929.201) initial complaints were difficulty with his 
proximal shoulders in his late twenties but was not fully evaluated until age 60 when 
he presented with facial weakness, shoulder and upper extremity weakness and foot 
dorsiflexor weakness. One sister (929.204) is also similarly affected whereas his other 
sister (929.206) is asymptomatic and clinically unaffected. By array analysis in individual
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929.201, we identified the same interstitial chromosome 18p deletion including 
SMCHD1 as was found in family Rf898 (Fig. 1D). This 1.2 Mb deletion was confirmed in 
affected individual 929.204. 
 Both families reside in the same state in the US and although these two families 
are not known to be related, the observation that they carry the same interstitial 18p 
deletion suggest otherwise. Detailed SNP analysis on chromosome 18 showed that 
the SNP difference between nephews 898.301 and 898.303 is 1.8% and the difference 
between 898.301 (or 898.303) and 929.201 is 4.9%, while the average difference at 
chromosome 18 between unrelated individuals is usually >15% (CAL Ruivenkamp, 
personal communication), strongly suggesting that both families are related. Array 
analysis in the remaining four FSHD2 families that showed absence of heterozygous 
SNPs in all 48 SMCHD1 exons and flanking sequences did not reveal evidence for a 
deletion in the SMCHD1 locus.
 Although one third of all identified SMCHD1 mutations in FSHD2 most probably lead 
to haploinsufficiency, SMCHD1 was not known as a dosage sensitive gene. Our current 
study emphasizes that monosomy of SMCHD1 can cause familial FSHD2, although we 
cannot rule out that genetic variants in other (currently unknown) epigenetic modifiers 
of D4Z4 are shared between both families. We identified two families with five affected 
family members who all carry the same 1.2Mb 18p microdeletion in combination 
with a D4Z4 repeat array with 11 or 13 units on a 4qA chromosome. This finding also 
corroborates our previous study in which we show that haploinsufficiency-causing 
SMCHD1 mutations in general result in positive Delta2 values, suggestive of a less 
deleterious outcome16. The Delta2 value in the 7 carriers of the SMCHD1 deletion varied 
between 1 and 7%.
 None of the other genes within the microdeletion have been reported to be 
sensitive to hemizygosity. Homozygous mutations in lipin 2 (LPIN2) have been associated 
with Majeed syndrome, characterized by chronic recurrent multifocal osteomyelitis and 
congenital dyserythropoietic anaemia18. METTL4 (methyltransferase-like 4) encodes 
for a putative methyltransferase of unknown function while NDC80 encodes a central 
component of the kinetochore protein complex necessary for proper chromosome 
segregation and spindle checkpoint signaling19.
 Structural and numerical aberrations of the short arm of chromosome 18 are 
relatively common amongst the chromosomal rearrangement syndromes. The incidence 
of monosomy 18p is estimated at about 1:50;000 newborns worldwide, and although 
the dysmorphic features in 18p deletion syndrome (18p-) individuals is not very uniform, 
muscular dystrophy has not been reported20. Given the association of SMCHD1 mutations 
with FSHD and the identification of two families carrying a deletion of SMCHD1, it raises 
the question whether individuals with 18p- are at increased risk of developing FSHD 
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when also carrying a chromosome 4q that contains a DUX4 polyadenylation signal. To 
address this possibility, analysis of CGH array data from 83 individuals with 18p-, showed 
that SMCHD1 was hemizygous in all but one case21. Subsequent CpG methylation 
analysis of the cases with SMCHD1 deletion confirmed a reduced methylation at D4Z4 in 
72/82 cases (Fig. 2A and B), suggesting that individuals with 18p- have a similar degree 
of D4Z4 chromatin relaxation as individuals with FSHD2. Previously, we showed that 
4qA chromosomes (containing a DUX4 polyadenylation signal) and 4qB chromosomes 
(without DUX4 polyadenylation signal) are almost equally common in the Caucasian 
and Asian populations, while 4qA is the most common chromosome 4 variant in the 
African population22. This suggests that about 25% of 18p- individuals carry two 4qB 
chromosomes and are therefore not at risk for developing FSHD. In two recent studies, we 
analyzed the D4Z4 repeat array size and haplotype distribution in control individuals16; 
23. These results showed that 20 out of 159 independent 4A161 chromosomes, the most 
common risk allele for FSHD in the Caucasian population accounting for 79% of all 4qA 
alleles22, had repeat arrays of ≤16 units, which gives an estimated incidence of 12.6% 
(Fig. 2C). Because half of the chromosomes 4 are of the 4qB variant, about 12.6% (1 in 
8) of individuals in the Caucasian population with 18p- carry a medium-short 4qA array 
and might therefore be at risk for FSHD. To investigate this possibility, we performed 
accurate D4Z4 repeat array sizing in nineteen individuals with 18p- that were selected 
on the basis that they carried a 4A161 allele and had D4Z4 hypomethylation and we 
found that two individuals carried an array ≤16 units and may have an increased risk of 
developing FSHD (Fig S2 and Table S2). Individual 18p-14 carries a 13 unit repeat array 
and is 27 years old, while 18p-37 carries a 15 unit repeat and is 24 years. At this time, 
we do not have information about these individuals clinical status. Contractions on 
other 4qA alleles, such as 4A159, 4A168 and 4A166H, may also confer a risk to FSHD12. 
However, these alleles are much less common than the 4A161 allele22, and therefore 
only increase the FSHD risk in the 18p- patient population by approximately 1.5%.
CONCLUSION
We report heterozygous deletions of SMCHD1 in two distantly related FSHD2 families 
and therefore 18p- deletions may constitute a risk factor for FSHD. While other genetic 
and epigenetic risk factors are likely to contribute to disease penetrance, in order to 
be at an increased risk of developing FSHD2, two other factors also must be present. 
First, the presence of a chromosome 4qA containing a DUX4 polyadenylation signal and 
second, the size of the D4Z4 repeat array with array sizes at the lower end of the normal 
repeat size spectrum being more sensitive to SMCHD1 hemizygosity than longer arrays.
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Supplementary materials and methods
Subjects
For FSHD2 families, this study was approved by the institutional review board of the 
University of Rochester Medical Center. Families Rf898 and Rf929 were studied after 
informed consent. Clinical assessment was performed with a standardized clinical form 
available at the website of the Fields Center for FSHD Research (www.urmc.rochester.
edu/fields-center/). The clinical severity score was based on the Ricci score and varied 
between 0 and 10 (0: unaffected – 10: wheelchair bound)1. Genetic diagnosis for FSHD2 
was based on previously established genetic, and epigenetic criteria2. 
For the 18p- individuals, the study was approved by the University of Texas Health 
Science Center at San Antonio Institutional Review Board. Participants were eligible for 
the study if they had a clinically suspected or diagnosed abnormality of chromosome 
18. Informed consent was appropriately documented at all stages of the process.
Genotyping and methylation analysis FSHD locus
High quality DNA was isolated from peripheral blood mononuclear cell. The detailed 
genotyping of the FSHD locus was based on the haplotype (SSLP variation), the D4Z4 
repeat array size and the distal variation A and B by using pulsed field gel electrophoresis3. 
Methylation of the D4Z4 repeat was measured at the proximal unit of the D4Z4 arrays 
and the Delta1 and Delta2 values were calculated as described previously4. Detailed 
protocols can be downloaded from the Fields Center website (www.urmc.rochester.
edu/fields-center/). D4Z4 repeat sizes on 4A161 alleles in the Caucasian population 
were derived from Schaap et al. and Lemmers et al4; 5.
Mutation Analysis SMCHD1
Mutation analysis for SMCHD1 was performed by Sanger sequencing for all 48 coding 
exons using intronic primers described previously4. Variant analysis was done using 
Sequence Pilot (JSI Medical Systems GmbH). The SMCHD1 genomic sequence was 
obtained from Ensemble (build 37) [GRCh37:18:2655286:2805615] (Genomic Refseq: 
NG_031972.1, Transcript Refseq: NM_015295.2).
Whole exome sequencing analysis
Whole exome sequencing was performed in the Neuromics project by deCODE Genetics 
(Reykjavik – Iceland). The WES data were analyzed using deCODE Clinical Sequence 
Miner. The report builder LOHZ (with standard settings) was used to identify regions 
with loss of heterozygosity.
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SNP Arrays
Genome wide array analysis on families Rf898 and Rf929 was performed on DNA using 
the Affymetrix Cytoscan HD Array platform (Affymetrix, Inc., Santa Clara, CA, USA) 
following the manufacturer’s protocols. Copy number was assessed using the Affymetrix 
Chromosome Analysis Suite (ChAS) Software.
Comparative Genomic Hybridization (CGH) of the 18p deletion DNA samples was 
performed as previously described (Heard et al., 2009)6. The oligonucleotide arrays were 
produced by Agilent Technologies (Santa Clara, CA) and scanned using the Agilent laser 
scanner. The scan data were extracted using Agilent Feature Extraction (version 8.1.1) 
and then analyzed using the CGH Analytics 3.4.27 software.
Supplementary figures




















SUPPLEMENTARY FIGURE S1. Shortest repeat array size on permissive 4qA allele in FSHD2 and 
controls. Distribution of the shortest D4Z4 repeat array size on permissive 4qA chromosomes 
in FSHD2 patients and controls. Previously, we categorized SMCHD1 mutations into disrupting 
ORF (D-ORF) mutations, that likely result in haploinsufficiency through nonsense mediated 
decay, and preserving ORF (P-ORF) mutations. The shortest repeat arrays were identified in 
controls (n=105) and FSHD2 patients with either D-ORF (n=17) or P-ORF (n=26) mutations4. 
The controls were randomly chosen from independent families that were not related to FSHD2 
patients4.
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SUPPLEMENTARY FIGURE S2. Example of genetic and methylation analysis in some 18p- 
individuals. (a) Representative example of D4Z4 repeat array size analysis in twelve 18p- 
individuals (18p-2, 18p-3, 18p-4, 18p-7, 18p-10, 18p-14, 18p-16, 18p-22, 18p-35, 18p-37, 
18p-40 and 18p-79) by pulsed field gel electrophoresis followed by Southern blotting and 
hybridization with probe p13E-113. Each DNA sample is double digested with EcoRI and HindIII 
(lane E) or EcoRI and BlnI (lane B). Lane E reveals all four repeat arrays on chromosomes 4 and 
10, while lane B only show the chromosome 10-type fragments. Cross hybridizing chromosome 
Y fragments are indicated (Y). The molecular weight marker (in kb) is indicated at the right of 
the blot. (b) 4qA (left) and 4qB (right) hybridizations of HindIII digested DNA from the same 
individuals as in A3. Nonspecific fragments in the region between 15 kb and 7 kb (4qA) and 
12 kb and 7kb (4qB) are Indicated. (c) Representative example of methylation analysis in eight 
18p- individuals (18p-3, 18p-7, 18p-10, 18p-37, 18p-4, 18p-14, 18p-35 and 18p-22) and four 
controls (C1-C4) according to previous study 2. Methylated (M) and unmethylated (UM) D4Z4 
fragments are indicated. Below each lane the methylation value is indicated in %. Y indicates 
cross hybridizing chromosome Y fragment. 
Supplementary tables
SUPPLEMENTARY TABLE S1. Clinical Data of the FSHD Families 
Rf Nr Sex AAE Age at onset CSS Diagnosis
Rf898 301 M 36 13 5 FSHD2
202 F 65 asymptomatic 5 FSHD2
204 F 59 asymptomatic 0 unaffected
205 M 55 10 5 FSHD2
303* F 36 24 0 FSHD2
Rf929 201 M 73 30 8 FSHD2
204 F 70 5 6 FSHD2
206 F 67 asymptomatic 0 unaffected
CSS, clinical severity score (ranging from 0-10) based on the Ricci score multiplied by two1; AAE, age at the last examination
* 898.303 reported muscle pain at age 24, EMG shows myopathic units at age 36
15127-vandenboogaard-layout.indd   79 09/01/2018   15:26
80
Chapter 3
SUPPLEMENTARY TABLE S2. D4Z4 repeats array size and methylation in 19 individuals with 
18p- 
ID Age Sex D4Z4 units OM Delta1 Delta2
18p-2 26 F 24 13 -39 -2
18p-3 25 F 18 16 -31 2
18p-4 21 M 49 15 -29 3
18p-7 21 F 36 17 -29 4
18p-10 29 F 51 13 -33 0
18p-14 25 M 13 17 -27 5
18p-16 26 M 22 13 -33 0
18p-20 17 M 57 14 -38 -2
18p-22 21 F 35 16 -40 -1
18p-25 22 F 29 35 -19 19
18p-30 20 F 30 23 -31 7
18p-35 25 F 21 17 -28 4
18p-37 23 M 15 18 -26 6
18p-40 59 M 33 24 -33 6
18p-41 16 F 60 14 -37 -1
18p-48 13 M 34 28 -27 11
18p-49 28 F 22 18 -23 7
18p-79 28 F 25 19 -27 6
D4Z4 units is the shortest repeat array size on the 4A161 chromosome
Methylation values (Delta1; Δ1, Delta2; Δ2 and the measured methylation; OM) 
Individuals that carry a repeat array size ≤16 units on a 4A161 allele are highlighted in grey.
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INTRONIC SMCHD1 VARIANTS IN FSHD
In preparation




Fascioscapulohumeral dystrophy is associated with partial chromatin relaxation 
of the DUX4 encoding D4Z4 macrosatellite repeat located on chromosome 4, and 
transcriptional derepression of DUX4 in skeletal muscle. The most common form, 
FSHD1, is caused by a D4Z4 repeat array contraction to 1-10 units (normal range 8-100 
units). The less common form, FSHD2, is most often caused by heterozygous variants 
in SMCHD1, which encodes a chromatin modifier which binds to D4Z4 to maintain a 
repressed chromatin state. In this study we identified intronic variants in SMCHD1 in 
two FSHD families. In the first family we identified a variant 15 nucleotides proximal 
from the 3’ splice site of exon 14. This SMCHD1 variant creates a 3’ splice site, which 
results in partial intron retention with inclusion of the distal 14 nucleotides of intron 13 
into the transcript. In the second family we identified a deep intronic variant in intron 
34. This SMCHD1 variant creates a 3’ splice site in intron 34, which results in exonisation 
of 53 nucleotides of intron 34. In this family the deep intronic variant acts as a modifier 
of disease severity. In both families the aberrant transcripts are predicted to lead to a 
premature stop codon. The identification of these intronic variants further expands the 
SMCHD1 mutation spectrum in FSHD2 and emphasizes the importance of screening for 
intronic variants in SMCHD1.
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INTRODUCTION
Fascioscapulohumeral dystrophy (FSHD, [OMIM 158900 and 158901]) is a common 
muscular dystrophy in adults (prevalence ~1:8.000) and is clinically mainly characterized 
by progressive weakness and wasting of the facial, shoulder girdle, trunk and upper arm 
muscles1; 2. Most often the onset of the disease occurs during the second decade of life. 
However, both within and between families there is a large variability in disease onset 
and progression3. Two genetic forms of FSHD have been identified, FSHD1 and FSHD2, 
which are clinically almost indistinguishable4, but seem to represent opposite extremes 
of a disease spectrum5. Both forms are associated with partial chromatin relaxation of 
the D4Z4 macrosatellite repeat array on chromosome 4 in somatic tissue, characterized 
by reduced CpG methylation and loss of repressive histone marks6-8. This chromatin 
relaxation results in transcriptional derepression of the D4Z4 encoded DUX4 gene in 
skeletal muscle9. DUX4 is a transcription factor normally expressed in the germ line and 
cleavage stage embryos, that is normally suppressed in most other somatic tissues9-12. 
DUX4 causes cell death when overexpressed in somatic cell lines or endogenously 
but inappropriately expressed in FSHD myotubes13; 14. The D4Z4 chromatin relaxation 
in FSHD must occur on a permissive chromosome 4 (4qA haplotype), which contains 
a polymorphic DUX4 polyadenylation signal distal to the D4Z4 repeat array15. This 
polyadenylation signal is required for the production of stable DUX4 mRNA in somatic 
cells. Chromatin relaxation on the homologous D4Z4 repeats on non-permissive 4qB 
or 10q chromosomes do not cause FSHD since these chromosomal backgrounds lack a 
somatic DUX4 polyadenylation signal15.
 FSHD1, the most common form of FSHD (>95%), is caused by contraction of the 
D4Z4 repeat array to 1-10 units on a 4qA chromosome16. FSHD2 is most often caused by 
heterozygous variants in structural maintenance of chromosomes flexible hinge domain 
containing 1 (SMCHD1) in combination with a smaller, but normal-sized permissive 
D4Z4 repeat array (8-20) on a 4qA chromosome5; 17. SMCHD1 is an atypical member of 
the SMC gene superfamily and originally identified as regulator of epigenetic silencing 
in an ENU mutagenesis screen in mice18; 19. SMCHD1 is normally binding to the D4Z4 
repeat, thereby repressing DUX4 expression in somatic cells17. FSHD2 patients with an 
SMCHD1 variant show reduced binding of SMCHD1 to the D4Z4 repeat, which leads 
to D4Z4 chromatin relaxation and DUX4 expression in skeletal muscle17. Additionally, 
SMCHD1 is also a modifier of disease severity and progression in FSHD1 since SMCHD1 
variants have been identified in some unusually severely affected members of FSHD1 
families who carry both a contracted repeat array and an SMCHD1 variant20. For some 
FSHD2 patients, however, we found D4Z4 hypomethylation but could not identify 
an (exonic) SMCHD1 variant. Two of these families are now explained by SMCHD1 
hemizygosity21. In two other unexplained FSHD2 families heterozygous variants in DNA 
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methyltransferase 3B (DNMT3B) have recently been identified22. DNMT3B is one of the 
de novo DNA methyltransferases23, and is likely important for establishing a repressed 
D4Z4 chromatin structure in somatic cells.
 Since the discovery of SMCHD1 as the most common FSHD2 gene, disease causing 
variants in SMCHD1 have been identified in approximately 80 FSHD2 families. The 
mutation spectrum of SMCHD1 in FSHD2 includes missense, nonsense, and splice site 
variants, insertions and deletions5; 17; 20; 21; 24-28. In this study we describe two families with 
an intronic variant in SMCHD1 which results in aberrant SMCHD1 transcripts. In the first 
family an intronic variant in SMCHD1 was identified which alters splicing and results in 
partial intron retention. In the second family a deep intronic variant in SMCHD1 was 
identified, resulting in exonisation of 53 nucleotides of intron 34. These variants further 
expand the SMCHD1 mutation spectrum in FSHD2.
MATERIAL METHODS
Subjects
A French family (Rf744, fig. 1A) and an American family (Rf1034, fig. 1B) were studied after 
informed consent and the study protocol was approved by the relevant institutional 
review boards. Clinical assessment of disease severity was performed using the 11 point 
(0: unaffected – 10: wheelchair bound) standardized Clinical Severity Score (CSS)29.
D4Z4 repeat sizing, haplotype analysis and methylation analysis
For genotyping high quality genomic DNA was isolated from peripheral blood 
mononuclear cells (PBMCs). The sizing of the D4Z4 repeats on chromosomes 4 and 
10 was done by pulsed field gel electrophoresis (PFGE) as described previously15. 
Haplotype analysis was done by hybridization of PFGE blots with probes specific for 
the 4qA and 4qB haplotype in combination with PCR-based SSLP analysis according to 
previously described protocols15. D4Z4 methylation analysis was measured using the 
FseI restriction site in the most proximal unit of the D4Z4 arrays on chromosomes 4 and 
10 as published previously17. The Delta1 value of D4Z4 methylation was calculated as 
described in Lemmers et al. 20145.
Genomic SMCHD1 variant analysis
For the index cases SMCHD1 variant analysis of all coding exons and splice regions was 
performed by Sanger sequencing after PCR amplification. The intronic primers were 
located at a position of at least 50 nucleotides from the splice donor or acceptor site and 
were previously published 5. For Rf1034 a PCR was performed in intron 34 to identify a deep 
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intronic variant using primers intron_34fwd (5’-TTGAAATACAAAACTGTCGCTTAGA-3’) 
and intron_34rev (5’-AGGGGGAAGGAATTCAAAGA-3’). The PCR product was analysed 
by Sanger sequencing.
 The SMCHD1 genomic sequence was obtained from Ensembl human assembly 
GRCh37 [GRCh37:18:2655286:2805615] (Genomic Refseq: NG_031972.1, Transcript 
Refseq: NM_015295.2), exons were numbered like in NG_031972.1. The functional 
consequences of SMCHD1 variants were predicted using Alamut Visual version 2.6 
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FIGURE 1. Pedigrees of families Rf744 (A) and Rf1034 (B). Clinically affected individuals are 
indicated in black. The following information is provided: the family identifier, D4Z4 methylation, 
Delta1 score, the size and type (A permissive, B non-permissive) of 4q-linked D4Z4 repeats, the 
clinical severity score, the age of examination and the SMCHD1 variant. Key is shown below.




RNA was isolated from PAXgene Blood RNA Tubes using the PAXgene Blood RNA 
Kit (PreAnalytiX, a Qiagen/BD company). cDNA was synthesized with 800 ng to 
2000 ng of RNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific) using random hexamer primers. A reverse transcriptase polymerase chain 
reaction (RT-PCR) for SMCHD1 exon 12 to 16 was performed using primers 1482F 
(5’-TCCTAAGAAGAGAGGGCTTGC-3’) and 2105R (5’-TCATCTCCTTCAGGCCAAGT-3’). 
A RT-PCR for SMCHD1 exon 32 to 35 was performed using primers 4098F 
(5’-AAAACCCGTTCGTCTCAATG-3’) and 4406R (5’-TCCATCATAAAACCAAACTGGA-3’). RT-
PCRs were performed in 30 μl reactions using 0.5 units DreamTaq DNA polymerase (5U/
μl Thermo Fisher Scientific), 1x DreamTaq buffer (Thermo Fisher Scientific), 3 μl of dNTPs 
(2mM of each nucleotide) and 25 pmol of each primer. The following RT-PCR protocol was 
used: 95°C 5 min, 35 cycles of: 95°C 30 sec, 60°C 30 sec, 72°C 30 sec, then 72°C 10 min. RT-
PCR products were separated by size on 2% agarose gels after which PCR products were 
gel purified (NucleoSpin® Gel and PCR Clean-up, Machery Nagel). Purified PCR products 
were cloned into a pCR™4-TOPO vector (Invitrogen, Life Technologies) and transformed 
in DH5α heat-shock competent cells (Subcloning Efficiency DH5α Competent Cells, 
Invitrogen, Life Technologies). Multiple clones were analysed by sequencing their insert 
to find the sequence of the altered transcript.
RESULTS
D4Z4 length and methylation analysis in Rf744 and Rf1034 individuals
Index case Rf744.1 was suspected of FSHD based on physical examination with a CSS 
of 9 at age 66. His physical examination showed asymmetric scapular winging, right 
foot drop, asymmetric distribution of facial weakness, symmetric weakness of fixator 
shoulder girdle muscles, weakness of the pelvic girdle muscles, humeral weakness 
involving both biceps and triceps brachii, abdominal weakness with positive Beevor’s 
sign and tibialis anterior weakness. Rf744.1 also has a benign myelodysplastic syndrome. 
D4Z4 repeat length and haplotype analysis showed that the shortest permissive D4Z4 
allele of Rf744.1 consists of 14 units (Fig. 1A). D4Z4 methylation was measured and the 
Delta1 value was calculated. The Delta 1 value ranges between -42% and -22% (5th and 
95th percentile, respectively) in carriers of an SMCHD1 variant which affects functions5. 
D4Z4 methylation analysis in Rf744.1 revealed a FseI methylation level of 19% (Delta1 
value -27%), indicative of FSHD2. The unaffected sister of the proband (Rf744.4) also 
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shows D4Z4 hypomethylation but she does not carry a permissive allele. The daughter 
of the proband (Rf744.3) does not show D4Z4 hypomethylation and she is unaffected 
(Fig. 1A).
 Index case Rf1034.5 was suspected of FSHD based on physical examination with a 
CSS of 3 at age 19 29. His physical examination showed a combination of pectus excavatum, 
progressive weakness of the right arm, bilateral scapular winging, facial weakness, and 
Beevor’s sign. D4Z4 repeat length and haplotype analysis showed that Rf1034.5 carries 
a 7 units D4Z4 repeat on a permissive chromosome and D4Z4 hypomethylation (Delta1 
score -29%), suggestive for both FSHD1 and FSHD2 (Fig. 1B). Additional family-member 
material was obtained and D4Z4 repeat sizes, haplotypes and D4Z4 methylation levels 
were determined and a physical examination was performed for the four additional 
family members of Rf103422 (Fig. 1B). The father (Rf1034.1) of the proband carries a 7 
unit D4Z4 repeat array, but he is unaffected. The unaffected mother (Rf1034.2) of the 
proband shows D4Z4 hypomethylation and she carries two permissive 4qA alleles of 
44 and 74 units. The two sisters (Rf1034.3 and Rf1034.4) of the proband both carry the 
7 unit D4Z4 repeat array as well as D4Z4 hypomethylation and they are also affected. 
The physical examination of Rf1034.3 showed a combination of weakness of the 
scapular stabilizers and weakness of the right arm. The physical examination of Rf1034.4 
showed only weakness of the facial muscles. This family information strengthened the 
suggestion that there is a combination of FSHD1 and FSHD2 in this family.







SpliceSiteFinder-like (0-100) 87.4 94.7 89.9
MaxEntScan (0-16) 8.9 10.8 7.4
NNSPLICE (0-1) 0.9 1 1
GeneSplicer (0-15) 5.7 0.54 5.1
Human Splicing Finder (0-100) 89.4 97.7 86.1
Identification of an intronic variant in SMCHD1 in Rf744
SMCHD1 variant analysis of all coding exons and splice regions in Rf744 identified an 
intronic SMCHD1 variant in Rf744.1. This variant (c.1843-15A>G) is located 15 base pairs 
proximal to exon 14 and various splicing prediction tools predict that this variant creates 
a 3’ splice site (Fig. 2A, Table 1). The variant was also identified in Rf744.4, which also 
shows D4Z4 hypomethylation, but not in Rf744.3 without D4Z4 hypomethylation (Fig. 
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S1A). To investigate whether this variant alters the transcript, an RT-PCR from SMCHD1 
exon 12 to 16 was performed and analysed by gel electrophoresis. Besides the normal 
PCR product of the expected size, two longer PCR products were identified (Fig. 2B). 
Sanger sequencing of TOPO clones of those two additional PCR products identified that 
the altered transcript contains the sequence from c.1843-14 to c.1843-1, confirming that 
c.1843-15A>G creates a 3’ splice site (Fig. 2C, S1B). The inclusion of these 14 nucleotides 
is predicted to disrupt the open reading frame with a premature stop codon in exon 
14. No other sequences were identified, suggesting that the highest band in the gel is a 
heteroduplex of the normal and altered transcript. No RNA was available from Rf744.3 
and Rf744.4.
Identification of a deep intronic variant in SMCHD1 in Rf1034
SMCHD1 variant analysis in all SMCHD1 exons and splice regions in the proband did 
not identify any putative SMCHD1 variants that affect function5. Therefore, whole 
exome sequencing (WES) was performed in Rf1034 but this did not identify a causative 
variant. By serendipity, an RT-PCR targeting SMCHD1 exon 32 to 35 followed by agarose 
gel electrophoresis revealed two PCR products for Rf1034.3, the normal PCR product 
with the expected size and a PCR product that was larger than expected (Fig. 3A). This 
larger PCR product was also identified with an RT-PCR for Rf1034.2, Rf1034.4 (Fig. 3A) 
and Rf1034.5 (not shown), while it was absent in Rf1034.1 (Fig. 3A). This additional 
PCR product contained a sequence corresponding to 53 nucleotides of intron 34, 
from c.-235 to c.-183 proximal to exon 35 (Fig S2A). These 53 nucleotides are included 
in the transcript as a new exon and are predicted to disrupt the open reading frame 
and lead to a premature stop codon in exon 35 (Fig. S2A). Subsequently, an intronic 
PCR was performed, followed by Sanger sequencing, to identify the variant which is 
responsible for this new exon. A heterozygous deep intronic variant (c.4347-236A>G, 
g.2760414A>G) in SMCHD1 was identified in individuals Rf1034.2, Rf1034.3, Rf1034.4, 
and Rf1034.5, which was absent in Rf1034.1 (Fig S2B). Various splicing prediction tools 
predict that this variant creates a 3’ splice site, while a cryptic 5’ splice site is already 
predicted in the reference sequence at position c.4347-183 (Table 1). In this family this 
deep intronic variant in SMCHD1 segregates with D4Z4 hypomethylation and modifies 
disease severity.
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FIGURE 2. Identification of intronic variant in SMCHD1 in Rf744. A) Sanger sequence track from 
Rf744.1 showing the intronic variant in SMCHD1 at position c.1843-15, highlighted with a red 
rectangle. * indicates common SNP rs8090988 (T/A, ancestral T, minor allele frequency 0.33 (A)) 
B) Gel of RT-PCR of SMCHD1 exon 12 to 16 in Rf744.1, a control and a negative PCR (no DNA). 
C) Schematic representation of splicing of the normal transcript and the altered transcript 
containing the intronic variant
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FIGURE 3. Identification of deep intronic variant in SMCHD1 in Rf1034. A) Gel of RT-PCR of 
SMCHD1 exon 32 to 35 in four members of family Rf1034 and a negative PCR (no DNA), B) 
Sanger sequence track showing the deep intronic variant in SMCHD1 at position c.4347-236 
in Rf1034.5, highlighted with a red rectangle C) Schematic representation of splicing of the 
normal transcript and the altered transcript containing the deep intronic variant and showing 
the exonisation of 53 basepairs in red.
DISCUSSION
In this study we identified a deep intronic variant in SMCHD1 to act as a modifier for 
disease severity in an FSHD1 family. Furthermore, we identified an intronic variant in 
SMCHD1 in an FSHD2 family. 
In family Rf744 we identified an intronic variant located at 15 base pairs proximal 
to exon 14, which creates a 3’ splice site. This SMCHD1 variant results in the inclusion of 
the distal 14 nucleotides of intron 13 (c.1843-14 to c.1843-1) into the transcript, which 
is predicted to disrupt the open reading frame with a premature stop codon in exon 14. 
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The intronic variant and D4Z4 hypomethylation were also detected in the unaffected 
sister of the proband. She carries two non-permissive alleles, which explains why she 
remained unaffected. The unaffected daughter of the proband does not carry the 
variant and shows no D4Z4 hypomethylation.
 In family Rf1034, exonic SMCHD1 variant analysis by SMCHD1 Sanger sequencing 
and WES did not identify any variants that affect function in SMCHD1 or elsewhere in the 
genome5. However, in this study, by serendipity, a deep intronic variant was identified, 
which segregates with D4Z4 hypomethylation. This SMCHD1 variant creates a 3’ splice 
site in intron 34 and this results in exonisation of 53 nucleotides of intron 34. Inclusion 
of these 53 nucleotides in the transcript is predicted to disrupt the open reading frame 
and to result in a premature stop codon in exon 35. In family Rf1034 this SMCHD1 variant 
acts as a modifier for disease severity. The proband and his two sisters all carry both a 
permissive D4Z4 repeat array of 7 units and the deep intronic variant in SMCHD1 and 
present an FSHD phenotype. The proband is more severely affected than his sisters, 
indicating clinical variability, which is common in FSHD5. The mother (Rf1034.2) carries 
the deep intronic variant in SMCHD1 and two permissive 4qA alleles of 44 and 74 units, 
while the median repeat size in controls is 23 units. The length of the D4Z4 repeats of 
the mother is much longer than the median length of the shortest permissive allele in 
FSHD2 patients, which is only 13 units5. Probably, the permissive allele of the mother is 
too long to develop FSHD2. This has also been shown in other FSHD2 families, where 
carriers of an SMCHD1 variant are most often only affected with FSHD when they 
also carry a relatively short but normal sized permissive D4Z4 repeat of 11-20 units5. 
The father (Rf1034.1) carries an FSHD1 sized allele of 7 units and is unaffected. Non-
penetrance and mild phenotypes are seen more often in carriers of a 7-10 units FSHD1 
size allele30. Additionally, in 1-3% of the control population D4Z4 repeats of 7–10 units 
on disease permissive 4qA chromosomes are found, indicating the reduced penetrance 
of these alleles31; 32. In conclusion, in Rf1034 only the combination of a permissive 
D4Z4 repeat array of 7 units with the deep intronic variant in SMCHD1 causes an FSHD 
phenotype, illustrating this SMCHD1 variant modifies disease severity. This modifying 
role of SMCHD1 variants has been described in multiple FSHD1 families with upper sized 
FSHD1 repeat arrays, which explains clinical variability in these families20; 24.
 The variants identified in this study affect splicing by introducing new 3’ splice sites 
in SMCHD1 outside the consensus sequence. Previously, an intronic SMCHD1 variant with 
a similar effect as the variant in Rf744 was identified in another FSHD2 patient (Rf1352 in 
Lemmers et al. 2014)5. The variant c.3634-19A>G creates a 3’ splice site, which results in 
the inclusion of the distal 18 nucleotides of intron 28 into the transcript and introduces 
a premature stop codon immediately proximal to exon 295. In total, we have identified 
approximately 100 variants in SMCHD1 which affect function (ref. 5,17,20,21,22 and 
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unpublished results), including 3 intronic variants outside the consensus sequence that 
introduce a 3’ splice site. This indicates that the frequency of intronic variants in SMCHD1 
that introduce a new splice site is approximately 3% and that this type of variants might 
explain FSHD in patients in which no variant was identified in the exonic SMCHD1 
region or in the splice site consensus.
 Therefore, it would be useful to perform whole genome sequencing in FSHD2 
patients without exonic SMCHD1 variants, in combination with RT-PCR to identify 
alternative splicing. However, the products of such variants might be masked by 
efficient nonsense mediate decay (NMD), which would make it difficult to study the 
splicing effect of intronic variants. One way to address this issue would be to culture 
cells from blood of FSHD patients and controls in the presence of cycloheximide to 
block NMD. Alternatively, intronic variants might influence expression levels of SMCHD1. 
Furthermore, variants in the promoter or regulatory regions of SMCHD1 might cause 
FSHD2. The functional consequences of these types of variants will be difficult to predict 
since the information on regulatory regions of SMCHD1 is limited. Recently, in two FSHD 
families a variant in a putative regulatory region of SMCHD1 was identified, however 
segregation with D4Z4 hypomethylation was inconclusive33. The functional effects of 
variants in regulatory regions could be studied with reporter assays in combination with 
segregation analysis of D4Z4 hypomethylation.
 In summary, this report expands the SMCHD1 mutation spectrum in FSHD2 
with two intronic variants in SMCHD1. Both variants lead to aberrant splicing and the 
altered SMCHD1 transcripts are predicted to lead to a premature stop codon. Our study 
also highlights the importance of the additional variant screening in FSHD2 patients 
negative for exonic SMCHD1 variants.
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SUPPLEMENTARY FIGURE 1. Intronic variant in SMCHD1 in Rf744. A) Sanger sequence 
track from Rf744.1, Rf744.3 and Rf744.4 showing the intronic variant in SMCHD1 at position 
c.1843-15 in Rf744.1 and Rf744.4, highlighted with a red rectangle. * indicates common SNP 
rs8090988 (T/A, ancestral T, minor allele frequency 0.33 (A)). B) Sanger sequence track of the 
altered SMCHD1 transcript in Rf744.1 shows the inclusion of the last 14 nucleotides of intron 13 
between exon 13 and exon 14. 
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SUPPLEMENTARY FIGURE 2. Deep intronic variant in SMCHD1 in Rf1034. A) Sanger sequence 
track of the altered SMCHD1 transcript in Rf1034 shows exonisation of 53 nucleotides of intron 
34 between exon 34 and exon 35. B) Sanger sequence track from family members of Rf1034, 
showing the deep intronic variant in SMCHD1 at position c.4347-236 in Rf1034.2, Rf1034.3, 
Rf1034.3 and Rf1034.5, highlighted with a red rectangle.
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MUTATIONS IN DNMT3B MODIFY 
EPIGENETIC REPRESSION OF THE D4Z4 
REPEAT AND THE PENETRANCE OF 
FACIOSCAPULOHUMERAL DYSTROPHY
Van den Boogaard et al. 2016, American Journal of Human Genetics, 5:98(5):1020-1029




Facioscapulohumeral dystrophy (FSHD) is associated with somatic chromatin relaxation 
of the D4Z4 repeat array and derepression of the D4Z4 encoded DUX4 retrogene coding 
for a germline transcription factor. Somatic DUX4 derepression is either caused by 
repeat array contraction to a size of 1-10 units (FSHD1), or by mutations in SMCHD1, 
which encodes a chromatin repressor that binds to D4Z4 (FSHD2). We here show 
that heterozygous mutations in the DNA methyltransferase 3B (DNMT3B) gene are a 
likely cause of D4Z4 derepression associated with low levels of DUX4 expression from 
the D4Z4 repeat and increased penetrance of FSHD. Recessive mutations in DNMT3B 
were previously shown to cause Immunodeficiency, Centromeric instability, and Facial 
anomalies (ICF) syndrome. This study suggests that transcription of DUX4 in somatic cells 
is modified by variations in its epigenetic state and provides a basis for understanding 
the reduced penetrance of FSHD within families.
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Facioscapulohumeral dystrophy (FSHD; OMIM 158900 and 158901) is a common 
muscular dystrophy typically presenting in the second decade and characterized 
by progressive weakness and atrophy of the facial and upper extremity muscles. 
With disease progression, also other muscles become affected1. A clinical hallmark of 
the disease is the variability in onset and progression with 20% of mutation carriers 
eventually becoming wheelchair dependent, and a similar proportion of mutation 
carriers remaining asymptomatic2.
 The common form of the disease, FSHD1, is associated with a contraction of the 
polymorphic D4Z4 macrosatellite repeat array on chromosome 4q to a size of 1-10 
units (Fig. 1A)3,4. In the healthy control population, this array varies between 8-100 units 
with 1-3% of individuals carrying an FSHD-sized allele of 8-10 units5,6. Each unit of the 
repeat array contains a copy of the double homeobox 4 (DUX4) retrogene, which is 
normally expressed in testis, and silenced in somatic tissue7. In FSHD1 the epigenetic 
repression of DUX4 is incomplete in somatic cells, leading to sporadic DUX4 expression 
in myonuclei7,8. Stable DUX4 transcripts are only produced in combination with a 
polymorphic polyadenylation signal (PAS) immediately distal to the D4Z4 repeat array 
present on 4qA chromosomes, of which two major variants exist (4qA-S and 4qA-L) (Fig. 
1A)9. Contractions of the highly homologous repeat arrays on chromosomes 4qB or 10 
are non-pathogenic due to the absence of a DUX4-PAS9.
 Somatic repression of DUX4 requires a combination of epigenetic mechanisms 
with D4Z4 hypomethylation consistently being reported as an aberrant epigenetic 
feature in FSHD10-13. In FSHD1 D4Z4 hypomethylation is restricted to the contracted 
allele. In the rare FSHD2 type of the disease, D4Z4 hypomethylation is observed on all 
D4Z4 repeat arrays in the absence of D4Z4 repeat array contractions (Fig. 1A)14,15. D4Z4 
methylation linearly correlates with the size of the D4Z4 array in controls and FSHD16. 
FSHD2 individuals often carry smaller but normal-sized D4Z4 repeat arrays (8-20 units) 
given that this renders them more susceptible to further D4Z4 hypomethylation14,16. 
Dominant segregation of D4Z4 hypomethylation in FSHD2 families was instrumental 
in identifying mutations in the structural maintenance of chromosomes flexible hinge 
domain-containing protein 1 gene (SMCHD1; OMIM 614982) in >85% of FSHD2 families17. 
SMCHD1 is a chromatin repressor involved in the establishment and/or maintenance of 
CpG methylation at specific loci and binds directly to D4Z417-19. Therefore, the disease 
presentation in FSHD2 depends on a combination of repeat length and damaging 
potential of the SMCHD1 mutation16. Mutations in SMCHD1 have also been reported 
as modifiers of disease severity in FSHD1 families with FSHD1 alleles of 8-10 D4Z4 
units20,21. Thus, D4Z4 methylation is dependent on repeat array size and on the activity 
of the partially characterized D4Z4-repressive mechanisms. Deviations of the expected 
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D4Z4 methylation, expressed as the Delta1 factor, can be diagnostic for the presence of 
damaging variants in D4Z4-chromatin modifiers. Indeed, Delta1 factors of ≤ -22% are 
generally associated with mutations in SMCHD116.
 Since not all FSHD2 families can be explained by SMCHD1 mutations, we applied 
exome sequencing in eight families in which we found D4Z4 hypomethylation without 
evidence for an exonic SMCHD1 mutation (Fig. 1B, 1C and Fig. S1). All samples were 
obtained in an anonymized manner, and all families gave consent. The study was 
approved by the Medical Ethical Committees of the Leiden University Medical Center 
and of the Radboud University Medical Center Nijmegen. Whole exome sequencing 
(WES) was performed by deCODE Genetics (Reykjavik – Iceland) in the context of the EU 
Neuromics project. To identify variants the WES data were analyzed using deCODE Clinical 
Sequence Miner. Dominant analysis for multiple cases and controls and annotation of 
gene variants (with variant effect predictor consequences moderate to high) were used 
to identify possible dominant mutations. Under these conditions, in two families we 
identified a potentially damaging variant in DNMT3B (DNA methyltransferase 3B; OMIM 
602900), encoding a known D4Z4-chromatin modifier. These variants have not been 
reported previously in dbSNP, the 1000 Genomes Project, the ESP Exome Variant Server, 
Exome Aggregation Consortium (ExAC), or in-house databases.
FIGURE 1. D4Z4 locus and FSHD2 families. (a) Schematic representation of the D4Z4 locus. In 
controls the D4Z4 repeat array ranges between 8-100 units and shows characteristics of a closed 
chromatin structure (black triangles) characterized by amongst others high CpG methylation. 
For both FSHD1 and FSHD2 the chromatin adopts a more open configuration (white triangles) 
marked by a loss of CpG methylation and other chromatin changes. FSHD1 is caused by a 
contraction of the D4Z4 repeat to 1-10 units while in FSHD2 there is chromatin relaxation due 
to mutations that affect a chromatin modifier (black dots), most often being SMCHD1. The 
chromatin relaxation must occur on a permissive 4qA (marked by 4qA-S in this figure) or 4qA-L 
chromosome to cause FSHD, 4qB chromosomes are non-permissive for FSHD (chromosome 4 
variants are displayed in the dashed boxes)9. 4qA-S and 4qA-L differ by the length of the last 
partial D4Z4 unit, and protein studies have demonstrated the production of DUX4 protein from 
both 4qA variants. The 3’ UTR region of DUX4 is missing in 4qB chromosomal regions (white 
square in dashed box), which makes them non-permissive to DUX4 expression. (b,c) Pedigrees 
of families Rf210 (b) and Rf732 (c). Clinically affected individuals are indicated in black. Key 
shows the family identifier (ID), the Delta1 score, age at examination (AAE), and the size of the 
smallest D4Z4 repeat array on a FSHD permissive allele (4qA-S and 4qA-L). Additionally, it is 
indicated when no permissive allele is present (4qB only). The cDNA position behind the family 
ID indicates the cDNA position of the DNMT3B mutation (NM_006892.3) present in this family. 
The asterisk indicates individuals carrying the DNMT3B mutation.
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 Family Rf210 is a FSHD1 family with an array of 9 D4Z4 units on a permissive 4qA 
chromosome (Fig. 1B, Table S1). Despite the presence of this disease allele in 7 family 
members, only four of them are clinically affected, while one carrier (Rf210.102 (I-2)) 
could not be clinically examined. D4Z4 methylation at the FseI site was determined by 
Southern blotting and expressed as the Delta1 score, which is the observed methylation 
at the FseI site in D4Z4 corrected for the repeat array size16. In Rf210, D4Z4 methylation 
analysis identified robust D4Z4 hypomethylation in two severely affected individuals 
(Rf210.201 (II-1) and Rf210.212 (II-5)) and one clinically unaffected individual (Rf210.319 
(III-6)) as evidenced by the strongly reduced Delta1 values. This reduced Delta1 value is 
indicative for the involvement of a defective D4Z4-chromatin modifier. Genetic studies 
excluded the involvement of the SMCHD1 locus (Fig. S2) but exome sequencing identified 
a potentially damaging variant in DNMT3B co-segregating with D4Z4 hypomethylation 
(Fig. 2A, 2B and Table S1). This variant (NM_006892.3(DNMT3B):c.1579T>C, p.Cys527Arg) 
was confirmed by Sanger sequencing and disrupts the C2C2-type zinc finger motif in 
the ATRX-DNMT3-DNMT3L (ADD) domain, a highly conserved domain which can be 
found in several chromatin-associated proteins that play a role in establishing and/or 
maintaining a normal DNA methylation pattern (Fig. 2B, 2D and 2F)22,23. Like SMCHD1, 
DNMT3B was previously identified as suppressor of metastable epialleles in mice, alleles 
that display unusual variable expressivity in the absence of genetic heterogeneity but 
depending on their epigenetic state18,24,25. In these Dnmt3b-hypomorphic mice also the 
ADD domain seems to be primarily affected26.
FIGURE 2. DNMT3B mutations in FSHD2. (a) Schematic representation of DNMT3B with the 
amino acid changes (NP_008823.1) found in FSHD2 families indicated in red. (b,c) Sanger 
sequence confirmation of DNMT3B variants (NM_006892.3) in Rf210 and Rf732, respectively. 
(d,e) Multiple sequence alignment (MSA) of DNMT3B protein across distinct species for DNMT3B 
variants in Rf210 and Rf732 respectively. MSA was performed with ClustalOmega, alignment 
was viewed in Jalview and coloured as ClustalX. (f) Ribbon representation of the NMR structure 
of the ADD domain of ATRX (PDB entry 2JM1)22. The cysteine residues are shown in sticks. 
Cys527 is shown in magenta. Zinc ions are represented as spheres. (g) Ribbon representation of 
the crystallography structure of the C terminal domain of DNMT3A (Chain A, PDB entry 2QRV). 
The proline residues are shown in sticks. Pro691 is shown in magenta.
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 In family Rf210 the DNMT3B variant perfectly segregates with D4Z4 hypomethylation, 
but not with disease presentation. DNMT3B mutation carrier Rf210.319 (III-6, Fig. 1B) may 
be protected from disease presentation because of the large size of the FSHD permissive 
D4Z4 repeat (44 units). This is reminiscent to the situation in SMCHD1 mutation carriers, 
where individuals with smaller normal-sized D4Z4 repeat arrays (11-20 units) have a 
greater likelihood of developing FSHD than individuals with larger repeat arrays16. 
The two DNMT3B variant carriers with an array of 9 D4Z4 units, however, have an age 
corrected clinical severity score (ACCS) that is greater than the carriers of only a 9 D4Z4 
units allele. This suggests that the DNMT3B variant acts as a modifier of disease severity 
in this FSHD1 family, similar to SMCHD1 mutation carriers in FSHD1 families20. Of the 
four carriers of an array of 9 D4Z4 units without DNMT3B variant, two are clinically 
unaffected (Rf210.104 (I-3) and Rf210.303 (III-2)). This variability in severity is typical 
for this borderline FSHD1 repeat array size. Indeed, 1-3% of the control population 
carries an array of 8-10 units on a permissive allele, demonstrating the strongly reduced 
penetrance for these alleles5,6. Penetrance is, amongst others, dependent on age and 
the degree of D4Z4-chromatin relaxation in somatic tissue12,16,27.
 In family Rf732, the index case Rf732.3 (II-1) carries a D4Z4 repeat array of 13 
units on a 4qA chromosome (Fig. 1C, Table S1), which is also present in his unaffected 
father and brother. Methylation analysis showed that the index case and his father 
(Rf732.3 (II-1) and Rf732.1 (I-1)) had severe D4Z4 hypomethylation on all four alleles 
with reduced Delta1 values. Exome sequencing identified a potentially damaging 
variant affecting a highly conserved residue in the enzymatic domain of DNMT3B 
(NM_006892.3(DNMT3B):c.2072C>T, p.Pro691Leu) in the index case and his father, 
which was confirmed by Sanger sequencing and absent in the son with normal D4Z4 
methylation (Fig. 2A, 2C, 2E and 2G). Although Rf732.1 (I-1) and Rf732.3 (II-1) both carry 
this DNMT3B variant, have the same Delta1 value, and a 13 units FSHD-permissive 
D4Z4 allele, only Rf732.3 (II-1) is clinically affected. This family emphasizes the reduced 
penetrance that is typical for FSHD16,27. The Delta1 value in this family is low, but not 
as low as typically found in SMCHD1 mutation carriers16. This suggests a lesser degree 
of D4Z4-chromatin relaxation in this family, which might explain why the father has 
remained unaffected.
 Analysis of all coding exons of DNMT3B in 25 additional cases with a permissive 
D4Z4 allele and borderline to severely reduced D4Z4 methylation, but excluded for 
exonic SMCHD1 mutations, did not identify additional mutations in DNMT3B (Table S2 
and Table S4).
 Biallelic DNMT3B mutations have been reported in autosomal recessive 
Immunodeficiency, Centromeric instability, and Facial anomalies syndrome type 1 
(ICF1; OMIM 242860)28,29. This primary immunodeficiency syndrome is characterized 
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by hypo- or agammaglobulinemia with B cells, and by distinct facial appearance. There 
is a progressive decrease of B- and T-cells during childhood and adolescence30,31. The 
cytogenetic hallmark of ICF syndrome is the presence of chromosome abnormalities 
involving the juxtacentromeric domains of chromosomes 1, 9 and 16 in metaphase 
spreads of phytohemagglutinin (PHA) stimulated cells30,32. ICF1 patients show 
CpG hypomethylation of juxtacentromeric satellite repeats type II and III, and the 
macrosatellite repeats NBL2 and D4Z433,34. ICF1 mutations most often affect the catalytic 
domain of DNMT3B and are believed to result in strongly reduced DNMT3B activity31.
 Since our data suggest that FSHD2 and ICF1 can both be caused by DNMT3B 
mutations, with dominant mutations in DNMT3B associated with FSHD2 and recessive 
mutations causing ICF syndrome, we analyzed six ICF1 patients belonging to five families 
(Rf285, Rf286, Rf614, Rf699, and Coriell Cell Repositories family 2081, here annotated as 
Rf1178) for D4Z4 repeat array sizes, presence of a DUX4-PAS, D4Z4 hypomethylation, 
and DUX4 expression (Fig. 3). If possible, we also included unaffected relatives. Table 
S3 lists all ICF1 families with reference to their original description. Consistent with 
earlier reports33, methylation analysis showed that all ICF1 patients tested had severe 
D4Z4 hypomethylation with Delta1 values varying between -35% and -46% (Fig. 3). 
However, depending on the mutation, some heterozygous carriers (parents of Rf699 
and mother of Rf1178) also showed reduced Delta1 values similar to what we observed 
in our FSHD2 families (-19% to -26%). This not only suggests an additive effect of both 
DNMT3B mutations in the affected ICF1 children, but also puts ICF1-mutation carriers 
with a reduced Delta1 value at risk of stable DUX4 expression and FSHD, if combined 
with a DUX4-PAS. Analysis of D4Z4-repeat sizes, however, showed that about half of 
the heterozygous DNMT3B carriers in our ICF1-affected families do not carry a FSHD-
permissive chromosome. For those who do have D4Z4 repeat arrays on FSHD-permissive 
chromosomes (containing a DUX4 PAS), the arrays are well beyond the size of what is 
typically found in FSHD2 individuals (Fig. 3). The smallest permissive D4Z4 repeat array 
found in these heterozygous DNMT3B carriers contained 32 units, suggesting that these 
individuals may be protected from somatic DUX4 expression because of their long D4Z4 
repeat arrays, since in FSHD2, we already demonstrated a D4Z4 repeat size-dependent 
penetrance for SMCHD1 mutations16. In concordance, to our knowledge, muscle 
weakness has never been reported in ICF1 mutation carriers.
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FIGURE 3. Pedigrees of autosomal recessive ICF1 families Rf286, Rf699, Rf1178, Rf285, and 
Rf614. Affected individuals are indicated in black and DNMT3B mutations (NM_006892.3) are 
shown below each individual. Their clinical phenotypes and DNMT3B mutations have been 
described before28,30,31,43,44. Key description identical to Fig. 1.
 To address the possibility of DUX4 expression in carriers of a single DNMT3B 
mutation, we trans-differentiated primary fibroblasts of controls, FSHD1 and FSHD2 
patients and of non-affected and affected carriers of an FSHD2 mutation in DNMT3B 
(Rf210.319 (III-6), Fig. 1B and Rf732.3 (II-1), Fig. 1C) into myotubes by lentiviral MyoD 
expression. A lentivirus containing GFP or FLAG was used as a control. MYOG and MYH3 
expression levels were measured by Q-PCR to examine differentiation35,36. For almost all 
cell lines we observed MYOG and MYH3 expression only in the fibroblasts transduced 
with MyoD, indicating that these cells were trans-differentiated into myogenic cells 
(Fig. 4A). In one FSHD2 cell line (FSHD2 (1)) MYH3 expression was detected in the GFP 
transduced fibroblast as well, possibly because of a technical or biological artifact. We 
next analyzed the expression of DUX4 and three DUX4 target genes (LEUTX, TRIM43 and 
PRAMEF2) by Q-PCR and gel electrophoresis37. We found DUX4 and DUX4 target gene 
expression in MyoD transduced fibroblasts of affected FSHD2 individual Rf732.3 (II-1) 
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with a D4Z4 repeat array of 13 units, but not in unaffected individual Rf210.319 (III-6) with 
a 44 units array on a 4qA chromosome (Fig. 4A and Fig. S3A). No DUX4 or upregulation 
of DUX4 target gene expression was detected in GFP transduced fibroblasts and no 
fibroblasts were available from other FSHD2 family members. These data are consistent 
with the suggestion that heterozygous DNMT3B mutations, only when combined with 























































































































































































































B DAPI DUX4 MYOSIN Merge
ICF1 Myotubes (Rf285.1)
FIGURE 4. DUX4 presence in FSHD and ICF1. (a) Expression of MyoG, MYH3, DUX4, and LEUTX 
(DUX4 target) by Q-PCR in GFP (G)- or MyoD (M)-lentivirus-transduced fibroblasts from controls, 
FSHD1, FSHD2, Rf210.319, Rf732.3 and ICF1 (Rf1178.2) individuals. All transductions were 
performed twice for each cell line, except for control 4 (1x transduced with GFP, 2x transduced 
with MyoD) and FSHD2 (2) (transduced 1x with GFP and 1x with MyoD). Mean expression 
values with standard deviations are shown relative to the reference genes GUSB and RPL27. 
DUX4 is measured with primers for the most common DUX4-4A-S variant, but the primers do 
not recognize DUX4-4A-L. The fibroblasts from control individual 4 and Rf1178.2 carry a 4qA-L 
allele, and are therefore excluded from analysis of DUX4 expression. Primers are listed in table 
S5. (b) Immunofluorescent staining for DUX4 and Myosin in fixed ICF1 myotubes from Rf285.1 
(Fig. 3) shows DUX4 immunoreactivity in a small percentage of myotubes.
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 To investigate DUX4 expression in ICF1 we trans-differentiated three primary 
fibroblast cell lines of ICF1 patients (Rf699.2 (II-1), Rf614.1 (I-1) and Rf1178.2 (II-1); Fig. 
3). In ICF1 patient Rf699.2 (II-1) with a permissive D4Z4 array of 32 units we detected 
DUX4 in the MyoD transduced fibroblasts (Fig. S3B). DUX4 could not be detected in ICF1 
patient Rf614.1 (I-1), because she carries two 4qB alleles, which are unable to produce 
a stable DUX4 transcript (Fig. S3B). Our DUX4 primers recognize the most common 
DUX4-4A-S variant, but not the DUX4-4A-L variant, which is produced from 4qA-L 
repeats. Since ICF1 patient Rf1178.2 (II-1) carries a 4qA-L repeat, we were unable to 
directly detect DUX4 in this patient (Fig. S3B). However, the expression of DUX4 target 
genes was detected in Rf1178.2 (II-1), suggesting that there is DUX4 produced in these 
fibroblasts (Fig. 4A and Fig. S3A). These results show that ICF1 patients can express 
small amounts of DUX4 in MyoD-transduced fibroblasts indicating that when both 
DNMT3B alleles are mutated, the epigenetic derepression is sufficient to facilitate DUX4 
expression from D4Z4 repeats (Fig. S3B). Additionally, we had myotubes available of one 
ICF1 patient from a different family (Rf285.1 (I-1), Fig. 3) with a D4Z4 repeat of 11 units 
on a FSHD permissive chromosome 4, where we detected small amounts of DUX4 by 
immunofluorescent staining (Fig. 4B). This ICF1 patient (Rf285.1 (I-1)) might still be too 
young (15 years) to develop FSHD. Possibly, the short life expectancy of ICF1 patients in 
general may obscure the diagnosis of muscle weakness. 
 Conversely, although ICF1 mutation carriers are reported to be unaffected, we 
explored the possibility that dominant DNMT3B mutations identified in our FSHD2 
families may have epigenetic consequences similar to what is found in ICF1, or clinical 
features reminiscent of ICF syndrome. Metaphase analysis of PHA stimulated peripheral 
mononuclear blood cell cultures of FSHD DNMT3B mutation carrier Rf210.319 (III-6, 
Fig. 1B), but not Rf732.3 (II-1, Fig. 1C), indicated a low frequency of formation of multi-
branched chromosomes (Fig. 5A and 5B). Chromosome decondensations, breaks and 
deletions, can be found at low frequency also in ICF1 mutation carriers and controls32. 
But the formation of multi-branched chromosomes may be specific to the presence 
of DNMT3B mutations, even in heterozygous carriers. Rf210.319 (III-6) also showed 
evidence for mild NBL2 hypomethylation in a Southern blot assay, as the NBL2 repeat 
is sensitive to digestion by the methylation-sensitive endonuclease Eco52I, albeit to a 
lesser degree than observed in ICF1 patients (Fig. 5C). Similarly, one heterozygous ICF1 
mutation carrier with strongly reduced Delta1 values for D4Z4 (Rf699.1 (I-1), Fig. 3), also 
showed mild NBL2 hypomethylation (Fig. 5C). Since not all carriers of the same variant 
showed NBL2 hypomethylation, this suggests that heterozygous DNMT3B variants can 
cause mild and variable NBL2 hypomethylation. Clinically, however, DNMT3B mutation 
carrier Rf210.319 (III-6) and his siblings Rf210.316 (III-4) and Rf210.317 (III-5), do not 
show signs or features of ICF syndrome and have normal serum immunoglobulin levels 
and normal numbers of B-cells and T-cell subsets (Fig. S4).
15127-vandenboogaard-layout.indd   114 09/01/2018   15:26
115
Mutations in DNMT3B in FSHD
5















































































































Family Nr Coriell ID Gender NM_006892.3 Metaphases Anomalies Details anomalies
100 (2013) 0
100 (2015) 0
Rf210 317 - M WT 100 0
100 (2013) 3
One cell with a multiradial of chromosome 1 (p,p,q,q,q) 
and a triradial of chromosome 16 (p,q,q) (see B-1)                    
Two cells with decondensation (stretching) in the 
pericentromeric region of chromosome 1 (see B-2)
100 (2015) 4
One cell with a triradial of chromosome 16 (p,q,q)      
One cell with a triradial of chromosome 16 (p,q,q) and  
decondensation in the pericentromeric region of 
chromosome 1 (see B-3)                                                   
One cell with a deletion of 9q (see B-4)                                 
One cell with a deletion of 16q                             
Rf732 3 - M c.[2072C>T];[=] 100 0
Rf1178 1 GM08729 M WT 95 0 See ref. 32 and 35
Rf1178 2 GM08714 M c.[1807G>A];[2421-11G>A] 28 2 One cell with a deletion of 1q and one cell with an   
extra 1q. See also ref. 32 and 43
Rf1178 3 GM08728 F c.[1807G>A];[=] 61 0 See ref. 32 and 35
c.[1579T>C];[=] MRf210 319 -
Rf210 316 - F WT
FIGURE 5. Metaphase analysis and NBL2 Southern blot analysis of Rf210, Rf732 and ICF1 
families (a) Metaphases were analyzed from 3 heterozygous DNMT3B mutation carriers 
(Rf210.319; Rf732.3 and Rf1178.3), one ICF1 patient (Rf1178.2) and three individuals without 
DNMT3B variant (Rf210.316, Rf210.317 and Rf1178.1). Identifiers from LUMC and Coriell are 
indicated, the mutation in DNMT3B (NM_006892.3) and the number of analyzed metaphases. 
Chromosomal anomalies are listed in the last column. (b) Four panels with examples of 
chromosomal anomalies identified in individual Rf210.319. Chromosomal anomalies are 
indicated with red arrows. (c) NBL2 Southern blot analysis in Rf210, Rf732 and ICF1 families 
after digestion of 2 μg genomic DNA with the methylation-sensitive endonuclease Eco52I 
using previously described protocols45. Numbers correspond with pedigrees in Fig. 1 and 3. 
Delta1 score is indicated between brackets. NBL2 is only hypomethylated in the four individuals 
indicated with an asterisk.
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 These observations raise the question why DNMT3B mutations can cause such 
discordant phenotypes. Mutations that affect the ADD domain of DNMT3B have never 
been reported in ICF syndrome, but mutations disrupting the ADD domain of DNMT3A 
(OMIM 602769) have been associated with Tatton-Brown-Rahman syndrome (OMIM 
615879), an overgrowth syndrome with intellectual disability38. Similarly, mutations 
that disturb the ADD domain of ATRX (OMIM 300032) have been reported in alpha 
thalassemia-mental retardation, X-linked (ATR-X; OMIM 301040) syndrome22. The ADD 
domains of ATRX, DNMT3A and DNMT3B bind to the N-terminus of the histone 3 (H3) 
tail lacking the active lysine 4 (H3K4) methylation mark, where they integrate histone 
modification status with DNA methylation39. Binding of the ADD domain of DNMT3A to 
the H3 tail stimulates the catalytic activity of this enzyme40-42. Likewise, it is possible that 
the mutation that affects the ADD domain of DNMT3B in family Rf210 also disrupts the 
DNA methylation activity of DNMT3B. Most of the ICF1 mutations, however, are located in 
exons that encode for the catalytic domain of DNMT3B, like the mutation in family Rf732. 
It is not well known why mutations in DNMT3B cause a primary immunodeficiency, but 
the absence of an immunological phenotype in our FSHD2 families may be explained 
by the presence of one wild type DNMT3B allele, as heterozygous ICF1 mutation carriers 
also do not present immunological abnormalities.
 Our study implicates that mutations in DNMT3B act as a modifier in FSHD. We 
propose that, like for SMCHD1, the effect of DNMT3B mutations on DUX4 expression 
and disease presentation depends on the presence of a DUX4-PAS and on D4Z4 repeat 
array size. This, combined with the relative young age at which ICF1 patients typically 
succumb from their immunodeficiency, may explain the absence of FSHD in ICF1 families. 
These observations also suggest that FSHD1 and FSHD2 represent polar extremes of a 
continuous disease mechanism determined by the interaction of D4Z4 repeat size, the 
presence of a DUX4-PAS, and variations in genes that modify the D4Z4 epigenetic state, 
and provides a firm basis for understanding reduced disease penetrance in the FSHD 
population.
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SUPPLEMENTARY FIGURE 1. FSHD2 families without SMCHD1 mutation. Families with 
evidence for hereditary D4Z4 hypomethylation that were tested negative for exonic SMCHD1 
and DNMT3B mutations. In all families, the Delta1 score was moderately to strongly reduced 
with possibility of dominant or recessive inheritance of D4Z4 hypomethylation. Family Rf854 
was presented previously as FSHD1 (Rf854.211) and SMCHD1 mutation negative FSHD2 family.1 
Key: ID = identifier, Delta1 score, AAE = age at examination, number of repeat units (U) on 
smallest permissive allele.





allele a b a a' a a' b a' a' a' a c d e d a d a d a b a d' c position dbSNP
G G G G G G G G NA NA G C C C C G C G C G G G C C exon 1 rs2430853
A A A A A A NA NA A A A G G G G A G A G A A A NA NA intron 1 rs555117
A A A A A A NA NA A A A A G G G A G A NA NA A A NA NA intron 1 rs611187
T A T T T T A T T T T T A A A T A T A T A T A T exon 14 rs8090988
G G G G G G G G G G G G A A A G A G A G G G A G exon 14 rs635132
A A A A A A A A A A A G A A A A A A A A A A A G exon 16 rs2276092
T T T T T T T T T T T A A A A T A T A T T T A A exon 21 rs633422
A A A A A A A A A A A G G G G A G A G A A A G G exon 28 rs521992
A A A A A A A A A A A G A G A A A A A A A A A G exon 28 rs12327477
A A A A A A A A A A A A G A G A G A G A A A NA NA intron 31 rs2304860
A A A A A A A A A A A G A G A A A A A A A A NA NA intron 31 rs2304861
T T T T T T T T T T T C C C C T C T C T T T C C exon 37 rs483547
A A A A A A A A A A A G A G A A A A A A A A NA NA intron 43 rs3213926
Delta1
201 301 303 306 202 209 211 316 317 319 212 104
-29% -8% -6% 5% -8% 8% -2% -8% -8% -29% -30% -2%
SUPPLEMENTARY FIGURE 2. Exclusion of SMCHD1 in Rf210. Haplotype analysis in family 
Rf210 based on common SNPs defined different alleles. Segregation analysis showed that the 
common SMCHD1 allele (allele a) found in individuals with D4Z4 hypomethylation (201, 212 
and 319; Delta1 values -29% and -30%) was also found in individuals with normal methylation 
(301, 303, 209, 316 and 317). The position of the SNPs (NA means not analyzed) and dbSNP 
identifier are shown on the right. Delta1 methylation values are shown below.
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SUPPLEMENTARY FIGURE 3. DUX4 target gene expression and DUX4 expression in FSHD and 
ICF1. (a) Expression of DUX4 target genes TRIM43 and PRAMEF2 by Q-PCR in GFP- (G) or MyoD- 
(M) transduced fibroblasts from controls, FSHD1, FSHD2, Rf210.319, Rf732.3 and ICF1 (Rf1178.2). 
All transductions were performed twice for each cell line, except for control 4 (1x transduced 
with GFP, 2x transduced with MyoD) and FSHD2 (2) (transduced 1x with GFP and 1x with MyoD). 
Mean expression values with standard deviations are shown relative to the reference genes 
GUSB and RPL27. (b) Gel of Q-PCR for DUX4 and GUS in Flag and MyoD transduced fibroblasts 
from control, FSHD2, Rf210.319, Rf732.3 and ICF1 (Rf699.2, Rf614.1, Rf1178.2). Technical 
duplicates are shown. The smallest D4Z4 repeat array on a FSHD permissive allele (4qA) in 
each individual is indicated below the gel. A PCR product for DUX4 is only detected in MyoD 
transduced fibroblasts from FSHD2, Rf732.3 and Rf699.2. The DUX4 RT-PCR is performed with 
primers for the most common DUX4-4A-S variant, but the primers do not recognize DUX4-4A-L. 
The fibroblast from Rf1178.2 carries a 4qA-L allele.
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ID IgG (g/L) IgA (g/L) IgM (g/L)
316 12.2 2.81 0.99
317 9.38 1.92 0.74
319 10.5 2.29 0.56
reference values 7-16 0.7-4 0.42-2.3
SUPPLEMENTARY FIGURE 4. Immunological analysis. (a) The numbers of lymphocytes (Ly), 
T-cells (T), CD4+ and CD8+ T-cell subsets (T4 and T8), NK cells (NK) and B-cells (b) in blood for 
siblings from family Rf210. The range of the normal values is depicted and represents the 5th 
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SUPPLEMENTARY TABLE 2A. Overview of individuals screened for exonic DNMT3B mutations. 
Table summarizing the clinical, D4Z4 methylation and genetic data from 20 FSHD cases 
screened for exonic mutations in DNMT3B at the LUMC, Leiden, the Netherlands. 
nr gender ACSS Delta1
4q allele 1 4q allele 2
Pedigreeunits A/B units A/B
Rf201.309 M 143 -21 7 4A161S 27 4B163
Rf242.3 M NA -22 10 4A161 105H2 4A157 see figure S2
Rf537.1 M NA -18 7 4A161S 37 4B163
Rf584.2 F 19 -18 9 4A161S 32 4B168
Rf661.2 F NA -18 15 4A161 20 4A161 see figure S2
Rf704.2 F 150 -21 18 4A161 48 4A161 see figure S2
Rf744.1 M 88 -27 14 4A161S 29 4B163 see figure S2
Rf838.1 F 100 -32 11 4A161L 58 4A161L
Rf854.203 F 34 -19 13 4A161S 15 4B163 see figure S2
Rf901.1 F 49 -17 18 4B168 37 4A161S
Rf946.2 M 63 -22 8 4A161S 27H1 4A166
Rf982.1 M 127 -18 7 4A161S 20 4B163
Rf1010.1 F NA -21 12 4A161S 51 4B163
Rf1034.5 M 158 -29 7 4A161S 45 4A161L see figure S2
Rf1049.1 F 54 -22 6 4A161S 37 4A161S
Rf1093.1 F NA -17 11 4A161 13 4A161
Rf1154.2 F NA -32 37 4A161 43 4B163
Rf1239.1 M 140 -19 8 4A161 36 4A161
Rf1449a.1 F 196 -27 7 4A161 36 4B168
Rf1464.1 M 94 -19 14 4A161S 12 4B163
Column 2 shows gender (F= female, M = male), column 3 shows the age corrected clinical severity score (ACSS), column 4 
shows the Delta1 score for D4Z4 methylation at the FseI site, column 5-8 show the sizes, SSLP size and haplotype (including 
S or L for 4qA-S or 4qA-L when available) of the 4q alleles. NA means not analyzed.
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SUPPLEMENTARY TABLE 2B. Overview of individuals screened for exonic DNMT3B mutations. 
Table summarizing the clinical, D4Z4 methylation and genetic data from 6 cases screened for 
exonic mutations in DNMT3B at the NCNP, Tokyo, Japan.
nr gender age CSS ACSS
DR1 
methylation 4qA allele
1 M 4 1 NA 23 >10
2 F 47 6 128 21 11A
3 F 44 7 159 24 8A
4 F 53 10 189 21 7A
5 F 62 6 97 17 8A
6 M 52 7 135 13 13A
Column 4 shows the DR1 methylation percentage, column 5 shows the size of the shortest 4qA allele, size information of 
the other 4q allele and SSLP sizes are not available.
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EXPANDING THE MUTATION SPECTRUM 
IN ICF SYNDROME: EVIDENCE FOR 
A GENDER BIAS IN ICF2
Van den Boogaard et al. 2017, Clinical Genetics Oct;92(4):380-387




Background: Immunodeficiency, centromeric instability, and facial anomalies (ICF) 
syndrome is a rare, genetically heterogeneous, autosomal recessive disorder. Patients 
suffer from recurrent infections caused by reduced levels or absence of serum 
immunoglobulins. Genetically, 4 subtypes of ICF syndrome have been identified to 
date: ICF1 (DNMT3B mutations), ICF2 (ZBTB24 mutations), ICF3 (CDCA7 mutations), and 
ICF4 (HELLS mutations).
Aim: To study the mutation spectrum in ICF syndrome.
Materials and methods: Genetic studies were performed in peripheral blood 
lymphocyte DNA from suspected ICF patients and family members.
Results: We describe 7 ICF1 patients and 6 novel missense mutations in DNMT3B, 
affecting highly conserved residues in the catalytic domain. We also describe 5 new ICF2 
patients, one of them carrying a homozygous deletion of the complete ZBTB24 locus. In 
a meta-analysis of all published ICF cases, we observed a gender bias in ICF2 with 79% 
male patients.
Discussion: The biallelic deletion of ZBTB24 provides strong support for the hypothesis 
that most ICF2 patients suffer from a ZBTB24 loss of function mechanism and confirms 
that complete absence of ZBTB24 is compatible with human life. This is in contrast to 
the observed early embryonic lethality in mice lacking functional Zbtb24. The observed 
gender bias seems to be restricted to ICF2 as it is not observed in the ICF1 cohort.
Conclusion: Our study expands the mutation spectrum in ICF syndrome and supports 
that DNMT3B and ZBTB24 are the most common disease genes.
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INTRODUCTION
Immunodeficiency, centromeric instability, and facial anomalies (ICF; OMIM 
#242860/#614069) syndrome is a rare, autosomal recessive disorder. Patients suffering 
from this characteristic triad have a severely decreased life expectancy if left untreated. 
In ICF syndrome, the primary immunodeficiency is characterized by an absence or 
strong reduction of serum immunoglobulins in the presence of circulating B-cells, 
leading to recurrent and eventually fatal infections of mainly the gastro-intestinal and 
respiratory tracts1; 2. Although humoral immunodeficiency is pronounced in patients 
with ICF syndrome, opportunistic infections observed in about 20% of the patients 
also suggest involvement of a T-cell dysfunction2. Currently, patients are most often 
treated by intravenous immunoglobulin therapy and few cases underwent successful 
hematopoietic stem cell transplantation1-4. ICF syndrome patients present with a 
distinct but variable set of facial anomalies, including, but not limited to, hypertelorism, 
flat nasal bridge, and epicanthus1; 2.
 The cytogenetic hallmark of ICF syndrome is centromeric instability. Upon 
phytohemagglutinin stimulation of lymphocytes, aberrant chromosomal 
configurations can be observed in metaphase spreads. These aberrant configurations 
mainly involve the centromeric regions of chromosomes 1, 9, and 16 and correlate 
with CpG hypomethylation of repeats located in these (peri)centromeric regions5; 6. 
The combination of a compromised humoral immune response, the abnormal facial 
appearance, and cytogenetic abnormalities is diagnostic for all ICF syndrome patients.
 ICF syndrome is a genetically heterogeneous disease. In recent years the number 
of disease genes has expanded from one to four, with still few cases left unexplained. 
About half of the cases carry biallelic mutations in the DNA methyltransferase 3B 
(DNMT3B; ICF1) gene, the first identified disease gene7; 8. ICF1 patients most often carry 
missense mutations in the catalytic methyltransferase domain of DNMT3B, leading to 
partial loss of function. Nonsense mutations in DNMT3B are only found in combination 
with missense mutations, suggesting that complete loss of DNMT3B activity is not 
compatible with life, which is consistent with Dnmt3b knock-out studies in mice2; 9.
 We and others have described mutations in the zinc finger and BTB (Broad-Complex, 
Tramtrack, and Bric a Brac) domain containing 24 (ZBTB24; ICF2) gene in some patients 
negative for mutations in DNMT3B2; 4; 10-14. Most often, homozygous nonsense mutations 
were identified, which are predicted to lead to an absence of full length protein in 
patients. In addition, a few ICF2 cases with homozygous or compound heterozygous 
missense mutations in ZBTB24 have been described. More recently, missense mutations 
in the cell division cycle associated 7 (CDCA7; ICF3) gene and splice site, missense, and 
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nonsense mutations in the helicase, lymphoid specific (HELLS; ICF4) gene were found 
to underlie ICF syndrome in almost all patients negative for mutations in DNMT3B and 
ZBTB2415.
 Here we report the identification of seven ICF1 cases with previously unreported 
mutations in DNMT3B. Additionally, we present five ICF2 cases, carrying both known 
and novel mutations, including one case with a homozygous deletion of the complete 
ZBTB24 gene. With these new cases included, the total number of genetically confirmed 
ICF cases reported to date is 77 (including patient 2 from Franceschini et al.16 with 
ZBTB24 mutations (unpublished F.Licciardi)), of which 56% have mutations in DNMT3B, 
31% have mutations in ZBTB24, and the remaining 13% have mutations in CDCA7 or 
HELLS. This study, combined with earlier mutation reports1; 2; 4; 11; 12; 15; 17-21, also revealed a 
gender bias specific to the ICF2 population with 79% of all ICF2 patients being male. In 
summary, we expand the mutation spectrum for the two most common genetic causes 
of ICF, show that complete absence of the ZBTB24 locus is compatible with human life, 
and identify a gender bias in ICF2.
MATERIALS AND METHODS
Patients
Nine ICF families were studied after informed consent and the study protocol was 
approved by the relevant institutional review boards. All patients fit the immunological, 
cytogenetic, and clinical criteria for ICF syndrome. Detailed clinical and immunological 
information is provided in the results section and in the Tables S1 and S2.
Sanger sequencing of ICF disease genes
For all index cases, DNMT3B and/or ZBTB24 variant analysis was performed by Sanger 
sequencing after polymerase chain reaction (PCR) amplification. For DNMT3B the exons 
encoding the catalytic domain (exons 16-23) were analysed using intronic primers at 
a position of at least 50 nucleotides from the splice donor or acceptor site. For ZBTB24 
all coding exons (exons 2-7) were analysed using intronic primers at a position of at 
least 50 nucleotides from the splice donor or acceptor site. Primers and amplification 
conditions were published previously10; 22. For exon 19 of DNMT3B a new primer pair 
was used (DNMT3Bex19fwd2: 5’-ACTGGTAGGCATCACCCTGA-3’ and DNMT3Bex19rev2: 
5’-CACCCACCAATCATCACTGC-3’). The DNMT3B genomic sequence was obtained from 
Ensemble (build 37) [GRCh37:20:31350191:31397162] (Genomic Refseq: NG_007290.1, 
Transcript Refseq: NM_006892.3). The ZBTB24 genomic sequence was obtained from 
Ensemble (build 37) [GRCh37:6:109781719:109806439] (Genomic Refseq: NG_029388.1, 
15127-vandenboogaard-layout.indd   138 09/01/2018   15:26
139
Expanding the mutation spectrum in ICF syndrome
6
Transcript Refseq: NM_014797.2). The functional consequences of variants were 
predicted using SIFT23, Mutation Taster24, PolyPhen-225, and PROVEAN26. Identified 
variants have been submitted to the Leiden Open Variant Database (http://databases.
lovd.nl/shared/genes/DNMT3B; http://databases.lovd.nl/shared/genes/ZBTB24).
SNP array analysis
For family Rf1875 a single nucleotide polymorphism (SNP) Array analysis was performed 
with the Human Cyto 12-SNP genotyping array (Illumina, San Diego, California, USA), 
according to the manufacturer’s instructions, to identify the breakpoints of the 
chromosome 6 deletion.
Statistical analysis
For the review of patient numbers and gender distributions we only included genetically 
confirmed cases with sufficient clinical follow up (including patient 2 from Franceschini 
et al.16 with ZBTB24 mutations (unpublished F.Licciardi)). A possible gender bias in the 
different subtypes of ICF was analysed using a non-parametric Chi-square test (SPPS 
version 23, IBM) under the null hypothesis of equal distribution between genders, which 
is expected for autosomal recessive disorders. Two confirmed ICF1 patients were added 
to the analysis as missing values because of discrepancies in gender between different 
publications they were reported in (PB and PM from Jiang et al.)1; 21; 27.
RESULTS
Clinical description of ICF syndrome patients
All twelve ICF patients that we describe in this report display facial dysmorphism 
characteristics and delayed development as previously described (Table S1). Recurrent 
infections were frequent: six out of seven ICF1 patients and all five ICF2 patients had 
suffered from bronchopneumonia, and one ICF1 patient and two ICF2 patients had 
suffered from meningitis. Until now, opportunistic infections, such as Candida and 
Pneumocystis jirovecii, have not been reported in the ICF1 patients in this study and 
were only observed in one ICF2 case (Table S1). Almost all ICF2 patients reported 
previously display a variable degree of intellectual disability2; 12. Among the ICF2 
patients reported in this study there is one with normal intelligence, whereas the 
others showed intellectual disability (Table S1). At first analysis and before initiation of 
intravenous immunoglobulin substitution (IVIG), all evaluable ICF1 and ICF2 patients 
displayed (strongly) decreased serum IgG and IgM levels, except for one ICF1 patient 
having a normal IgM concentration (Table S2). IgA showed a normal level in one ICF2 
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case and was (strongly) decreased in the remaining seven evaluable ICF patients. After 
diagnosis, all patients were treated with IVIG. Peripheral blood B cells were present in 
normal numbers in six out of seven ICF1 patients and one out of five ICF2 patients and 
(strongly) decreased in the remaining cases.
ICF1 patient mutations
In seven ICF patients from four different families, mutations in DNMT3B were identified 
(Fig. 1A). In total, six missense mutations in DNMT3B were found, which have not 
previously been reported in ICF syndrome. Five of them have not previously been 
described in dbSNP, the National Heart, Lung, and Blood Institute Exome Sequencing 
Project (ESP) Exome Variant Server or the Exome Aggregation Consortium (ExAC) Browser. 
The mutation DNMT3B c.2221G>A (p.G741R) has been described heterozygously in three 
out of 121,408 exomes in the ExAC database and dbSNP (rs769823434), a frequency 
concordant with the recessive nature of ICF syndrome.
 All six missense mutations affect highly conserved residues in the catalytic domain 
of DNMT3B (Fig 1B). Each missense mutation is predicted as damaging or deleterious 
by at least two out of four prediction tools (Table S3). In two ICF1 families the patients 
(Rf1648-2.1, Rf1771-2.1, 4.2, and 4.3) carry a homozygous missense mutation in DNMT3B 
(Fig. 1C, 1D, S1A and S1B). In the two other ICF1 families the patients (Rf1840-2.1 and 2.2, 
Rf1693-2.4) carry compound heterozygous missense mutations (Fig 1E, 1F, S1C and S1D) 
in DNMT3B. All homozygous or compound heterozygous mutations were identified in 
both or only one parent, respectively, as expected for the recessive inheritance pattern 
of ICF syndrome (Table S1).
ICF2 patient mutations
In four ICF2 patients from four different families we identified nonsense mutations 
in ZBTB24. In a fifth family a microdeletion affecting several genes, including the 
complete ZBTB24 locus, was identified (Fig. 2A). The affected individuals from the non-
consanguineous family Rf1225 and the consanguineous families Rf1461 and Rf1462 carry 
a one base pair deletion on both alleles, which is predicted to create a frameshift and 
a premature stopcodon in ZBTB24 (Fig. 2B, 2C, 2D, S2A, S2B and S2C). Their parents are 
all heterozygous carriers of this mutation. This mutation has been previously described 
in one other ICF2 patient10. The ICF2 patient Rf1759B-2.1 (case 1 in Franceschini et al. 
199516) carries a homozygous duplication in ZBTB24 (Fig. 2E and S2D), which creates a 
premature stopcodon. Both non-consanguineous parents are heterozygous carriers of 
this mutation. This mutation is described heterozygously in one out of 121,392 exomes 
in the ExAC database and dbSNP (rs770082593), again in concordance with the rare 
and recessive nature of ICF syndrome. Rf1875 is a consanguineous family (Fig. 2F, 2G),
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FIGURE 1. DNMT3B mutations in ICF1 families. (a) Schematic representation of the DNMT3B 
protein (GenBank: NP_008823.1). The identified amino acid changes of the ICF1 families are 
indicated. (b) Multiple-sequence alignment (MSA) of DNMT3B across distinct species for 
DNMT3B mutations in the ICF1 families. MSA was performed with ClustalOmega and alignment 
was viewed in Jalview and colored as in ClustalX. (c-f) Overview of the ICF1 pedigrees and 
their DNMT3B mutations. For families with multiple ICF patients, probands are indicated with an 
arrow. ICF, immunodeficiency, centromeric instability, and facial anomalies.








































109,750,000 109,800,000 109,850,000 109,900,000 109,950,000 110,000,000 110,050,000 110,100,000
Deletion including ZBTB24: 
GRCh37:6:109,734,377-110,024,284
(g)
FIGURE 2. ZBTB24 mutations in ICF2 families. (a) Schematic representation of the ZBTB24 
protein (GenBank: NP_055612.2). The identified amino acid changes of the ICF2 families are 
indicated. (b-e) Overview of the ICF2 pedigrees and their ZBTB24 mutations. (f) Overview of 
pedigree Rf1875 and (g) schematic overview of the deletion on chromosome 6 which was 
identified in this family. ICF, immunodeficiency, centromeric instability, and facial anomalies.
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in which patient Rf1875-2.2 carries a homozygous deletion on chromosome 6 that 
includes ZBTB24 and several other genes. Both parents carry this deletion heterozygously, 
while the genotype of the brother is unknown.
Clinical heterogeneity
The ZBTB24 mutation c.917delA was found in a total of four ICF2 patients from four 
unrelated families from Turkey. This suggests that this is a founder mutation. Three 
of these families are described in this paper, while the fourth family was previously 
described (P1 in de Greef et al. 201110 and P49 in Weemaes et al. 20132). To assess 
whether there is clinical heterogeneity among patients carrying an identical mutation, 
we compared the clinical characteristics of the four male ICF2 patients carrying the 
c.917delA mutation. We found that the patients from these four families have similar 
facial anomalies and they all show signs of intellectual disability. In addition, they all 
have infections, such as bronchopneumonia, however only two (including patient P1 
with a reported Candida infection10) have opportunistic infections. IgM serum levels 
are strongly decreased in all of them, whereas IgA levels are strongly decreased in 
one of them (out of three evaluable cases), and IgG levels are strongly decreased in 
three of them (except in P110). Finally, B cell numbers are strongly decreased in one, 
decreased in two, and normal in one (patient P1) of them. They were all treated with 
IVIG. We also identified two ICF1 patients from one family (Rf1840) which are compound 
heterozygotes for two missense mutations in DNMT3B (c.1750A>G and c.2468G>C). 
They share similar facial anomalies and bronchopneumonia, however only one of them 
shows signs of intellectual disability (Rf1840.2.2). They both have strongly decreased 
IgA levels and normal B-cell numbers. IgM and IgG are strongly decreased in the boy 
(Rf1840.2.2) and normal and decreased, respectively, in the girl (Rf1840.2.1).
 Finally, we identified three ICF1 patients from one family (Rf1771) with the same 
DNMT3B mutation (c.2009G>A). However, two of these patients (twin Rf1771-4.2 and 
4.3) were born in 2016, which currently limits the comparison of their phenotypes with 
that of the third patient (Rf1771-2.1, born in 2013).
Gender bias in ICF2
With the identification of mutations in twelve ICF syndrome cases, a total of 77 
genetically confirmed ICF patients has been reported1; 2; 4; 11; 12; 15; 17-21. 56% of the ICF 
syndrome patients carry mutations in DNMT3B, 31% carry mutations in ZBTB24, 6.5% 
carry mutations in CDCA7, and 6.5% carry mutations in HELLS (Fig. 3A). We observed a 
gender bias in the ICF2 population, with 19 male patients and only 5 female patients out 
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of 24 patients reported (Fig. 3B). This gender bias is statistically significant (χ2 (1) = 8.167, 
p = 0.004) and seems to be specific for ICF2 as it is not observed for the ICF1 cohort or 


























FIGURE 3. Subtype and gender distribution in ICF, immunodeficiency, centromere instability, 
and facial anomalies (ICF) syndrome. (a) Subtype distribution of the ICF patients described in 
the literature and in this study. (b) Gender distribution of the ICF patients described in the 
literature and in this study. P-values are calculated with the Chi-square test. Out of the 43 
reported ICF1 cases, 41 were included in this analysis, 2 were added as missing values. P-values 
in red reflect a statistically significant difference. 
DISCUSSION
In seven ICF1 patients we identified a total of six DNMT3B missense mutations, which 
have not previously been described in ICF1. However, in Rf1840 the arginine residue at 
postion 823 is replaced by a proline (R823P) and this residue was previously reported 
to be mutated into a glycine (R823G) in ICF119. All mutations we identified affect 
highly conserved residues in the catalytic domain of DNMT3B, which is in line with the 
majority of the previously described ICF1 mutations2. Multiple missense mutations 
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in the catalytic domain have been shown to reduce the methyltransferase activity 
of DNMT3B28; 29. Therefore, we expect that the mutations identified in this study also 
reduce the catalytic activity of DNMT3B. Three of the newly identified ICF1 patients are 
from one family and carry the same homozygous missense mutation. Comparison of 
their clinical phenotypes may facilitate a better understanding of clinical variability at 
later ages, which is observed in the ICF1 affected siblings from the family Rf1840.
 We also identified ZBTB24 mutations in five previously unreported ICF2 patients. In 
four ICF2 patients homozygous nonsense mutations in ZBTB24 were found. Nonsense 
mutations are the most common type of mutations in ICF2, indicating that most ICF2 
patients are expected to completely lack production of ZBTB24 protein. In concordance, 
we also identified an ICF2 patient (Rf1875) with a homozygous deletion on chromosome 
6 that includes ZBTB24 and several other genes. This indicates that complete absence 
of ZBTB24 is compatible with human life and supports the conclusion that most ICF2 
patients suffer from a ZBTB24 loss of function. In contrast to humans, a Zbtb24 BTB 
domain deletion in mice, which leads to non-functional Zbtb24 protein, was found to 
be embryonic lethal30.
 The deletion in ICF2 patient Rf1875-2.2 is not confined to ZBTB24 but includes SMPD2, 
MICAL1, AK9, and parts of PPIL6 and FIG4. Most of these genes have not been implicated 
in disease. PPIL6 is a member of the Cyclophilin Family of Peptidyl-Prolyl Isomerases with 
unknown activity31. SMPD2 is predicted to encode a sphingomyelin phosphodiesterase, 
which is able to hydrolyze sphingomyelin in vitro, but its in vivo function is unclear32. 
MICAL1 is involved in cytoskeleton dynamics via its mono-oxygenase domain that can 
oxidize target proteins, such as actin, or produce reactive oxygen species33. Reduced 
levels of MICAL1 were detected in the temporal neocortex of patients with temporal 
lobe epilepsy (TLE) as well as in the hippocampus and temporal lobe of a rat model 
for TLE after seizures34. AK9 is one of the nine adenylate kinases (AK), which regulate 
adenine nucleotide ratios. Some AK isoforms have been related to human disease, but 
for AK9 no relation to disease has been identified35. In contrast, mutations in FIG4 are 
associated with Charcot-Marie-Tooth disease type 4J (CMT4J)36, Yunis-Varón syndrome 
(YVS)37, amyotrophic lateral sclerosis (ALS)38, and polymicrogyria39. FIG4 encodes a 
5’-phosphoinositide phosphatase involved in endosomal trafficking and autophagy39. 
In patient Rf1875-2.2 the first exon of FIG4, which contains the start codon, is deleted, 
possibly resulting in the absence of full length FIG4 protein in Rf1875-2.2. This patient 
suffers from epilepsy, which is not a common feature of the ICF syndrome, however 
was reported in a family where FIG4 mutations were linked to polymicrogyria. Although 
none of the other deleted genes have been linked to human disease, we cannot rule out 
contribution of any of those to the clinical presentation in this patient. Therefore, careful 
follow up with extra attention on co-morbidities normally not seen in ICF is warranted 
for this patient.
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 With the addition of twelve genetically confirmed patients, we re-analyzed the 
frequencies of the different ICF subtypes. For ICF1 and ICF2 we find similar frequencies, 
as previously reported2. ICF3 and ICF4 are much less frequent than ICF1 and ICF2. 
Unexpectedly, for ICF2 we found a significant gender bias, with 79% males and only 21% 
females. This suggests that lacking functional ZBTB24 is more deleterious for females. 
The mechanistic basis for this difference is currently unclear and warrants further 
studies focusing on the function of ZBTB24 during (female) development and perhaps 
X-chromosome inactivation, since ZBTB24 seems to colocalize with heterochromatin12. 
Currently, the limited number of female patients makes it difficult to study phenotype/
genotype relations or to compare their phenotypes with those of male ICF2 patients.
 In summary, in this report we describe the mutations and clinical characteristics 
of seven ICF1 cases and five ICF2 cases. We expand the ICF1 mutation spectrum 
with six new DNMT3B mutations and the ICF2 mutation spectrum is extended with 
a nonsense mutation and a homozygous deletion of chromosome 6, which includes 
the entire ZBTB24 locus. For ICF2 we identify a gender bias towards male cases, which, 
in combination with the embryonic lethality in mice lacking functional Zbtb24, is 
intriguing and will require follow up studies into the function of ZBTB24.
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SUPPLEMENTARY FIGURE S1. DNMT3B mutations in ICF1 families. (a-d) Overview of the ICF1 
pedigrees, their DNMT3B mutations and the Sanger sequence track of these mutations. For 
families with multiple ICF patients, probands are indicated with an arrow.
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SUPPLEMENTARY FIGURE S2. ZBTB24 mutations in ICF2 families. (a-d) Overview of the ICF2 
pedigrees, their ZBTB24 mutations and the Sanger sequence track of these mutations. 




SUPPLEMENTARY TABLE 1. Overview of the clinical data of the ICF patients.
Patient
ICF1 ICF2











Year of birth 2004 2013 2016 2016 2007 2009 2009 2011 2012 2001 1985 1995
Gene defect DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B ZBTB24 ZBTB24 ZBTB24 ZBTB24 ZBTB24 ZBTB24 ZBTB24
Mutation Paternal Allele c.2003C>T c.2009G>A c.2009G>A c.2009G>A c.1705A>G c.1705A>G c.1973A>G c.917delA c.917delA c.917delA c.909dup Deletion
Mutation Maternal Allele c.2003C>T c.2009G>A c.2009G>A c.2009G>A c.2468G>C c.2468G>C c.2221G>A c.917delA c.917delA c.917delA c.909dup Deletion
Patients included 7 23 5 13
Facial anomalies 7/7 21/22 5/5 13/13
hypertelorism +  +  +  +  -  4/5 14/18 +  +  +  +  +  5/5 7/13
flat nasal bridge -  +  +  +  +  +  +  6/7 13/16 +  +  +  +  +  5/5 8/9
epicanthus +  -  +  +  +  +  +  6/7 14/17 +  +  +  +  -  4/5 7/8
up-turned nose +  -  +  +  +  +  -  5/7 6/9 +  +  +  -  3/4 4/7
macroglossia -  -  -  -  -  -  0/6 5/11 +  -  +  -  2/4 1/5
telecanthus -  -  -  -  +  +  2/6 3/11 +  +  +  +  -  4/5 2/4
micrognathia +  -  +  +  -  +  4/6 5/12 +  +  -  -  +  3/5 3/8
low-set ears +  +  -  -  +  +  -  4/7 6/14 +  +  +  +  4/4 5/7
round face +  +  +  +  +  +  +  7/7 8/10 +  +  +  -  3/4 6/8
Growth and development
gestional age < 37 weeks -  -  -  -  -  -  -  0/7 3/20 +  -  -  +  -  2/5 1/7
birth weight  < P10 +  -  -  -  +  -  2/6 9/20 +  +  +  +  -  4/5 4/6
failure to thrive -  -  +  -  -  +  -  2/7 8 -  -  -  -  -  0/5 3
delay in motor development -  -  -  +  1/4 9/16 -  +  +  -  +  3/5 7/8
delay in speech development +  -  +  2/3 14/16 +  +  +  +  +  5/5 11/13
Malformations
congenital +  1 7 2
cerebral 2 2
Intelligence
normal +  +  2/5 11/20 +  1/5 0/13
retardation +  +  +  3/5 9/20 +  +  +  +  4/5 13/13
Neurology
seizures 0 3 -  -  -  +  +  2 1
Gastrointestinal problems
diarrhea +  1 7/14 -  -  -  -  -  0 2/6
Infections
otitis +  1 8/13 +  1 2/6
bronchopneumonia +  +  +  +  +  +  -  6/7 16/16 +  +  +  +  +  5/5 5/7
sepsis  5 1
meningitis +* 1 +** +** 2
Candida 4 +  1 2
Pneumocystis jirovecii 2 +  1 2
cytomegalovirus -  +  -  -  -  -  -  1 2 +  -  -  -  -  1
Malignancy 2 1
The gene defects and clinical data of the ICF patients described in this study are listed per patient. Columns 9 and 16 list the total number of patients displaying the 
respective trait/total number of patients of which data on the respective trait is reported. As a comparison the same data are listed from an earlier study in column 10 and 
17 1. *: Pseudomonas, **: Streptococcus pneumoniae
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Year of birth 2004 2013 2016 2016 2007 2009 2009 2011 2012 2001 1985 1995
Gene defect DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B DNMT3B ZBTB24 ZBTB24 ZBTB24 ZBTB24 ZBTB24 ZBTB24 ZBTB24
Mutation Paternal Allele c.2003C>T c.2009G>A c.2009G>A c.2009G>A c.1705A>G c.1705A>G c.1973A>G c.917delA c.917delA c.917delA c.909dup Deletion
Mutation Maternal Allele c.2003C>T c.2009G>A c.2009G>A c.2009G>A c.2468G>C c.2468G>C c.2221G>A c.917delA c.917delA c.917delA c.909dup Deletion
Patients included 7 23 5 13
Facial anomalies 7/7 21/22 5/5 13/13
hypertelorism +  +  +  +  -  4/5 14/18 +  +  +  +  +  5/5 7/13
flat nasal bridge -  +  +  +  +  +  +  6/7 13/16 +  +  +  +  +  5/5 8/9
epicanthus +  -  +  +  +  +  +  6/7 14/17 +  +  +  +  -  4/5 7/8
up-turned nose +  -  +  +  +  +  -  5/7 6/9 +  +  +  -  3/4 4/7
macroglossia -  -  -  -  -  -  0/6 5/11 +  -  +  -  2/4 1/5
telecanthus -  -  -  -  +  +  2/6 3/11 +  +  +  +  -  4/5 2/4
micrognathia +  -  +  +  -  +  4/6 5/12 +  +  -  -  +  3/5 3/8
low-set ears +  +  -  -  +  +  -  4/7 6/14 +  +  +  +  4/4 5/7
round face +  +  +  +  +  +  +  7/7 8/10 +  +  +  -  3/4 6/8
Growth and development
gestional age < 37 weeks -  -  -  -  -  -  -  0/7 3/20 +  -  -  +  -  2/5 1/7
birth weight  < P10 +  -  -  -  +  -  2/6 9/20 +  +  +  +  -  4/5 4/6
failure to thrive -  -  +  -  -  +  -  2/7 8 -  -  -  -  -  0/5 3
delay in motor development -  -  -  +  1/4 9/16 -  +  +  -  +  3/5 7/8
delay in speech development +  -  +  2/3 14/16 +  +  +  +  +  5/5 11/13
Malformations
congenital +  1 7 2
cerebral 2 2
Intelligence
normal +  +  2/5 11/20 +  1/5 0/13
retardation +  +  +  3/5 9/20 +  +  +  +  4/5 13/13
Neurology
seizures 0 3 -  -  -  +  +  2 1
Gastrointestinal problems
diarrhea +  1 7/14 -  -  -  -  -  0 2/6
Infections
otitis +  1 8/13 +  1 2/6
bronchopneumonia +  +  +  +  +  +  -  6/7 16/16 +  +  +  +  +  5/5 5/7
sepsis  5 1
meningitis +* 1 +** +** 2
Candida 4 +  1 2
Pneumocystis jirovecii 2 +  1 2
cytomegalovirus -  +  -  -  -  -  -  1 2 +  -  -  -  -  1
Malignancy 2 1
The gene defects and clinical data of the ICF patients described in this study are listed per patient. Columns 9 and 16 list the total number of patients displaying the 
respective trait/total number of patients of which data on the respective trait is reported. As a comparison the same data are listed from an earlier study in column 10 and 
17 1. *: Pseudomonas, **: Streptococcus pneumoniae
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SUPPLEMENTARY TABLE 2. Serum levels of the different immunoglobulin isotypes and 





































































































Patients included x x x x x x x 7 23 x x x x x 5 13
IgG
Patients analyzed x x x x x x x 7 13 x x x x x 5 12
Normal 0 1 0 2
Decreased x x 2 1 x 1 4
Strongly decreased x x x 3 11 x x x x 4 6
Inconclusive* x x 2 0 0 0
IgA
Patients analyzed x x x x x x x 7 19 x x x x x 5 13
Normal 0 0 x 1 5
Decreased x 1 0 x 1 0
Strongly decreased x x x 3 13 x x 2 4
Inconclusive* x x x 3 6 x 1 4
IgM
Patients analyzed x x x x x x x 7 19 x x x x x 5 13
Normal x 1 3 0 1
Decreased 0 0 x x 2 3
Strongly decreased x x x x x x 6 16 x x x 3 9
B-cells
Patients analyzed x x x x x x x 7 9 x x x x x 5 8
Normal x x x x x x 6 4 x 1 7
Decreased x 1 2 x x 2 0
Strongly decreased 0 3 x x 2 1
The serum immunoglobulin levels of the ICF patients described in this study are categorized as normal, decreased and 
strongly decreased for each isotype using reference values for age-matched healthy controls according to Kanariou et al., 
19952. Peripheral blood B-cell numbers are categorized as normal, decreased and strongly decreased based on reference 
values for age-matched healthy controls according to Comans-Bitter et al., 1997 3. As a comparison, the same data are listed 
from an earlier study 1. For some patients from this earlier study IgG data is not included because of IVIG treatment already 
initiated at time of first analysis. In other cases data are lacking because they were not included at first analysis.
*: Inconclusive: measured IgA concentrations as well as lower threshold for normal range in healthy age-matched controls 
are at or below the sensitivity level of the quantitative assay applied; two ICF1 cases were diagnosed at 4 months of age and 
the measured decreased IgG levels might be from maternal origin.
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SUPPLEMENTARY TABLE 3. Variant predictions for identified DNMT3B missense variants
c.2003C>T, (p.T668I) c.1750A>G, (p.I584V) c.2468G>C, (p.R823P)
SIFT Deleterious (score: 0) Deleterious (score: 0) Deleterious (score: 0.01)
Mutation 
Taster
Disease causing (p-value: 1) Disease causing (p-value: 
0.995)





Possibly damaging (score: 
0.610)
Benign (score: 0.180)
PROVEAN Deleterious (score: -5.692) Neutral (score: -0.854) Deleterious (score: -6.419)
c.1973A>G, (p.N658S) c.2221G>A, (G741R) c.2009G>A, p.(R670Q)
SIFT Tolerated (score: 0.16) Deleterious (score: 0.02) Deleterious (score: 0)
Mutation 
Taster
Disease causing (p-value: 
0.924)
Disease causing (p-value: 1) Disease causing (p-value: 1)
PolyPhen-2 
HumVar




PROVEAN Deleterious (score: -4.638) Deleterious (score: -7.378) Deleterious (score: -3.817)




1. Weemaes, C.M., van Tol, M.J., Wang, J., van Ostaijen-ten Dam, M.M., van Eggermond, M.C., 
Thijssen, P.E., Aytekin, C., Brunetti-Pierri, N., van der Burg, M., Graham Davies, E., et al. (2013). 
Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene 
defects. European journal of human genetics : EJHG 21, 1219-1225.
2. Kanariou, M., Petridou, E., Liatsis, M., Revinthi, K., Mandalenaki-Lambrou, K., and Trichopoulos, 
D. (1995). Age patterns of immunoglobulins G, A & M in healthy children and the influence of 
breast feeding and vaccination status. Pediatr Allergy Immunol 6, 24-29.
3. Comans-Bitter, W.M., de Groot, R., van den Beemd, R., Neijens, H.J., Hop, W.C., Groeneveld, K., 
Hooijkaas, H., and van Dongen, J.J. (1997). Immunophenotyping of blood lymphocytes in 
childhood. Reference values for lymphocyte subpopulations. The Journal of pediatrics 130, 
388-393.
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FSHD and ICF are two chromatin diseases characterized by hypomethylation of 
repetitive DNA. In FSHD there is hypomethylation of the macrosatellite repeat D4Z4 and 
the associated DUX4 gene, which is caused by a repeat contraction and/or variants in 
chromatin modifiers essential for a repressive D4Z4 chromatin structure in somatic cells. 
In ICF there is hypomethylation of centromeric repeats, which is caused by recessive 
variants in one of four ICF genes, of which two are established chromatin modifiers. 
In this thesis, the mutation spectrum of FSHD and ICF has been expanded, and this 
includes the identification of a new modifier gene for FSHD as well as variant types that 
had not previously been described for FSHD and ICF. These findings are important to 
genetically explain disease in patients, and they contribute to the understanding of 
disease mechanisms.
Synergistic effect of double SMCHD1 variants
In chapter 2 we have described three FSHD2 families in which we identified two 
potentially damaging variants in SMCHD1 in the proband of each family. For each family, 
we investigated whether the variants were present in cis or in trans, used variant effect 
prediction tools to predict the effect of the variants and determined whether the SMCHD1 
variants contribute to D4Z4 hypomethylation. There were no cell lines available from these 
families, making it impossible to study the effects of the variants on protein level.  
 Southern blot-based methylation analysis using probe p13E-11 and methylation 
sensitive restriction enzyme FseI was used to measure the D4Z4 methylation in the 
DUX4 promoter of the most proximal unit of the D4Z4 repeat arrays of chromosomes 
4 and 10 simultaneously, as previously described1. With this method, the percentage of 
D4Z4 methylation was calculated, which we refer to as the observed FseI methylation, 
and a threshold for FSHD2 was determined as ≤25%1. Since the D4Z4 methylation level 
is dependent on repeat size, we also calculated the Delta1 value, which represents 
the D4Z4 methylation corrected for the size of the D4Z4 repeat array (observed FseI 
methylation minus predicted methylation based on the four D4Z4 repeat array sizes). 
To determine the Delta1 value, complete information on the D4Z4 repeat array sizes 
on chromosomes 4 and 10 was necessary, which required high molecular weight DNA. 
In individuals that carry an SMCHD1 variant affecting function, the Delta1 value ranges 
between –42% and –22% (5th and 95th percentile, respectively)2.
 In the first family containing two SMCHD1 variants, a splice site variant and 
a nonsense variant, both in exon 21 were identified in cis in the proband. By RT-PCR 
analysis we were able to demonstrate that the splice site variant disrupts the splice 
donor site and results in skipping of exon 21. This removes the nonsense variant from 
the transcript. However, skipping of exon 21 disrupts the open reading frame resulting 
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in a predicted stop codon in exon 22. Thus, although both variants are individually 
expected to affect function, in this patient only the splice site variant seems to affect the 
transcript and to be responsible for causing FSHD2.
 In the second family containing two SMCHD1 variants, a 4 nucleotides deletion 
in the splice donor site of exon 25 and a missense variant in exon 28, were identified. 
These variants were found to be located in trans. The missense variant in exon 28 was 
suggested to affect function by two prediction tools, however segregation analysis 
revealed that this variant is not causing D4Z4 hypomethylation independently (based 
on Delta1 value), and thus is likely a neutral variant. In this case it was helpful to have 
DNA available from family members to measure D4Z4 methylation and to determine 
the functional consequence of the missense variant in exon 28. Deletions in the splice 
donor site of exon 25 were already identified in 8 FSHD2 families, suggesting that this 
is a mutation hotspot1-3. In this proband we expect that only the variant in exon 25 
contributes to D4Z4 hypomethylation and FSHD2.
 In the third family, the proband carries two SMCHD1 missense variants in exon 24 
and 45 in trans. The father and mother carry the missense variant in exon 24 and 45, 
respectively. Since both parents also show low D4Z4 methylation values (based on Delta1 
value), these variants independently cause D4Z4 hypomethylation. A more deleterious 
effect of both variants on D4Z4 methylation was detected in the proband and his sister 
who also carries both variants. The proband is severely affected, which is probably 
explained by the synergistic effect of the two variants. Due to other phenotypes, it was 
impossible to establish whether the sister of the proband was also affected with FSHD. 
Both parents of the proband were unaffected. For the father this is explained by the 
absence of a permissive 4qA allele. The mother carries a permissive 4qA allele of 27 units, 
similar to the proband, which might be too long to develop FSHD2 with only a single 
SMCHD1 variant. A study of a large cohort of FSHD2 families indeed provided evidence 
that D4Z4 repeat array sizes up to 20 units are most sensitive to SMCHD1 variants2. This 
family also demonstrates that having two SMCHD1 copies, each containing a missense 
variant affecting function, is compatible with life in males and females. Possibly, these 
missense variants create hypomorphic alleles in which SMCHD1 protein function is only 
partially diminished. In mouse models, homozygous knockout of Smchd1 is embryonic 
lethal in females, because of a defect in X-chromosome inactivation4. However, no 
models with heterozygous or homozygous missense variants have been reported.
Hemizygosity for SMCHD1 in FSHD2 and 18p deletion syndrome
In chapter 3 we describe microdeletions that delete the entire SMCHD1 locus and 
neighboring genes in two distantly related FSHD2 families. These families were first 
described as negative for SMCHD1 variants because of technical limitations of the 




variant analysis. This study shows that in FSHD2 patients SMCHD1 hemizygosity should 
be considered in the absence of heterozygous SMCHD1 SNPs. Four genes neighboring 
SMCHD1 were also deleted in these families, however hemizygosity of these genes 
has not been linked to disease thus far. This study also has important implications 
for patients with 18p deletion syndrome, who most often also have only one copy of 
SMCHD1. As expected, D4Z4 hypomethylation (based on observed FseI methylation) 
could be detected in most of these patients. However, only 18p deletion syndrome 
patients with an intermediate-sized permissive D4Z4 allele (≤16 units) are expected 
to be at risk of developing FSHD. Based on the prevalence of these intermediate-sized 
permissive D4Z4 alleles in the population, 1:8 18p deletion syndrome patients might 
be at risk of developing FSHD. From the current study, two 18p deletion syndrome 
patients have a D4Z4 repeat array in this size range, and are thus at risk to develop 
FSHD. However, information on their clinical status was unavailable. So far no muscular 
dystrophy phenotypes have been reported in 18p deletion syndrome patients. 
Nevertheless, clinicians should be aware of possible co-occurrence of 18p deletion 
syndrome with FSHD. To study possible D4Z4 derepression in 18p deletion patients 
with an intermediate-sized D4Z4 repeat array, it would be interesting to obtain muscle 
or skin biopsies from these individuals to study DUX4 expression. Since DUX4 is not 
expressed in fibroblasts derived from skin biopsies, a MyoD transduction would need to 
be performed to transdifferentiate them into myogenic cells in order to explore DUX4 
expression.
(Deep) intronic variants in SMCHD1 in FSHD2
In chapter 4 we identified an intronic variant and a deep intronic variant in SMCHD1 in 
two FSHD families. As a consequence of these variants, the intron is partially retained 
into the transcript. In the first family, a splice region variant was identified at c.1843-
15A>G (15 base pairs upstream of exon 14), which creates a 3’ splice site and results in 
the inclusion of 14 nucleotides of intron 13 into the transcript. The inclusion of these 14 
nucleotides in the transcript is predicted to disrupt the open reading frame by creating 
a premature stop codon. The intronic variant was detected in the proband and his 
unaffected sister, which both show D4Z4 hypomethylation (based on Delta1 values). 
The daughter of the proband was negative for the variant and does not show D4Z4 
hypomethylation. The proband carries a 14 unit permissive D4Z4 repeat array, which 
is in the common size range for FSHD2 (8-20 units). The sister remained unaffected 
because she carries two non-permissive alleles.
 In the second family, a deep intronic variant was identified at c.4347-236A>G (236 
base pairs upstream of exon 35), which results in the exonisation of 53 nucleotides from 
intron 34 into the transcript. This new exon is predicted to disrupt the open reading 
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frame by creating a premature stop codon in exon 35. The mother, the proband, and 
his siblings are all carriers of this deep intronic variant which segregates with D4Z4 
hypomethylation (based on Delta1 value). In addition, the father, the proband and his 
siblings are carriers of a 7 unit FSHD1 allele. In this family, the deep intronic variant in 
SMCHD1 is modifying disease severity since all three siblings are (severely) affected, while 
the father remained asymptomatic. The modifying role of SMCHD1 for FSHD disease 
severity has already been described in multiple FSHD1 families with borderline repeat 
array sizes where carriers of both an SMCHD1 variant and a FSHD1-sized allele are more 
severely affected than family members with only one of these conditions3; 5. Indeed, in 
this family the father carries a 7 units D4Z4 repeat array and remained unaffected as is 
seen more often for these upper sized FSHD1 alleles6; 7. The mother carries a permissive 
allele of 44 units, which is likely too long to develop FSHD2. This may explain why she 
remained unaffected.
Genome wide consequences of SMCHD1 variants
SMCHD1 is a chromatin modifier with an important role in silencing of D4Z4 and in 
X chromosome inactivation1; 4; 5. Additionally, SMCHD1 might have a role in epigenetic 
regulation of other loci, which also might be affected in FSHD2. Genome wide 
consequences of loss of Smchd1 have mainly been studied in mice, where Smchd1 has 
been shown to play an important role in methylation of CpG islands and gene silencing 
on the inactive X-chromosome as well as at some autosomal loci, including imprinted 
genes and the clustered protocadherin (Pcdh) genes4; 8-11. Also in human cell lines, human 
embryonic kidney (HEK293) cells and SH-SY5Y cells (a human neuroblastoma derived 
cell line), knockdown of SMCHD1 results in misregulation of X-chromosomal genes and 
autosomal genes, such as the PCDHβ gene cluster and imprinted genes12. However, the 
genome wide consequences of heterozygous SMCHD1 variants have not been studied 
extensively. A recent study compared the methylome of female carriers of an SMCHD1 
variant with female controls, and revealed that the majority of autosomal differentially 
methylated regions (DMRs) were located within or near gene clusters, with the PCDH 
gene cluster being most severely affected13. Using ChIP-qPCR, binding of SMCHD1 at 
PCDHβ cluster control region (CCR) hypersensitivity (HS) sites was identified in control 
primary myoblasts, which was reduced in FSHD2 primary myoblasts. In addition, 
expression of some of the PCDHβ isoforms was upregulated in FSHD2 myoblasts13. Also, 
in mouse neural stem cells binding of Smchd1 to the Pcdh cluster was identified, at the 
Pcdhα cluster regulatory HS site HS5-1, coinciding with upregulation of Pcdh genes in 
the alpha, beta and gamma clusters in mouse Smchd1-null neural stem cells and whole 
brain of male adult SMCHD1-null mice14. This suggests that there is tissue specific or 
species specific binding and regulation of the Pcdh genes by SMCHD1/Smchd1.




 Besides the PCDH gene cluster, some other gene clusters, such as the HOXB and 
HOXD clusters and the tRNA and 5S rRNA clusters, were also hypomethylated in SMCHD1 
variant carriers. In FSHD2 myoblasts expression of some tRNA isoforms and HOXB7 was 
upregulated. This study emphasizes that, besides the effect on D4Z4, heterozygous 
SMCHD1 variants also affect methylation at a limited number of autosomal gene clusters 
and influence expression levels of some genes in these regions. However, the changes 
in gene expression are limited.
 Limited effects of heterozygous SMCHD1 variants on transcriptional profiles in FSHD 
patients were already suggested by an earlier study of Yao et al., which revealed very few 
differentially expressed genes between FSHD1 and FSHD2 biopsies. However, the small 
sample size and large transcriptional effect due to DUX4 upregulation in FSHD patients 
might obscure subtle transcriptional changes because of SMCHD1 dysfunction15.
 The relevance of genome wide effects of SMCHD1 variants for the FSHD phenotype 
remains to be investigated. The phenotypic effects of SMCHD1 variants could be 
studied best in carriers of SMCHD1 variants without an FSHD permissive allele. No overt 
phenotypes have been described for carriers of an SMCHD1 variant in combination 
with two 4qB chromosomes and comorbidities in FSHD2 have not been reported. The 
limited effects of heterozygous SMCHD1 variants on genome wide methylation and 
gene expression suggest that upregulation of SMCHD1 might also have limited side-
effects. This would be beneficial when exploring SMCHD1 upregulation as a therapeutic 
strategy for FSHD.
DNMT3B variants in FSHD families
In chapter 5 we describe heterozygous missense variants in DNMT3B identified in two 
FSHD families. The first family is an FSHD1 family with a D4Z4 repeat array of 9 units, 
and D4Z4 hypomethylation (based on Delta1 value) in some family members. SMCHD1 
was excluded as the causative gene for D4Z4 hypomethylation by haplotype analysis 
of common SNPs in SMCHD1. Whole exome sequencing (WES) identified a missense 
variant in the ADD domain of DNMT3B segregating in three family members with D4Z4 
hypomethylation (based on Delta1 value). This variant was absent in all other family 
members with normal D4Z4 methylation levels. In this family, the DNMT3B variant 
explains the high clinical severity in two family members with both the FSHD1 allele and 
D4Z4 hypomethylation. Family members who carry only the FSHD1 allele of 9 units were 
either mildly affected, or even unaffected, as is seen more often for borderline FSHD1 
alleles6; 7. One of the family members carries the DNMT3B missense variant and shows 
hypomethylation (based on Delta1 value), but is unaffected, which can be explained by 
his relatively long permissive D4Z4 repeat array of 44 units. In concordance, no DUX4 
expression was detected in MyoD transduced fibroblasts from this individual with the 
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array of 44 units. Also for carriers of SMCHD1 variants the likelihood to develop FSHD is 
higher for individuals with smaller, normally sized D4Z4 repeat arrays (8-20 units) than 
for individuals with larger arrays2. In the second family, a missense variant in the catalytic 
domain of DNMT3B was identified in the proband and his unaffected father that shares 
a similar degree of D4Z4 hypomethylation (based on Delta1 value). Hypomethylation 
was absent in the brother of the proband with normal D4Z4 methylation. The father 
and the proband both carry a permissive D4Z4 repeat array of 13 units, which is in the 
common size range for FSHD2 patients. Incomplete penetrance is seen more often in 
FSHD families and this may explain the absence of disease in the father. In both carriers 
of this variant the Delta1 value is -22%, which is not as low as seen in most carriers of 
an SMCHD1 variant (average Delta1 value -31%)2. Possibly, this milder degree of D4Z4 
chromatin relaxation might contribute to the incomplete penetrance in this family. We 
were able to detect DUX4 expression in MyoD transduced fibroblasts from the proband 
of this family. Together, this suggests that heterozygous DNMT3B variants can only 
derepress DUX4 in combination with smaller D4Z4 repeat arrays and have incomplete 
penetrance.
 Homozygous or compound heterozygous variants in DNMT3B cause ICF1 syndrome. 
Due to the identification of heterozygous DNMT3B variants in FSHD2, we compared the 
clinical and epigenetic characteristics of carriers of heterozygous and homozygous/
compound heterozygous variants in DNMT3B from ICF1 and FSHD2 families. Severe 
D4Z4 hypomethylation was already described in ICF1 patients, and was also identified 
in the ICF1 patients we studied. Some of their parents, being carriers of a DNMT3B 
variant, also showed D4Z4 hypomethylation (based on Delta1 value), in a similar range 
as in the FSHD2 families with a DNMT3B variant. More severe hypomethylation (based 
on Delta1 value) is seen in the ICF1 patients, which suggests an additive effect of both 
DNMT3B variants, similar to what we have seen for carriers of two SMCHD1 variants. The 
D4Z4 hypomethylation detected in ICF1 patients and some of their parents, suggests 
that they might be at risk for expressing DUX4 and developing FSHD if they carry 
a permissive D4Z4 array. Indeed, we were able to detect DUX4 protein in myotubes 
of one ICF1 patient with a permissive D4Z4 array of 11 units. Additionally, we were 
able to detect DUX4 expression in MyoD transduced fibroblasts from two other ICF1 
patients, with permissive D4Z4 repeat arrays of 32 and 67 units, respectively. These in 
vitro experiments suggest that with homozygous or compound heterozygous DNMT3B 
variants there is sufficient epigenetic derepression to facilitate DUX4 expression, also 
from longer D4Z4 repeat arrays. However, muscular dystrophy has not been reported 
in ICF1 patients. The short life-expectancy of ICF1 patients might explain why they do 
not develop FSHD. There were no fibroblasts or myoblasts available from the parents 
of ICF1 patients that carry heterozygous DNMT3B variants associated with D4Z4 




hypomethylation. However, none of the ICF1 parents we studied carried a permissive 
D4Z4 array in the FSHD2 range, so we expect that they are unlikely to develop FSHD2. 
Nevertheless, clinicians should be aware of the possible co-occurrence of FSHD in ICF1 
families.
 We also examined some characteristics of ICF syndrome (chromosomal anomalies, 
NBL2 hypomethylation and immune deficiency) in carriers of heterozygous DNMT3B 
variants from the FSHD families. For one individual in the first family, which carries a 
missense variant in the ADD domain of DNMT3B, mild NBL2 hypomethylation and a 
low frequency of chromosomal anomalies was detected. However, no immunological 
features of ICF syndrome were identified in this individual. Similarly, no immunological 
abnormalities have been reported in the parents of ICF patients. The FSHD2 patient in 
the second family with a variant in the catalytic domain of DNMT3B did not show NBL2 
hypomethylation or chromosomal anomalies. The variant in this patient might cause 
a milder methylation defect, which also corresponds with the less severe effect of this 
variant on D4Z4 methylation.
Unexplained FSHD cases
With the identification of intronic variants in SMCHD1 in two families, SMCHD1 
hemizygosity in two families, and DNMT3B missense variants in two other families, 
we were able to explain D4Z4 hypomethylation in six families for which the disease 
etiology had remained enigmatic. These families emphasize the importance of further 
variant screening when D4Z4 hypomethylation is present in the absence of exonic 
SMCHD1 variants. However, some FSHD families with D4Z4 hypomethylation (based on 
Delta1 value) cannot be explained by exonic variants in SMCHD1 or DNMT3B. We expect 
that D4Z4 hypomethylation in these families could be explained by other variants in 
SMCHD1 or DNMT3B, other gene defects, or a combination of variants. Possibly, similar 
to the family we described in chapter 4, deep intronic variants in SMCHD1 or DNMT3B 
might be involved in unexplained families with D4Z4 hypomethylation. Whole genome 
sequencing (WGS) or RNA sequencing could be performed to identify deep intronic 
variants. In addition, variants in introns, promotor, or regulatory regions of SMCHD1 might 
alter SMCHD1 transcript and protein levels and could result in D4Z4 hypomethylation 
and disease presentation. These types of variants can be identified by WGS or Sanger 
sequencing of these regions. However, reduced SMCHD1 protein levels might be muscle 
specific, making it more difficult to assess effects of these variants when no myogenic 
cells are available. Furthermore, the information on regulatory regions of SMCHD1 is 
limited and therefore the functional consequences of identified variants will be difficult 
to predict. Indeed, a recent study performed an in silico prediction of regulatory regions 
of SMCHD1 and screened these regions for variants in FSHD patients. In two FSHD 
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families a variant in a putative regulatory region was identified, however segregation 
with D4Z4 hypomethylation was inconclusive16. To study the functional effects of 
variants in regulatory regions reporter assays should be developed, in combination with 
segregation analysis of D4Z4 hypomethylation.
 In addition to variants in SMCHD1 and DNMT3B, there might be other gene defects, 
possibly in genes encoding proteins of the D4Z4 silencing complex, involved in FSHD 
patients with unexplained D4Z4 hypomethylation (based on Delta1 value). However, 
with WES we were so far unable to explain D4Z4 hypomethylation in these individuals. For 
these cases identification of causative variants will be more successful when DNA from 
multiple family members with and without hypomethylation is available. Alternatively, 
(combinations of ) rare variants in chromatin modifiers, might have an unknown effect 
on protein function and therefore contribute to defects in D4Z4 methylation.
 We also identified some patients clinically diagnosed with FSHD who don’t have a 
contracted allele nor D4Z4 hypomethylation (Lemmers et al. unpublished results). Some 
of these patients might be affected with another muscular dystrophy with a (partially) 
overlapping phenotype, as differential diagnosis is sometimes challenging17. For those 
of whom a firm clinical FSHD diagnosis has been established, it would be interesting to 
focus not only on one aspect of D4Z4 chromatin relaxation, i.e. hypomethylation, but 
rather to assess DUX4 expression. Since muscle biopsies are quite invasive, it would be 
more convenient to obtain skin biopsies from these patients and to perform a MyoD 
transduction on skin fibroblasts, followed by a transdifferentiation to study DUX4 
expression. Recently, a protocol describing MyoD transformation and differentiation of 
urine derived cells was published18. This makes urine cells very useful as a non-invasive 
source of myogenic cells. However, it remains to be tested if DUX4 expression can be 
detected in urine derived myotubes from FSHD patients, and is absent in urine cells 
from controls. Another recent publication identified DUX4 expression in Epstein–
Barr virus (EBV) transformed B-LCLs (lymphoblastoid cell lines) from FSHD patients19. 
Upregulation of DUX4 target genes was also identified in a LCLs from an ICF1 patient20. 
Since LCLs can be derived from blood, this suggest that this might also be a less invasive 
source of cells, compared to skin or muscle biopsies, to study DUX4 expression.
Gender bias in ICF2
In chapter 6 we extend the mutation spectrum for the two most common forms of ICF 
syndrome, ICF1 (recessive DNMT3B variants) and ICF2 (recessive ZBTB24 variants). In 
seven ICF patients recessive missense variants in DNMT3B were identified (ICF1). Four 
ICF1 patients from consanguineous families had homozygous DNMT3B variants, and 
the remaining three were compound heterozygotes for DNMT3B variants. All missense 
variants we identified are located in the catalytic domain of DNMT3B, and are expected to 




decrease the catalytic activity of DNMT3B. In four ICF patients we identified homozygous 
nonsense variants in ZBTB24 (ICF2). Homozygous nonsense variants are often detected 
in ICF2 patients, and are suggested to result in the absence of ZBTB24 protein. In one 
ICF2 patient we identified a homozygous deletion on chromosome 6, which includes 
ZBTB24 and several neighboring genes. This patient confirms that complete absence 
of ZBTB24 is compatible with life. This is in contrast to homozygous Broad-Complex, 
Tramtrack, and Bric a Brac (BTB) domain deletion in mice, a condition that is embryonic 
lethal. This suggests that ZBTB24 has (partial) different functions in human and mice. 
With the addition of these 12 patients, a total of 77 genetically confirmed ICF patients 
have been reported. We calculated the frequencies of the different ICF subtypes: 56% 
of the ICF patients carry DNMT3B variants (ICF1), 31% carry ZBTB24 variants (ICF2), 7% 
carry CDCA7 variants (ICF3) and 7% carry HELLS variants (ICF4). A statistically significant 
gender bias was detected for ICF2 patients, with 79% male and 21% female patients. 
This gender bias seems to be restricted to ICF2, since no gender bias was identified in 
the ICF1 cohort or the total ICF patient population. So far five female ICF2 patients have 
been reported, three of them carry homozygous or compound heterozygous nonsense 
variants. This suggests that although ZBTB24 variants seem to be more deleterious 
in females, female embryos can survive in the absence of full length ZBTB24 protein. 
To explain the mechanism behind this gender bias in ICF2, studies addressing the 
function of ZBTB24 are required. So far, studies of ZBTB24 function revealed that it acts 
as a transcriptional activator and/or repressor21; 22. Since GFP-ZBTB24 colocalizes with 
heterochromatin in NIH3T3 cells23, it might have a function in X-inactivation, although 
ZBTB24 colocalization with the Barr body has not been reported.
 It is important to perform genotype-phenotype studies in ICF patients to better 
understand the clinical spectrum of this disease. However, since the disease is very rare 
and patients are seen by different clinicians, it is currently impossible to draw conclusions 
about genotype-phenotype correlations. One of the ICF2 variants (ZBTB24 c.917delA) is 
found within multiple families, and the effect on immunoglobulin subtype abundance 
and B-cell numbers vary among these patients. Similarly, from two siblings with ICF1, 
only one shows intellectual disability. This indicates that already with the same variant, 
the phenotype is variable.
 Remarkably, homozygous missense variants in ZBTB24 were recently also identified 
in a male patient with congenital anomalies of the kidneys and urinary tract (CAKUT) 
syndrome, which was characterized by bilateral vesicoureteral reflux (VUR). The 
patient also had intellectual disability, growth retardation and deafness, but no overt 
immunodeficiency. Intellectual disability and growth retardation are also seen in ICF 
patients, and specifically in ICF2 intellectual disability is very common24. Furthermore, 
congenital abnormalities in ICF patients have been reported more frequently24, and 
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in one ICF1 patient vesicoureteral reflux has been described25. However, it is very 
remarkable that this patient doesn’t have an immune defect, since no asymptomatic 
carriers of homozygous ZBTB24 variants that affect function have been reported. The 
missense variant in this patient (c.1457G>A p.Gly486Asp) affects a highly conserved 
amino acid in the seventh Zinc finger of ZBTB2426. Missense variants are rare in ICF2, 
and no missense variants in this part of the protein have been identified in ICF2 patients. 
Possibly, the absence of an overt immunodeficiency might be related to difficulties in 
establishing disease causality, to the location of the variant in the protein, or the patient 
might be protected by an unknown mechanism. It would be interesting to investigate 
whether this patient has centromeric instability and hypomethylation of pericentromeric 
repeats. Furthermore, this case exemplifies the need for functional tests for ZBTB24. 
Since ZBTB24 has been reported to regulate CDCA7 transcriptional activity21, a Cdca7 
reporter assay in mouse embryonic stem (ES) cells might help to define the functional 
consequences of Zbtb24 variants (Wu et al. in preparation).
DNMT3B variants cause discordant phenotypes: ICF and FSHD
The identification of DNMT3B variants in FSHD families, indicates that recessive or 
dominant variants in the chromatin modifier DNMT3B can cause very discordant 
phenotypes. In one of the FSHD families a variant in the ADD domain of DNMT3B 
was identified. Variants in the ADD domain of DNMT3B have never been reported in 
ICF1 syndrome. However, variants in the highly homologous ADD domain of DNMT3A 
and ATRX have been reported in Tatton-Brown-Rahman overgrowth syndrome (TBRS 
[OMIM: 615879])27 and alpha thalassemia-mental retardation syndrome, X-linked (ATR-X 
[OMIM: 301040])28, respectively.
 For DNMT3A a model was proposed where DNMT3A exists in two forms, an active 
and an auto-inhibitory form. In the auto-inhibitory form, the ADD domain interacts with 
the catalytic domain, preventing it from binding to DNA. When DNMT3A is recruited 
to chromatin, unmethylated histone H3 lysine 4 (H3K4me0) binds to the ADD domain 
and stimulates a conformational change into the active form of DNMT3A, which is not 
induced by H3K4me3. This mechanism connects histone modification status with DNA 
methylation29. Moreover DNMT3B binds H3K4me0, and this interaction is disrupted by 
methylation of H3K430. Since DNMT3A and DNMT3B are highly homologous, a similar 
auto-inhibitory mechanism of the ADD domain could be envisioned for DNMT3B. This 
suggests that the variant in the ADD of DNMT3B could disturb the auto-inhibitory form 
of DNMT3B, but it might also disturb the total structure of the protein.




 Although variants in the ADD domain have never been reported in ICF1 patients, 
the missense variant in the ADD domain described in our FSHD family, might cause ICF1 
when present in a homozygous or compound heterozygous state. This is supported by 
the observation of mild ICF features (NBL2 hypomethylation, chromosomal anomalies) 
detected in one of the carriers.
 The DNMT3B variant in the second FSHD family is located in the catalytic domain 
of DNMT3B, similar to most variants in ICF1 patients. This type of variants is expected to 
reduce the methyltransferase function of DNMT3B. The variant identified in this family 
has never been reported in ICF patients, but might also cause ICF when present in a 
homozygous or compound heterozygous state.
 To study the effect of heterozygous DNMT3B variants on D4Z4 methylation, 
we measured D4Z4 methylation in some parents and siblings of ICF1 patients. It is 
interesting that some but not all heterozygous missense variants in the catalytic 
domain of DNMT3B cause D4Z4 hypomethylation (based on Delta1 value) in the 
parents or siblings of ICF1 patients. The DNMT3B c.2177T>G (p.Val726Gly) variant 
did not cause D4Z4 hypomethylation in three heterozygous carriers from one ICF1 
family. On the other hand the DNMT3B c.1807G>A (p.Ala603Thr) variant and DNMT3B 
c.1918G>C (p.Gly640Arg) variant present in two other ICF1 families are associated with 
D4Z4 hypomethylation in one and two heterozygous carrier(s), respectively. Possibly 
the methylation status at D4Z4 could be related to differences in residual activity, 
protein interactions, or localization of mutant DNMT3B protein. For some ICF1 variants 
(including p.Val726Gly and p.Ala603Thr) the functional consequences were studied by 
in vitro assays using human DNMT3B or the corresponding variants in mouse Dnmt3b. 
Although normal levels of D4Z4 methylation are present in heterozygous carriers of 
DNMT3B p.Val726Gly, recombinantly produced Dnmt3b containing the corresponding 
variant in mouse (p.Val732Gly) showed no or very little residual activity in in vitro 
functional assays31-33. Similarly, DNMT3B p.Ala603Thr or the corresponding variant in 
mouse (p.Ala609Thr) also shows little residual activity when recombinantly produced 
or introduced in Dnmt3a–/–Dnmt3b–/– embryonic stem (ES) cells32; 34, although in one 
study the in vitro activity of Dnmt3b p.Ala609Thr was slightly higher than for Dnmt3b 
p.Val732Gly32. Thus, the difference in D4Z4 hypomethylation does not seem to be 
explained by the presence/absence of residual activity in in vitro assays. Alternatively, 
the difference might be related to the disturbance of protein-protein interactions of 
DNMT3B. Co-immunoprecipitation indicated that Dnmt3b p.Ala609Thr disturbs the 
interaction with Dnmt3a as well as homodimerization of Dnmt3b34. The interaction 
between Dnmt3a and Dnmt3b was not disrupted by Dnmt3b p.Val732Gly34. However, 
in a glutathione S-transferase (GST) pull down assay this variant reduced the strength 
of the interaction with Dnmt3L31. In addition, both Dnmt3b p.Ala609Thr and Dnmt3b 
15127-vandenboogaard-layout.indd   177 09/01/2018   15:26
178
Chapter 7
p.Val732Gly showed altered subcellular localization in NIH3T3 embryonic fibroblasts34. 
Although the disturbance of protein-protein interactions might be relevant, thus far 
these functional studies were limited to few ICF1 variants, and therefore they cannot 
provide an explanation why some heterozygous DNMT3B variants do not cause D4Z4 
hypomethylation. To better understand these differences, more information on D4Z4 
methylation status (Delta1 values) from ICF1 family members, in combination with 
extended functional studies of mutant proteins is necessary. To determine the Delta1 
value, full D4Z4 repeat array sizing information is necessary, for which high molecular 
weight DNA in agarose plugs is required. Unfortunately, in most cases only low quality 
DNA is available from ICF1 patients and their family members, which is insufficient 
to determine their Delta1 value. Therefore, for many heterozygous DNMT3B variants 
the effect on D4Z4 methylation based on the Delta1 value is unknown. It would 
be interesting to study the effect of more heterozygous DNMT3B variants on D4Z4 
methylation in more carriers by bisulfite sequencing of D4Z4, for which less DNA of a 
lower quality is required35; 36.
 An alternative way to study the effects of DNMT3B variants on D4Z4 chromatin 
structure and DUX4 expression, is to individually introduce these variants by CRISPR/
Cas9 genome editing in a controlled genetic background with an intermediate-sized 
D4Z4 repeat array, for example in genetically defined human induced pluripotent stem 
(iPS) cells or in embryonic stem (ES) cells from the transgenic D4Z4-12.5 mice carrying 
a human D4Z4 repeat array of 12.5 units (12.5 D4Z4 mES cells). In human iPS cells DUX4 
is expressed, which is silenced upon differentiation to embryoid bodies in control iPS 
cells, but not in FSHD iPS cells37. Similarly, DUX4 is expressed in 12.5 D4Z4 mES cells, 
and silenced during differentiation. iPS cells or 12.5 D4Z4 mES cells with heterozygous 
or homozygous DNMT3B variants could be differentiated to assess the effect of the 
variants on D4Z4 methylation and DUX4 expression. Furthermore, to study if the FSHD 
variants in DNMT3B might also cause ICF1 when present homozygously, these variants 
could be introduced homozygously in iPS cells to compare genome wide methylation 
patterns with ICF1 iPS cells.
 For the other ICF subtypes (ICF2, ICF3 and ICF4), no D4Z4 hypomethylation has 
been reported, although the availability of high molecular weight DNA often limits 
the calculation of Delta1 values. From the observed FseI methylation we can conclude 
that the D4Z4 methylation is not as low as for ICF1 patients. Currently, it is also unclear 
if variants in ZBTB24, CDCA7, and/or HELLS have other effects on D4Z4 chromatin 
structure. With MyoD transductions and ChIP experiments the effects of these variants 
on D4Z4 repression and chromatin structure could be studied. However, the limited 




availability of patient material (with a permissive D4Z4 allele) hampers these studies. 
Therefore, perhaps a better way to study these effects is to make use of CRISPR/CAS9 
edited human iPS cells or 12.5 mES cells, as suggested above for DNMT3B variants.
SMCHD1 variants cause discordant phenotypes: FSHD and arhinia/BAMS
Very recently, two papers described variants in SMCHD1 in a total of 40 probands 
with arhinia, a rare congenital malformation characterized by the complete or partial 
absence of an external nose38; 39. Other craniofacial defects can co-occur with arhinia, 
and a severe combination of arhinia with ocular and reproductive defects is referred to 
as Bosma arhinia microphthalmia syndrome (BAMS, OMIM 603457). SMCHD1 variants 
were identified in individuals with BAMS as well as isolated arhinia.
 In contrast to FSHD2, where SMCHD1 variants can be found over the entire locus 
and include both haploinsufficiency and loss of function variants2, the SMCHD1 variants 
found in arhinia/BAMS patients are all missense variants in exons 3 to 1338; 39. These 
exons encode the GHKL type ATPase domain and an adjacent region of SMCHD1. 
Missense variants in these exons have also been identified in FSHD2 patients, and one 
of the SMCHD1 variants identified in an arhinia patient, was previously identified in an 
FSHD2 patient38.
D4Z4 methylation was tested in both studies with bisulfite sequencing of D4Z4 at 
chromosomes 4 and 10 simultaneously. Interestingly, Shaw et al. detected D4Z4 
hypomethylation in 74% of the arhinia/BAMS patients. Gordon et al. identified only 
a trend towards D4Z4 hypomethylation in arhinia/BAMS patients compared to their 
unaffected relatives and controls. Since the D4Z4 repeat array size influences D4Z4 
methylation, some of the arhinia/BAMS patients might not show hypomethylation with 
this assay because of long D4Z4 repeat arrays. Nevertheless, this shows that FSHD2 
patients and (some) arhinia/BAMS patients share D4Z4 hypomethylation.
 Gordon et al. suggest that the SMCHD1 variants found in arhinia/BAMS patients 
might result in a gain of function of the SMCHD1 protein, as opposed to a loss of function 
mechanism in FSHD. This was based on the observation that three different arhinia/
BAMS variants introduced in the recombinant N-terminal domain of mouse Smchd1 
gave increased ATPase activity compared to wildtype SMCHD1. One other arhinia/BAMS 
variant did not have an effect in this assay. In contradistinction, two FSHD2 variants in 
SMCHD1 resulted in slightly or strongly decreased ATPase activity. Injections in Xenopus 
embryos with mutant and wildtype human SMCHD1 revealed craniofacial defects only 
in tadpoles with arhinia/BAMS variants or very high levels of wildtype SMCHD1, but 
not with an FSHD2 variant. Together these experiments suggest that the arhinia/BAMS 
variants in SMCHD1 might have a gain of function effect, in contrast to FSHD2 variants, 
which result in a loss of function effect. However, this effect has only been tested for a 
15127-vandenboogaard-layout.indd   179 09/01/2018   15:26
180
Chapter 7
small number of SMCHD1 variants. On the contrary, Shaw et al. performed experiments 
with a zebrafish model which gave opposite results for arhinia/BAMS variants. 
Knockdown of the orthologue of SMCHD1 in zebrafish results in craniofacial, ocular 
defects and a reduction of gonadotropin-releasing hormone (GnRH)-positive terminal 
nerve length. However, overexpression of SMCHD1 wildtype or mutants did not result in 
craniofacial defects, arguing against a gain of function mechanism. In the zebrafish with 
a knockdown for endogenous Smchd1 the GnRH-positive terminal nerve length could 
be rescued with wildtype SMCHD1, but not with SMCHD1 with an arhinia/BAMS or FSHD2 
variant. This suggests that a loss of function effect is shared by FSHD2 and arhinia/BAMS 
variants in SMCHD1, which fits with the fact that one SMCHD1 variant was found in both 
an FSHD2 and an arhinia family and with the shared D4Z4 hypomethylation. On the 
other hand, the specificity for missense variants in exons 3-13 in arhinia/BAMS patients, 
indicates that mutant SMCHD1 protein is produced in all arhinia/BAMS patients and that 
this domain has a specific role in the disease mechanism of arhinia/BAMS. Although the 
gain of function and loss of function mechanisms suggested by Gordon et al, and Shaw 
et al. respectively, seem to be contradictory, they might both result in the absence of 
SMCHD1 on chromatin, by either more active release or by less binding40.
 Besides an SMCHD1 variant and D4Z4 hypomethylation, FSHD2 requires a permissive 
4qA allele with a D4Z4 repeat array <20 units, therefore only some of the arhinia/BAMS 
patients might be at risk for FSHD2. Phenotypic evaluation of two arhinia/BAMS patients, 
which likely met all these criteria for FSHD2, was performed and at least one of them 
showed FSHD2 symptoms. This confirms that at least some SMCHD1 variants can cause 
both FSHD2 and arhinia/BAMS, even in the same individual. However, the question 
remains why FSHD2 patients, especially with a missense variant in exons 3 to 13, do 
not show signs of arhinia/BAMS. One explanation could be that SMCHD1 variants are 
insufficient by themselves to cause an arhinia/BAMS phenotype, like SMCHD1 variants 
by themselves are insufficient to cause FSHD2. Therefore, it seems reasonable that there 
is a second locus involved in arhinia/BAMS, similar to FSHD. Although, one of the groups 
reports that they were unable to identify significant differences in genome-wide de-
repression of repeats between arhinia/BAMS subjects and familial controls, there might 
be a specific repeat that is involved in arhinia/BAMS. There is large clinical variability 
among carriers of an SMCHD1 variant within arhinia/BAMS families, with some carriers 
remaining completely unaffected. If a repeat would be involved, it is possible that size 
and/or haplotype differences might help to explain clinical variability, similar to what is 
observed in FSHD.
 Shaw et al. also performed studies to identify differential gene expression between 
arhinia/BAMS subjects and familial controls. Some genes involved in craniofacial 
development were downregulated in arhinia/BAMS patients, indicating that SMCHD1 




is a regulator of these genes38. It would be interesting to study the expression of these 
genes in FSHD2 patients and to compare genome wide expression profiles of arhinia/
BAMS and FSHD2 patients with an SMCHD1 variant, to assess similarities and differences 
between the two syndromes.
Identifying functional convergence among ICF genes
The number of ICF genes has recently been increased to four: DNMT3B, ZBTB24, CDCA7 
and HELLS. Almost all patients show the phenotypic characteristics of immunodeficiency, 
facial anomalies and centromeric instability. The phenotypes vary amongst patients, 
but this cannot be attributed to a specific gene defect. Besides these characteristics, ICF 
patients often have a delay in motor and/or speech development. Intellectual disability 
is also regularly seen in ICF syndrome. Almost all ICF2 patients present with intellectual 
disability, compared to about half of the ICF1 patients24. However, in our study we 
also identified an ICF2 patient with normal intelligence, indicating that the absence of 
intellectual disability does not exclude ZBTB24 variants in ICF patients.
 The high similarity in phenotypes between the different ICF patient subgroups 
indicates that the function of the proteins involved converge somewhere in the disease 
mechanism. Furthermore, although the molecular phenotype of centromeric instability 
and hypomethylation of repetitive regions is detected for all ICF disease entities, no 
clear relation with the immunodeficiency and facial anomalies has been described.
 DNMT3B and HELLS interact in the establishment of CpG methylation during early 
development41. Hells recruits Dnmt3b to repeat sequences (IAP elements, minor satellites 
and Line1 elements) in mouse ES cells41, and knockdown of Hells leads to reduced 
methylation at these repetitive regions41; 42. Besides its role in methylation of repetitive 
regions, Hells knockdown also affects methylation at non-repeat sequences sites and 
alters gene expression of some of the affected genes43-46. In addition, the transient 
depletion of Hells in mouse embryonic fibroblasts (MEFs) resulted in a reduction in DNA 
methylation at murine minor satellite repeats47. A transient depletion of Dnmt3b did 
not result in a reduction in DNA methylation at murine minor satellite repeats47. This 
indicates that Hells, but not Dnmt3b, is involved in the maintenance of DNA methylation 
at repetitive regions. In agreement with a role in methylation maintenance, Hells is also 
involved in the methylation at an imprinted region44, binds indirectly to Dnmt148, and 
colocalizes with late replication foci49. On the other hand, Hells was not required for the 
maintenance of methylation of an episomal vector50. Possibly, Hells has a role in the 
maintenance of methylation at specific loci.
 In MEFs transiently depleted for Zbtb24 and Cdca7, decreased methylation at minor 
satellite repeats was detected, indicating that these proteins might also have a role in the 
maintenance of CpG methylation47. However, for ZBTB24 and CDCA7 there is currently 
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no functional explanation for their role in maintaining (and possibly establishing) 
DNA methylation at repetitive DNA. The functions of ZBTB24 and CDCA7 have not 
been studied extensively. ZBTB24 belongs to the BTB-ZF family of proteins and might 
function as a transcription factor51. CDCA7 has a role in neoplastic transformation and 
hematopoietic stem cell emergence, through interactions with Myc and activation by 
Notch, respectively52-54. Recently, a functional connection between ZBTB24 and CDCA7 
was discovered, since ZBTB24 controls expression of CDCA721. In mouse embryonic stem 
cells siRNA knockdown of Zbtb24 reduced not only Zbtb24 expression but also Cdca7 
expression, indicating that ZBTB24 is a transcriptional activator of CDCA7. A similar 
effect was also detected in fibroblast of ICF2 patients, which have reduced expression 
of both ZBTB24 and CDCA7. ChIP-qPCR also confirmed binding of ZBTB24 to the CDCA7 
promoter, suggesting that ZBTB24 modulates CDCA7 expression via a direct interaction 
with the CDCA7 promoter. siRNA knockdown of the other ICF genes did not reveal any 
other transcriptional interactions between the ICF genes21.
 Although two links between two ICF genes have been made, the pathological 
mechanism involved in ICF syndrome has not been unraveled. Most functional studies 
have thus far been performed in ICF1 patient cell lines, which revealed hypomethylated 
regions, differentially expressed genes, alternative transcription start sites usage, 
alternative splicing, deregulated antisense transcription, changes in nuclear architecture 
and altered replication timing55-67. Although these studies did not deduce a complete 
disease mechanism, it would be valuable to study these alterations in all ICF subtypes 
to identify common changes, which likely contribute to the development of ICF.
 Besides studies in human cell lines, mouse models might also be valuable to 
study the functions of ICF genes. However, knockout mouse models of Dnmt3b, Hells 
and Zbtb24 were found to be embryonic lethal21; 68; 69. For Hells and Zbtb24 this is in 
contrast to the situation in humans, where homozygous nonsense alleles are viable24; 
47. For CDCA7 only homozygous missense variants have been identified so far in ICF3 
patients47, suggesting that it might be more relevant to create missense variants in Cdca7 
to establish a ICF3 mouse model, then to make a knockout. Indeed, while homozygous 
knock out of Dnmt3b is embryonic lethal, mouse models with homozygous or 
compound heterozygous ICF missense variants in Dnmt3b are viable and show some 
characteristics of ICF syndrome such as facial anomalies and hypomethylation of germ 
line genes and repetitive regions34; 70; 71. A B-cell defect is absent in these mice, however, 
they show increased T-cell apoptosis and reduced numbers of total thymocytes34. 
About 20% of ICF patients show opportunistic infections, which suggest that there 
might also be T-cell dysfunction in ICF patients. However, the B-cell dysfunction is more 
pronounced in ICF syndrome24.




 Because of the lethality in mice from the loss of Dnmt3b, Hells and Zbtb24, an 
alternative approach to study their role in immune cell development would make use of 
immune compromised recipient mice transplanted with fetal liver cells of embryo’s with 
a knockout of one of these genes. Such an approach was already performed for Hells, 
where fetal liver cell suspensions from Hells knockout embryos were injected in Rag2 
knockout mice, which lack lymphoid cells. The resulting chimeras showed a reduction in 
peripheral T lymphocytes and a reduction in mature B-cells 69. To understand the disease 
mechanism of ICF, it will be essential to study the role of all four ICF genes in immune 
cell development in more detail.
The role of DUX4 in development and FSHD pathology
DUX4 has been identified as a transcription factor that becomes inappropriately 
expressed in FSHD myocytes with toxic consequences to the muscle. Although both 
overexpression and endogenous expression of DUX4 lead to apoptosis, it is not entirely 
clear which mechanisms contribute to DUX4 induced cell death and how this results in 
the development of a muscular dystrophy72; 73.
 DUX4 was first identified as a toxic protein in by Kowaljow et al., who reported 
that DUX4 activates caspase 3/7 activity, indicative of apoptosis73. Since then various 
pathways have been identified that might contribute to the induction of apoptosis 
after DUX4 expression. DUX4 induced apoptosis was shown to be dependent on P53 
in HEK293T cells transfected with DUX4 as well as in skeletal muscle of mice injected 
with DUX4 AAV virus74. However, in C2C12 mouse myoblasts and a mouse model with a 
doxycycline-inducible DUX4 transgene, DUX4 induced pathogenicity was independent 
of P5375. In addition, in human myoblasts and a RD rhabdomyosarcoma cell line 
DUX4 efficiently induced apoptosis in the absence of functional P5376. Furthermore, 
doxycycline induction of DUX4 expression increases MYC protein levels by stabilization 
of MYC mRNA and activates components of the MYC-mediated apoptotic pathway 
in a RD rhabdomyosarcoma cell line and immortalized human myoblasts. Both cell 
lines also showed an accumulation of nuclear double stranded RNA (dsRNA) foci. The 
accumulation of dsRNAs might induce apoptosis via a pro-apoptotic dsRNA-sensing 
innate immune response. In addition, the accumulation of dsRNAs is associated with 
the formation of EIF4A3 protein aggregates76. Since EIF4A3 plays a role in mRNA 
surveillance and decay, DUX4 might inhibit nonsense mediated decay (NMD) via EIF4A3 
aggregation, amongst other mechanisms such as the degradation of UPF177. The 
inhibition of NMD might result in an accumulation of alternative transcripts containing 
premature stop codons and aberrant spliced exons, which is detected in DUX4 
expressing myoblasts72; 77. In addition, DUX4 also binds and activates transcription of 
transposable elements such as mammalian apparent LTR-retrotransposons (MaLRs) and 
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endogenous retrovirus (ERVL and ERVK) elements78; 79. At some of these elements DUX4 
creates alternative transcription start sites, therefore creating novel transcripts, which 
are expressed in FSHD muscle cells but not in control muscle cells79. DUX4 also induces 
genes that are involved in muscle atrophy in FSHD myoblasts and elevates levels of 
reactive oxygen species and DNA damage, which might affect myogenic differentiation 
of FSHD myoblasts80; 81. Furthermore, DUX4 expression in myotubes also alters nuclear 
body structure (PML bodies and SC35 speckles) and induces coaggregation of two RNA/
DNA handling protein (FUS and TDP43)82; 83. All these pathways might play a role in the 
FSHD disease mechanism, however their exact contributions to FSHD pathology remain 
to be investigated.
 In addition to the toxic effects of DUX4 in FSHD, the evolutionary conservation of 
DUX4 suggests that there is an important normal function for DUX4. Studies of early 
human embryos revealed that DUX4 is specifically expressed at the 4-cell stage, which 
corresponds to early embryonic genome activation, and activates cleavage specific 
genes and repetitive elements84; 85. Mouse Dux is also expressed during the 2-cell stage, 
which corresponds to the onset of embryonic genome activation in mouse84. Mouse 
Dux also activates cleavage specific genes and repetitive elements, while embryonic 
genome activation is disrupted in the absence of mouse Dux84-86. Therefore, human 
DUX4 and mouse Dux have a conserved role in activating cleavage specific genes 
and repetitive elements84-86, although they show only modest amino acid sequence 
conservation87. These studies indicate a normal function for DUX4 in early embryonic 
development, besides its role in FSHD pathology. However it remains to be investigated 
what activates and subsequently silences DUX4 during early cleavage stage, and how 
this is relevant to DUX4 expression in FSHD muscle.
The FSHD disease continuum
FSHD1 and FSHD2 have been described as two separate disease entities, with a shared 
disease mechanism of D4Z4 chromatin relaxation and DUX4 derepression. However, 
older and recent studies emphasize the importance of the size of the D4Z4 repeat array 
in both FSHD1 and FSHD2, and indicate that there is a repeat array size dependent 
disease severity in both forms of the disease2; 88-91. In addition, multiple families with 
both an FSHD1-sized allele of 7-10 units and an SMCHD1 or DNMT3B variant have been 
identified during the last years2; 3; 5. Permissive D4Z4 repeat arrays of 7-10 units are also 
found in 1-3% of the control population6; 7. This suggests that, rather than two separate 
disease entities, FSHD1 and FSHD2 are opposite extremes of a disease continuum. With 
very short D4Z4 repeat arrays of 1-6 units the contraction by itself is largely sufficient 
for DUX4 derepression and disease presentation in somatic cells. With longer repeat 
arrays the ability to repress DUX4 depends on a combination of the repeat array size 




and the functionality or level of epigenetic modifiers of D4Z4 such as SMCHD1 and 
DNMT3B. Variability in disease penetrance between families with SMCHD1 variants is 
dependent on the type of variant and the repeat length, while variability within families 
often depends on the repeat array size. Not all variability can be explained by repeat 
array size and variants in SMCHD1 or DNMT3B. Thus, there are likely other genetic risk 
factors including in cis (e.g. differences in the sequence of the FSHD1 locus) and in 
trans modifiers (other epigenetic modifiers) that influence disease severity, in addition 
to other modifiers such as those that affect the DUX4 downstream pathways. The 
involvement of additional genetic risk factors may also explain why variants in SMCHD1 
and DNMT3B are associated with the discordant phenotypes: FSHD, ICF1 or BAMS. In 
isolation, damaging variants in one allele of these chromatin modifiers is insufficient 
to cause disease, as evidenced by the absence of disease phenotypes in carriers of an 
DNMT3B variant, or carriers of an SMCHD1 variant in the absence of a permissive DUX4 
allele. However, when combined with other genetic risk factors, such as a short D4Z4 
repeat array size, the presence of a DUX4 PAS, and/or yet unknown risk factors, these 
variants are lowering the threshold for disease presentation.
Concluding remarks
In this thesis, the mutation spectrum of FSHD and ICF, two diseases with very distinct 
phenotypes that share a common feature of hypomethylation of repetitive DNA, has 
been expanded. The SMCHD1 mutation spectrum in FSHD2 has been expanded with 
the discovery of exonic SMCHD1 variants, intronic SMCHD1 variants, and whole SMCHD1 
gene deletions. In addition, we identified heterozygous variants in a new FSHD2 gene, 
DNMT3B, in two FSHD2 families. For ICF syndrome we expanded the mutation spectrum 
in the two most common ICF genes, DNMT3B and ZBTB24. All of the aforementioned 
findings enabled us to identify the causative variants in previously unexplainable cases 
of FSHD and in new ICF patients, expanding the knowledge base for these diseases and 
setting the stage for further studies.
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Epigenetic regulation by chromatin modifiers needs to be tightly controlled to ensure 
correct patterns of gene expression. Misregulation of epigenetic processes can lead to 
disease, as is the case in FSHD and ICF syndrome. FSHD and ICF share a common hallmark 
of hypomethylation of repetitive DNA. FSHD is a muscular dystrophy mainly affecting the 
facial, shoulder girdle, and upper arm muscles. It is characterized by partial chromatin 
relaxation of the DUX4 encoding D4Z4 macrosatellite repeat located on chromosome 
4, and transcriptional derepression of the DUX4 transcription factor in skeletal muscle. 
D4Z4 chromatin relaxation is consistently marked by CpG hypomethylation of the D4Z4 
repeat, including the DUX4 promoter. In the most common form, FSHD1, this chromatin 
relaxation is the result of a repeat contraction of the D4Z4 repeat to 1-10 units (normal 
range 8-100 units). In the rare form of FSHD, FSHD2, D4Z4 chromatin relaxation occurs 
on all D4Z4 arrays and is most often caused by variants in the D4Z4 chromatin repressor 
SMCHD1.
 ICF is an immunodeficiency syndrome mainly characterized by hypo- or 
agammaglobulinemia in the presence of B cells, developmental delay and facial 
anomalies. Compared to FSHD, ICF patients show more genome-wide hypomethylation 
at repetitive elements and this results in, amongst others, centromeric instability, which 
is the cytogenetic hallmark of ICF. Recessive variants in four genes have been identified 
to cause ICF syndrome: DNMT3B (ICF1), ZBTB24 (ICF2), CDCA7 (ICF3) and HELLS (ICF4). In 
this thesis the variant spectrum for chromatin modifiers involved in FSHD and ICF has 
been expanded.
 In chapter 2 three FSHD2 families are described in which two potentially damaging 
variants in SMCHD1 were identified in the proband. For each family we investigated 
whether these variants were located in cis or in trans as well as their contribution to 
D4Z4 hypomethylation. In the first family, a splice site variant and a nonsense variants 
in cis were identified in exon 21. The splice variant results in skipping of exon 21, which 
neutralizes the nonsense variant in exon 21. However, skipping of exon 21 is predicted 
to disrupt the open reading frame by a premature stop codon in exon 22. In the second 
family, the proband carries a missense variant in exon 28 and a splice site variant in 
exon 25. Although the missense variant in exon 28 was predicted to affect function, no 
D4Z4 hypomethylation was detected in the mother of the proband who also carries 
this variant. This suggests that only the splice site variant in exon 25, which seems 
to be in an SMCHD1 mutation hotspot, affects SMCHD1 function and contributes to 
disease. This family also emphasizes the predictive value of D4Z4 methylation analysis 
in establishing the functional consequences of SMCHD1 variants. In the third family, 
the proband carries two SMCHD1 missense variants in exon 24 and exon 45 in trans 
and shows severe D4Z4 hypomethylation. D4Z4 hypomethylation was also detected in 
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the father and the mother of the proband, who carry the missense variant in exon 24 
and exon 45, respectively. This revealed that both missense variants contribute to D4Z4 
hypomethylation independently. The combination of these missense variants has an 
additive effect on D4Z4 hypomethylation, since this was more strongly reduced in the 
proband and his sister who carry both missense variants. Although the mother and the 
proband both carry a permissive D4Z4 allele of 27 repeat units, only the proband with 
two SMCHD1 missense variants is affected. This suggests that these variants also have an 
additive effect on disease presentation. Interestingly, this family also shows that having 
two SMCHD1 missense variants in trans is compatible with life in males and females. 
 In chapter 3 whole SMCHD1 gene deletions were identified in two FSHD2 families, 
which were previously tested negative for exonic SMCHD1 variants. Some neighbouring 
genes were also deleted in these families, however these genes have not been reported 
to be sensitive to hemizygosity. This study emphasizes that hemizygosity of SMCHD1 can 
also cause FSHD2, and results in a haploinsufficiency mechanism as is also expected for 
the open reading frame disrupting variants identified in one third of the FSHD2 patients. 
SMCHD1 hemizygosity is also present in most patients with 18p-deletion syndrome, 
however muscular dystrophy has not been reported in these patients. D4Z4 methylation 
analysis in 18p-deletion patients revealed a similar degree of hypomethylation in most 
of the 18p-deletion patients as is seen in FSHD2 patients. Based on the prevalence of 
permissive 4qA alleles with a D4Z4 repeat size in the FSHD2 range (11-16 units) in the 
control population, it is expected that approximately 1:8 18p-deletion patients with 
SMCHD1 hemizygosity might be at risk of developing FSHD. 
 In chapter 4 we described a (deep) intronic variant in two FSHD families. In the 
first family an intronic variant located 15 base pairs proximal to exon 14 was identified 
(c.1843-15A>G), which creates a splice acceptor site. The variant results in the inclusion 
of the distal 14 nucleotides of intron 13 into the transcript and this is predicted to 
disrupt the open reading frame by a premature stop codon in exon 14. The variant was 
identified in the proband and his sister, and segregates with D4Z4 hypomethylation. In 
the second family a deep intronic variant in SMCHD1 was identified in intron 34 (c.4347-
236A>G). This variant creates a splice acceptor site, while a cryptic splice donor site is 
predicted at position c.4347-183 of SMCHD1. Together this results in exonisation of 53 
nucleotides from intron 34 into the transcript, which is predicted to disrupt the open 
reading frame by a premature stop codon in exon 35. In this family this deep intronic 
variant segregates with D4Z4 hypomethylation and modifies disease severity in family 
members with a permissive 7 units D4Z4 repeat array.
 D4Z4 hypomethylation cannot always be explained by SMCHD1 variants in all 
FSHD2 families. In chapter 5 we described the identification of heterozygous missense 
variants in DNMT3B in two of these families. These DNMT3B variants segregate with D4Z4 




hypomethylation and increased penetrance of FSHD. We identified DUX4 expression 
in MyoD transduced fibroblasts from an affected individual from one of these families 
with a permissive D4Z4 repeat array of 13 units, but not in an unaffected individual 
from the other family with a permissive D4Z4 repeat array of 44 units. This suggests that 
heterozygous DNMT3B variants can only derepress DUX4 in combination with smaller 
D4Z4 repeat arrays. 
Since homozygous or compound heterozygous DNMT3B variants cause autosomal 
recessive ICF1 syndrome, we made a clinical and epigenetic comparison between some 
ICF1 patients and FSHD2 families with a DNMT3B variant. D4Z4 hypomethylation is 
shared between FSHD2 patients and ICF1 patients, and is also found in some parents 
of ICF1 patients who carry a heterozygous DNMT3B variant, like our FSHD2 patients. 
In addition, DUX4 expression was detected in myoblasts from one ICF1 patient, as 
well as in MyoD transduced fibroblasts from two other ICF1 patients. Some epigenetic 
characteristics of ICF were also detected in one DNMT3B variant carrier from these FSHD2 
families. Although some epigenetic characteristics are shared, muscular dystrophy has 
not been reported in ICF1 patients or their parents and no immunodeficiency was 
detected in FSHD2 families, in concordance with parents of ICF1 patients. We propose 
that the effect of DNMT3B variants on DUX4 expression and disease presentation, like for 
SMCHD1, depends on several aspects associated with the FSHD1 locus including D4Z4 
repeat array size, and the presence of a polymorphic DUX4 polyadenylation signal. This 
study suggests that multiple factors are involved in the epigenetic state at D4Z4 and the 
regulation of DUX4 in muscle cells.
 Finally, in chapter 6 we expand the spectrum of ICF1 and ICF2 variants. In seven 
ICF1 patients from four different families we identified in total six missense variants in 
the catalytic domain of DNMT3B. These variants were not previously described in ICF1 
patients. In addition, we describe five ICF2 cases from five different families. Four of 
these ICF2 patients carry homozygous nonsense variants in ZBTB24, including one 
which was not previously identified in ICF2 patients. The fifth ICF2 patient carries a 
homozygous deletion on chromosome 6 which includes ZBTB24. This observation 
shows that complete absence of ZBTB24 protein is compatible with life and supports 
the hypothesis that most ICF2 patients suffer from a functional loss of ZBTB24. With 
these 12 ICF patients included, a total of 77 genetically confirmed patients has been 
reported. 56% of the ICF patients carry DNMT3B variants, 31% carry ZBTB24 variants, 
7% carry CDCA7 variants and 7% carry HELLS variants. Only for ICF2, a gender bias was 
detected, with 79% male patients. This suggests that ZBTB24 variants might be more 
deleterious for females.




Een correcte epigenetische regulatie van het genoom is van groot belang om de 
juiste patronen van genexpressie te garanderen. Hierbij spelen chromatine modifiers, 
eiwitten die de organisatie van het eiwit-DNA complex “chromatine” reguleren, een 
grote rol. Verkeerde regulatie van epigenetische processen kan ziektes veroorzaken, 
zoals het geval is bij Facioscapulohumerale dystrofie (FSHD) en Immunodeficiëntie, 
Centromeerinstabiliteit, Faciale anomalieën (ICF) syndroom. FSHD en ICF worden 
beide gekarakteriseerd door lage hoeveelheden DNA methylatie (hypomethylatie) van 
repeterend DNA. 
 FSHD is een spierziekte die vooral de spieren in het gezicht, de schoudergordel 
en de bovenarmen treft. FSHD wordt gekenmerkt door gedeeltelijke relaxatie van de 
chromatine structuur van de D4Z4 macrosatelliet repeat op chromosoom 4. Dit zorgt 
ervoor dat het DUX4 gen, wat zich bevindt in de D4Z4 repeat en codeert voor een 
transcriptie factor, per abuis tot expressie komt in skeletspieren. Eén van de consistente 
kenmerken van de relaxatie van de chromatine structuur in FSHD is CpG hypomethylatie 
van de D4Z4 repeat, inclusief de DUX4 promotor. In de meest voorkomende vorm, 
FSHD1, is deze chromatine relaxatie een gevolg van een contractie van de D4Z4 repeat 
tot 1-10 kopieën (normale lengte: 8-100 kopieën). In de zeldzame vorm van FSHD, 
FSHD2, ontstaat D4Z4 chromatine relaxatie op alle D4Z4 repeats en dit wordt in de 
meeste gevallen veroorzaakt door varianten in de D4Z4 chromatine repressor SMCHD1.
ICF syndroom is een primaire immuundeficiëntie, gekenmerkt door lage hoeveelheden 
of afwezigheid van immunoglobulinen in de aanwezigheid van B-cellen in de circulatie, 
ontwikkelingsachterstand en dysmorfologiën. Vergeleken met FSHD, hebben ICF 
patiënten hypomethylatie van meer repeterende DNA sequenties verspreid over het 
genoom en dit zorgt voor onder andere centromeer instabiliteit, het cytogenetische 
kenmerk van ICF syndroom. Er zijn recessieve varianten in vier genen geïdentificeerd 
die ICF syndroom kunnen veroorzaken: DNMT3B (ICF1), ZBTB24 (ICF2), CDCA7 (ICF3) en 
HELLS (ICF4). In dit proefschrift worden het variantspectrum van chromatine modifiers 
die een rol spelen in FSHD en ICF uitgebreid.
 In hoofdstuk 2 worden drie FSHD families beschreven waarin twee mogelijk 
schadelijke SMCHD1 varianten zijn geïdentificeerd in de proband. Voor elke familie 
hebben we de fasering onderzocht; d.w.z. of deze varianten zich op één (in cis) of twee 
(in trans) allelen bevonden en of ze individueel bijdragen aan D4Z4 hypomethylatie. 
In de eerste familie hebben we een splice site variant en een nonsense variant in cis in 
exon 21 gevonden. De splice site variant zorgt voor exon skipping van exon 21, wat als 
consequentie heeft dat de nonsense variant in exon 21 geneutraliseerd wordt. Echter, 
de skipping van exon 21 zorgt ervoor dat het open reading frame verstoord wordt met 
een premature stop codon in exon 22. 




 In de tweede familie is de proband drager van een missense variant in exon 28 en 
een splice site variant in exon 25. Hoewel van de missense variant in exon 28 voorspelt 
wordt dat die de functie van SMCHD1 verstoort, zorgt deze variant niet voor D4Z4 
hypomethylatie in de moeder van de proband, die ook drager is van deze variant. Dit 
suggereert dat alleen de splice site variant in exon 25, een variant die in meer FSHD2 
families voorkomt, SMCHD1 functie verstoort en bijdraagt aan het fenotype. Deze 
familie laat ook de voorspellende waarde van de analyse van D4Z4 methylatie zien voor 
het bepalen van de functionele consequenties van SMCHD1 varianten.
 De proband van de derde familie is drager van twee missense varianten in SMCHD1 
in exon 24 en exon 45 in trans en heeft sterke hypomethylatie van D4Z4. Ook in de 
vader en de moeder van de proband, beide drager van één van de twee missense 
varianten, wordt D4Z4 hypomethylatie gedetecteerd. Dit geeft aan dat beide missense 
varianten onafhankelijk bijdragen aan D4Z4 hypomethylatie. De proband en zijn zus, 
die drager zijn van beide varianten, hebben sterkere D4Z4 hypomethylatie, dan hun 
ouders die drager zijn van maar één van de varianten. Dit laat zien dat de combinatie 
van de missense varianten een sterker effect heeft op D4Z4 hypomethylatie. Zowel de 
moeder en de proband zijn drager van een permissief D4Z4 allel van 27 kopieën, maar 
alleen de proband met beide SMCHD1 missense varianten heeft een FSHD fenotype. 
Dit suggereert dat de varianten ook een additief effect hebben op de presentatie van 
de ziekte. Deze familie laat ook zien dat een combinatie van twee missense varianten in 
trans niet lethaal is in mannen en vrouwen. 
 In hoofdstuk 3, hebben we een deletie van het volledige SMCHD1 gen gedetecteerd 
op één van de chromosomen 18 in twee FSHD2 families, die eerder negatief getest 
waren voor exonische SMCHD1 varianten. De deletie bevat ook een aantal naastgelegen 
genen, waarvan het niet bekend is dat ze sensitief zijn voor hemizygotie. Deze studie 
laat zien dat FSHD2 ook veroorzaakt kan worden door SMCHD1 hemizygotie en dat dit 
resulteert in een haploinsufficiëntie mechanisme. Eenzelfde mechanisme wordt ook 
verwacht bij 1/3 van de FSHD2 patiënten die drager zijn van varianten die het open 
reading frame van SMCHD1 verstoren. 
 SMCHD1 hemizygotie is ook aanwezig bij de meeste patiënten met 18p-deletie 
syndroom, hoewel er geen klinische kernmerken van FSHD zijn beschreven in deze 
patiënten. Analyse van de D4Z4 methylatie in 18p-deletie syndroom patiënten geeft 
aan dat de meeste van hen eenzelfde mate van D4Z4 hypomethylatie hebben als 
FSHD2 patiënten. Gebaseerd op de frequentie in de controle populatie van permissieve 
4qA allelen in combinatie met een lengte van de D4Z4 repeat in de FSHD2 range (11-16 
kopieën), is de inschatting dat ongeveer 1 op de 8 18p-deletie syndroom patiënten met 
SMCHD1 hemizygotie een risico lopen om FSHD te krijgen. 
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 In hoofdstuk 4 hebben we twee FSHD families beschreven met een intronische 
variant in SMCHD1. In de eerste familie is een variant gevonden 15 baseparen proximaal 
van exon 14 (c.1843-15A>G), die een splice acceptor site creëert. Deze variant resulteert 
in de inclusie van de laatste 14 nucleotiden van intron 13 in het transcript. Voor deze 
variant wordt voorspeld dat die het open reading frame verstoort en leidt tot een 
premature stopcodon. Deze variant is gevonden in de proband en zijn zus, en segregeert 
met hypomethylatie.
 In de tweede familie hebben we een diep intronische variant in intron 34 van 
SMCHD1 gevonden. Deze variant creëert een splice acceptor site (c.4347-236A>G), 
terwijl er al een cryptische splice donor site voorspeld wordt op positie c.4347-183 
van SMCHD1. Deze variant zorgt voor de inclusie van 53 baseparen van intron 34 in 
het transcript. Hiervan wordt voorspeld dat dit het open reading frame zal verstoren 
met een premature stopcodon in exon 35 tot gevolg. In deze familie segregeert deze 
variant met D4Z4 hypomethylatie en versterkt het fenotype in de familieleden met een 
permissieve D4Z4 repeat array van 7 kopieën.
 D4Z4 hypomethylatie kan niet in alle FSHD2 families verklaard worden door een 
variant in SMCHD1. In hoofdstuk 5 hebben we de identificatie van heterozygote missense 
varianten in DNMT3B in twee FSHD families beschreven. Deze DNMT3B varianten 
segregeren met D4Z4 hypomethylatie en verhoogde ziekte-ernst. We hebben DUX4 
expressie gedetecteerd in MyoD getransduceerde fibroblasten van een aangedaan 
familielid van een van deze families met een permissieve D4Z4 repeat van 13 kopieën, 
maar niet in een niet-aangedaan familielid van de andere familie met een permissieve 
D4Z4 repeat van 44 kopieën. Dit suggereert dat heterozygote DNMT3B varianten alleen 
tot DUX4 expressie leiden in spiercellen wanneer dit gecombineerd is met kortere D4Z4 
repeats. 
 Omdat homozygote of compound heterozygote DNMT3B varianten het autosomaal 
recessieve ICF1 syndroom veroorzaken, hebben we een klinische en epigenetische 
vergelijking gemaakt tussen ICF1 patiënten en FSHD2 families met een DNMT3B 
variant. Zowel ICF1 patiënten als FSHD2 patiënten hebben D4Z4 hypomethylatie. Ook 
een deel van de ouders van ICF1 patiënten, die net zoals deze FSHD2 patiënten drager 
zijn van een heterozygote DNMT3B variant, hebben D4Z4 hypomethylatie. Daarnaast 
hebben we ook DUX4 expressie gevonden in myoblasten van een ICF1 patiënt en in 
MyoD getransduceerde fibroblasten van twee andere ICF1 patiënten. Een aantal van 
de epigenetische karakteristieken van ICF hebben we ook gedetecteerd in een drager 
van een heterozygote DNMT3B variant uit een van de FSHD2 families. Hoewel een 
aantal epigenetische karakteristieken overeenkomen, is er geen spierziekte beschreven 
in ICF1 patiënten en hun ouders, en geen immunodeficiëntie in FSHD2 families, in 
overeenstemming met ouders van ICF1 patiënten. 




 We concluderen dat het effect van DNMT3B varianten op DUX4 expressie en FSHD 
ziekte presentatie, net zoals bij SMCHD1 varianten, afhankelijk is van verschillende 
aspecten die geassocieerd zijn met het FSHD1 locus, zoals D4Z4 repeat lengte en 
de aanwezigheid van een DUX4 polyadenylatie signaal. Deze studie suggereert dat 
meerdere factoren betrokken zijn bij de epigenetische status van D4Z4 en de regulatie 
van DUX4 expressie in spiercellen. 
 Tot slot hebben we in hoofdstuk 6 het spectrum van ICF1 en ICF2 varianten 
uitgebreid. In zeven ICF1 patiënten van vier verschillende families hebben we in totaal 
zes missense varianten gevonden in het katalytische domein van DNMT3B. Deze 
varianten zijn niet eerder beschreven in ICF1 patiënten. Verder beschrijven we vijf ICF2 
patiënten uit vijf verschillende families. Vier van deze ICF2 patiënten zijn drager van 
homozygote nonsense varianten in ZBTB24, waaronder één nonsense variant die niet 
eerder is geïdentificeerd in ICF2. De vijfde ICF2 patiënt heeft een homozygote deletie 
op chromosoom 6, inclusief ZBTB24. Deze observatie laat zien dat volledige afwezigheid 
van het ZBTB24 eiwit niet lethaal is en bevestigt de hypothese dat de meeste ICF2 
patiënten functioneel ZBTB24 eiwit missen.
 In totaal zijn er nu 77 ICF patiënten beschreven met een gen defect in één van de 
vier ICF genen die tot nu toe bekend zijn. 56% van de ICF patiënten heeft mutaties in 
DNMT3B (ICF1), 31% heeft mutaties in ZBTB24 (ICF2), 7% heeft mutaties in CDCA7 (ICF3) 
en 7% heeft mutaties in HELLS (ICF4). Alleen voor ICF2, hebben we een gender bias 
gevonden, met 79% mannelijke ICF2 patiënten. Dit suggereert dat ZBTB24 varianten 
schadelijker zijn voor vrouwen.
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jullie steun en liefde. Jullie zijn altijd geïnteresseerd in wat ik doe en staan altijd voor me 
klaar. Lieve Remco, wat ben ik je dankbaar voor je steun, je vertrouwen en voor al het 
plezier dat we samen hebben. Dankjewel dat je er altijd voor me bent!
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